levodopa has been researched along with Dyskinesia, Drug-Induced in 1837 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 171 (9.31) | 18.7374 |
| 1990's | 226 (12.30) | 18.2507 |
| 2000's | 538 (29.29) | 29.6817 |
| 2010's | 730 (39.74) | 24.3611 |
| 2020's | 172 (9.36) | 2.80 |
| Authors | Studies |
|---|---|
| Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K | 1 |
| Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y | 1 |
| Bartlett, MJ; Falk, T; Morrison, HW; Pottenger, AE; Sherman, SJ | 1 |
| Gourdon, JC; Huot, P; Maddaford, S; Nuara, SG | 1 |
| Annesi, G; Blankenburg, H; Ciullo, M; Domingues, FS; Esposito, T; Gialluisi, A; Hicks, AA; König, E; Melotti, R; Modugno, N; Nicoletti, A; Pattaro, C; Picard, A; Pichler, I; Pramstaller, PP; Schwienbacher, C; Zappia, M | 1 |
| Feldman, M; Margolesky, J; Marmol, S; Singer, C | 1 |
| Liu, L; Xie, ZY; Zhao, Y; Zhao, YT | 1 |
| Bariotto-Dos-Santos, K; Guimarães, RP; Padovan-Neto, FE; Ribeiro, DL | 1 |
| Fabbri, M; Poewe, W; Rascol, O | 1 |
| Caulfield, ME; Stancati, JA; Steece-Collier, K | 1 |
| Baik, K; Chung, SJ; Jeong, SH; Jeong, Y; Jung, JH; Kim, YJ; Lee, HS; Lee, PH; Lee, YG; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Blass, BE; Bohmann, J; Chen, PJ; Daadi, ES; Daadi, EW; Daadi, MM; Kim, J; Oh, T; Roy-Choudhury, G | 1 |
| Harrison, DJ; Hills, R; Lane, EL; Lelos, MJ; Ramos-Varas, E; Turner, S | 1 |
| Brambilla, R; Brugnoli, A; Fasano, S; Mazzocchi, M; Mercatelli, D; Morari, M; Morella, I; Neubig, RR; O'Keeffe, GW; Pisanò, CA; Zaveri, NT | 1 |
| Armstrong, MJ; Billinghurst, L; Cothros, N; Day, GS; de Bie, RMA; Espay, AJ; Fitts, MS; Gronseth, G; Gurwell, JA; Hagerbrant, L; Hall, DA; Hastings, T; Hauser, RA; Lang, AE; Licking, N; Martello, JP; Miyasaki, JM; O'Brien, MD; Pringsheim, T; Rae-Grant, A; Rafferty, M; Roze, E; Silsbee, H; Smith, DB; Sullivan, K | 1 |
| Bortolanza, M; Del-Bel, EA; Faccioli, LH; Gardinassi, LG; Peti, APF; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V | 1 |
| Müller, T | 2 |
| Bédard, D; Belliveau, S; Frouni, I; Huot, P; Kang, W; Kim, E; Kwan, C | 1 |
| Bédard, D; Clarke, PB; Frouni, I; Hamadjida, A; Huot, P; Kwan, C; Lévesque, C; Lévesque, D; Yesuf, JM | 1 |
| Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL | 1 |
| Annarumma, S; Hansen, CA; Khoshbouei, H; Miller, DR; Ramirez-Zamora, A; Rusch, CT | 1 |
| Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K | 1 |
| Bourque, M; Di Paolo, T; Morissette, M; Tremblay, MÈ | 1 |
| Chagraoui, A; De Deurwaerdère, P; Di Giovanni, G | 1 |
| deVries, T; Jacobs, D; Jaros, M; Quartel, A; Rascol, O; Tönges, L | 1 |
| Cenci, MA; Odin, P; Skovgård, K | 1 |
| Arias-García, M; Bargas, J; Calderón, VM; Galarraga, E; Gómez-Paz, A; Lara-González, E; Luna-Leal, A; Ramírez-López, F | 1 |
| Kochoian, BA; Leventhal, L; Masilamoni, GJ; McRiner, AJ; Papa, SM; Singh, A; Sinon, CG | 1 |
| Drummond, N; Elabi, OF; Kirkeby, A; Kunath, T; Lane, EL; Nolbrant, S; Parmar, M; Pass, R; Sormonta, I | 1 |
| Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E | 1 |
| Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C | 1 |
| Frouni, I; Huot, P | 1 |
| Takeda, A | 1 |
| Chen, YH; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Brys, I; Dias, CMV; Leal, DAB | 1 |
| Combes, A; Coutant, B; Degos, B; Frontera, JL; Léna, C; Mailhes-Hamon, C; Menardy, F; Perez, S; Perrin, E; Popa, D; Tarpin, T; Venance, L | 1 |
| Cerquera-Cleves, C; Dulski, J; Koziorowski, D; Kwiatek-Majkusiak, J; Milanowski, L; Pentela-Nowicka, J; Ross, OA; Sławek, J; Wszolek, ZK | 1 |
| Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L | 1 |
| Chung, SJ; Lee, EC; Lee, PH; Seong, JK; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A | 1 |
| Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M | 1 |
| Chung, J; Chung, SJ; Min, S; Ryu, HS; Yoon, W | 1 |
| Cao, X; Gan, C; Si, Q; Sun, H; Wang, L; Wang, M; Yuan, Y; Zhang, H; Zhang, K | 1 |
| Barrientos, SA; Cenci, MA; Halje, P; Petersson, P; Skovgård, K | 1 |
| Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R | 1 |
| Blandini, F; Cerri, S; Cesaroni, V | 1 |
| Ko, HS; Kwatra, M; Kwon, DK; Wang, J | 1 |
| Bishop, C; Centner, A; Cohen, S; Glinski, J; Lipari, N; Manfredsson, FP | 1 |
| Morelli, M; Parekh, P; Pinna, A | 1 |
| Cenci, MA; Espa, E; Fanni, S; Skovgård, K; Song, L | 1 |
| Goetz, CG; Kaasinen, V; Luo, S; Martinez-Martin, P; Stebbins, GT | 1 |
| Cao, X; Lian, P; Wu, Y; Xu, Y; Yuan, Y; Zhang, X | 1 |
| Chen, J; Ge, YL; Jin, H; Li, D; Li, K; Li, W; Liu, CF; Mao, CJ; Wang, F; Wang, PZ; Yan, JH; Zhang, JR | 1 |
| Farhadi, K; Hosseini, N; Mehrabi, S; Mohtasham Kia, Y; Noori, A | 1 |
| Braccagni, G; Carta, M; Caruso, D; Cioffi, L; Corsi, S; Diviccaro, S; Fanni, S; Frau, R; Gambarana, C; Gentile, M; Melcangi, RC; Pardu, A; Scheggi, S; Stancampiano, R | 1 |
| Chen, YH; Choi, HI; Greig, NH; Hoffer, BJ; Huang, EY; Jung, J; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Feng, J; Gao, R; Gao, S; Liu, K; Song, M; Wang, L; Wang, Y; Yao, L; Zhang, L | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Xiao, Q; Yang, X | 1 |
| Kuhn, W; Müller, T | 1 |
| Aguirre-Pérez, A; Alfaro-Rodriguez, A; Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Hidalgo-Bravo, A; Ríos, C | 1 |
| Buberwa, W; Gao, D; Kambey, PA; Liu, WY; Nyalali, AMK; Saro, A; Tang, C; Wu, J | 1 |
| Bi, Y; Deng, Y; Guan, J; Wang, P; Wang, Z; Yang, H; Yu, J; Zhang, W | 1 |
| Al-Kassmy, J; Huot, P; Sun, C | 1 |
| Almela, P; Arenas-Betancur, L; Cuenca-Bermejo, L; De Pablos, V; Del Bel, E; Fernández-Villalba, E; Gonzalez-Cuello, A; Herrero, MT; Navarro-Zaragoza, J; Yuste, JE | 1 |
| Brito, MMCM; Cavalcanti, RTO; Del-Bel, E; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V | 1 |
| Huot, P | 2 |
| Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G | 1 |
| Alberico, SL; Ding, Y; Hu, Y; Jin, L; Kang, UJ; Ma, TC | 1 |
| Girault, JA; Hervé, D; Nakamura, Y; Pelosi, A | 1 |
| Cenci, MA; Elabi, OF; Espa, E; Fanni, S; Skovgård, K | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Nuara, SG | 1 |
| Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN | 1 |
| Abe, Y; Dantsuji, M; Hata, J; Inoue, T; Matsumoto, M; Mochizuki, A; Nambu, A; Ohno, N; Okano, H; Sano, H; Suematsu, M; Sugiura, Y; Suzuki, T; Taira, S; Takeuchi, H; Tanaka, KF; Watanabe, M; Yagishita, S; Yoshimaru, D | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Lu, D; Porreca, F; Samtani, G; Seaton, BT; Sexauer, MR; Sherman, SJ; Siegenthaler, JR; Weintraub, NC | 1 |
| Dunnett, SB; Lane, EL; Lelos, MJ; Lindgren, HS; Murphy, EM | 1 |
| Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L | 1 |
| Caron, MG; Jin, J; Martini, ML; Pogorelov, VM; Wetsel, WC | 1 |
| Goehring, CM; Herfert, K; Kuebler, L; Pichler, BJ; Walker, M | 1 |
| Espiritu, AI; Jamora, RDG; Pajo, AT | 1 |
| Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L | 2 |
| Calabresi, P; Standaert, DG | 1 |
| Chen, H; Feng, T; Jiang, Y; Liu, G; Ma, H; Su, D; Wang, D; Wang, X; Wang, Z; Yang, Y; Zhang, M | 1 |
| Beck, G; Mochizuki, H; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Woo, JM; Zhang, J | 1 |
| Altwal, F; Beverley, JA; F Voelkner, NM; Padovan-Neto, FE; Patterson, S; Steiner, H; West, AR | 1 |
| Luan, XQ; Shao, B; Wang, WW; Wang, XS; Wang, XY; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Chou, KL; Mossner, JM; Patil, PG | 1 |
| Antonini, A; Chaudhuri, KR; Jenner, P; Leta, V | 1 |
| Gan, C; Ma, K; Si, Q; Wang, L; Wang, M; Yuan, Y; Zhang, K | 1 |
| Del Bel, E; Dos-Santos-Pereira, M; Guimarães, FS; Junior, NCF | 1 |
| Choi, YH; Chung, SJ; Lee, JM; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Klivényi, P; Salamon, A; Szpisjak, L; Vécsei, L; Zádori, D | 1 |
| Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL | 1 |
| Barroso, SDS; Gomes, MZ; Lopes, LES; Santos, KS | 1 |
| Cao, SW; Gan, CT; Ma, KW; Shen, YT; Si, QQ; Wang, LN; Wang, M; Yuan, YS; Zhang, KZ; Zhi, Y | 1 |
| Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY | 1 |
| Cannas, A; Dagostino, S; Follesa, P; Marrosu, F; Pisu, MG; Puligheddu, M; Sanna, A; Serra, M; Solla, P; Tacconi, P | 1 |
| Eisinger, RS; Fan, SY; Han, A; Han, CL; Hu, W; Meng, FG; Michitomo, S; Ramirez-Zamora, A; Wang, F; Wang, KL; Wang, Q; Zhang, JG | 1 |
| Antonini, A; Chaudhuri, KR; Jenner, P | 3 |
| Bishop, C | 1 |
| Cenci, MA; Eidelberg, D; Hauser, RA; Pahwa, R; Riggare, S | 1 |
| Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X | 1 |
| Chernick, D; Hauser, RA; Hubble, J; Isaacson, SH; Jankovic, J; Johnson, R; Oertel, WH; Pahwa, R; Tanner, CM | 1 |
| Beaudry, F; Bédard, D; Gaudette, F; Gourdon, JC; Hamadjida, A; Huot, P; Michaud, V; Nuara, SG; Panisset, M; Sid-Otmane, L | 1 |
| Chalimoniuk, M; Fiszer, U; Jówko, E; Krygowska-Wajs, A; Langfort, J; Michałowska, M; Przybylska, I; Toczylowska, B | 1 |
| Baik, K; Chung, SJ; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 2 |
| Castello, J; Cortés, M; Friedman, E; Kottmann, A; Malave, L; Rebholz, H; Sibley, DR | 1 |
| Cao, X; Chen, G; Cheng, C; Nie, S; Tan, Y; Wang, J; Xu, Y; Yang, X; Zeng, W; Zhang, Z; Zheng, C | 1 |
| Arakawa, K; Maehara, S; Yuge, N | 1 |
| Bartlett, MJ; Falk, T; Heien, ML; Parent, KL; Polt, R; Sherman, SJ; Skinner, DP; So, LY; Szabò, L; Vanderah, TW | 1 |
| Agosta, F; Canu, E; Donzuso, G; Filippi, M | 1 |
| Chen, X; Cheng, C; Le, W; Wang, Y; Wu, H | 1 |
| Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS | 1 |
| Koski, SK; Leino, S; Panula, P; Rannanpää, S; Salminen, O | 1 |
| Altwal, F; Collier, TJ; Kordower, JH; Manfredsson, FP; Sandoval, IM; Sellnow, RC; Sortwell, CE; Steece-Collier, K; West, AR | 1 |
| Duty, S; Fisher, R; Jackson, M; Lincoln, L; Mann, E; Rose, S | 1 |
| Shao, M; Wang, R | 1 |
| Borges, V; Ferraz, HB; Hutz, MH; Mata, IF; Rieder, CRM; Santos-Lobato, BL; Schumacher-Schuh, AF; Tumas, V; Zabetian, CP | 1 |
| George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S | 1 |
| Kempster, P | 1 |
| Chang, Y; Li, Y; Liu, X; Wang, L; Yan, Y; Zhang, L | 1 |
| AlShimemeri, S; Fox, SH; Visanji, NP | 1 |
| Bishop, C; Cole-Strauss, A; Collier, TJ; Conti, MM; Lipton, JW; Manfredsson, FP; Mercado, NM; Nillni, EA; Sellnow, R; Sortwell, CE; Stancati, JA; Steece-Collier, K; Winn, ME | 1 |
| Bermúdez de León, M; González-Hernández, B; González-Horta, A; Leija-Salazar, M | 1 |
| Bezard, E; Crynen, G; De Rosa, A; Eshraghi, M; Galli, N; Li, Q; Nuzzo, T; Ramírez-Jarquín, UN; Rivera, O; Scharager-Tapia, C; Shahani, N; Subramaniam, S; Swarnkar, S; Thiolat, ML; Tsaprailis, G; Usiello, A | 1 |
| Cannas, A; Carta, M; Defazio, G; Farris, R; Figorilli, M; Meloni, M; Puligheddu, M; Sanna, F; Tronci, E | 1 |
| Mukai, Y; Nishikawa, N; Shiraishi, T; Takahashi, Y | 1 |
| Evans, AH; Farrell, M; Sung, S; Vijiaratnam, N | 1 |
| Arai, A; Ichinohe, N; Kon, T; Mori, F; Nishijima, H; Okada, M; Suzuki, C; Tomiyama, M; Ueno, S; Wakabayashi, K; Zhu, G | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 2 |
| Bartlett, MJ; Besselsen, DG; Cowen, SL; Dollish, HK; Doyle, KP; Falk, T; Farrell, DC; Flores, AJ; Heien, ML; Parent, KL; Sherman, SJ; Smidt, SI; Stancati, JA; Steece-Collier, K; Ye, T | 1 |
| Amara, RR; Beck, G; Dyavar Shetty, BL; Dyavar, SR; Fletcher, CV; Lawson, B; Papa, SM; Podany, AT; Potts, LF | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 2 |
| Awogbindin, IO; Benadjal, A; Bordeleau, M; Bourque, M; Cantin, L; Di Paolo, T; Gagnon, D; Ibanez, FG; Lecours, C; Parent, M; Picard, K; St-Pierre, MK; Tremblay, ME | 1 |
| Hatano, T; Hattori, N; Kanai, K; Oyama, G; Shimo, Y; Ueno, SI | 1 |
| Bézard, E; Blanchet, PJ; Bogard, S; Duval, C; Goubault, E; Martino, D; Monchi, O; Sarna, J; Vincent, C | 1 |
| Crippa, JAS; Marchioni, C; Queiroz, MEC; Santos-Lobato, BL; Tumas, V | 1 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Franco, R; Labandeira-García, JL; Muñoz, A; Navarro, G; Reyes-Resina, I; Rivas-Santisteban, R; Rodriguez-Perez, AI | 1 |
| Hong, JY; Kang, SY; Kim, SH; Lee, PH; Sohn, YH; Sunwoo, MK; Yoon, JH | 1 |
| Cho, JW; Kim, JS; Kim, M; Park, H; Youn, J | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Beaudry, F; Huot, P | 1 |
| Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A | 1 |
| Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D | 1 |
| Lang, AE; Saranza, G | 1 |
| Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T | 1 |
| Angelopoulou, E; Julian, T; Paudel, YN; Piperi, C; Shaikh, MF | 1 |
| Boezwinkle, SA; Collier, TJ; Duffy, MF; Fischer, DL; Manfredsson, FP; Mercado, NM; Mueller, RL; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C | 1 |
| Bishop, C; Centner, A; Coyle, M; Del Priore, I; Lanza, K; Manfredsson, FP | 1 |
| Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C | 1 |
| Baschi, R; Cicero, CE; Davì, M; Luca, A; Monastero, R; Mostile, G; Nicoletti, A; Restivo, V; Zappia, M | 1 |
| Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L | 1 |
| Jang, M; Jeon, B; Kim, A; Kim, HJ; Kim, Y; Paek, SH | 1 |
| Andrén, PE; Bezard, E; Crossman, AR; Fernagut, PO; Fridjonsdottir, E; Nilsson, A; Odell, LR; Schembri, LS; Shariatgorji, R; Svenningsson, P; Vallianatou, T | 1 |
| Betrouni, N; Carrière, N; Chupin, M; Defebvre, L; Devos, D; Kuchcinski, G; Lopes, R; Moreau, C; Rolland, AS; Viard, R | 1 |
| Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR | 1 |
| Di Fonzo, A; Fabbrini, G; Falla, M; Hicks, AA; Pramstaller, PP | 1 |
| Chiken, S; Dwi Wahyu, I; Hasegawa, T; Nambu, A; Sano, H | 1 |
| Bartlett, MJ; Cowen, SL; Falk, T; Sherman, SJ; Ye, T | 1 |
| Bortolanza, M; Del Bel, EA; Ferrari, DP | 1 |
| Beck, G; Fong, K; Mochizuki, H; Mouradian, MM; Papa, SM; Zhang, J | 1 |
| Bortolanza, M; Del-Bel, E; do Nascimento, GC; Raisman-Vozari, R | 1 |
| Enomoto, T; Fujii, Y; Goda, M; Ikeda, K; Kitamura, A; Nakako, T; Wada, E | 1 |
| Carta, M; Corsi, S; Stancampiano, R | 1 |
| Burack, MA; Ghoraani, B; Hssayeni, MD; Jimenez-Shahed, J | 1 |
| Cheng, L; Li, L; Wang, Y | 1 |
| Grill, WM; Schmidt, SL | 1 |
| Güttler, C; Nikulin, VV; van Riesen, C | 1 |
| Baik, K; Chung, SJ; Hong, N; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 1 |
| Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J | 1 |
| Murer, MG; Paz, RM | 1 |
| Fukuda, T; Kawahara, Y; Kuroiwa, M; Miyamoto, Y; Nishi, A; Ohnishi, YN; Shuto, T; Sugiyama, K | 1 |
| Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS | 1 |
| Aranyi, T; Barta, C; Devay, P; Fothi, A; Hengerer, B; Liko, I; Nespoli, E; Pagliaroli, L; Szeri, F; Veto, B | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
| Andica, C; Aoki, S; Hatano, T; Hattori, N; Hori, M; Ito, M; Iwamuro, H; Kamagata, K; Ogawa, T; Oyama, G; Saito, Y; Shimo, Y; Takeshige-Amano, H; Uchida, W; Umemura, A | 1 |
| Cao, B; Chen, YP; Gu, XJ; Hou, YB; Lin, JY; Liu, KC; Ou, RW; Shang, HF; Wei, QQ; Wu, Y; Zhang, LY; Zhao, B | 1 |
| Zhang, F; Zheng, C | 1 |
| Barone, P; Buonomo, AR; Erro, R; Pellecchia, MT | 1 |
| Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O | 1 |
| Arai, A; Baba, M; Funamizu, Y; Haga, R; Kon, T; Nishijima, H; Nunomura, JI; Suzuki, C; Tomiyama, M; Ueno, T | 1 |
| Amanzio, M; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M | 1 |
| Brodsky, M; Factor, SA; Fox, SH; Knowles, N; Lang, AE; Metman, LV; Nutt, JG; Pope, LE; Siffert, J | 1 |
| Berardelli, A; Blankenburg, H; Domingues, FS; Fabbrini, G; Falla, M; Pramstaller, PP; Schwienbacher, C | 1 |
| Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ | 1 |
| Kordower, JH | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Ghilardi, MF; Kishore, A; Popa, T; Quartarone, A; Rajan, R | 1 |
| Espay, AJ; Lang, AE | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Blandini, F; Cerri, S; Siani, F | 1 |
| Bastide, MF; Bézard, E; Bourdenx, M; Doudnikoff, E; Dumont, ÉC; Fernagut, PO; Georges, F; Glangetas, C; Li, Q | 1 |
| Hashizume, T; Kaneko, S; Kusaka, H; Morise, S; Nakamura, M; Oki, M; Takenouchi, N; Tsuge, A; Wate, R | 1 |
| Casteels, C; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Elsinga, PH; Zhou, X | 1 |
| Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD | 1 |
| Andersen, AD; Binzer, M; Blaabjerg, M; Faergeman, NJ; Gramsbergen, JB; Havelund, JF; Heegaard, NHH; Stenager, E | 1 |
| Bishop, C; Cantu, MA; Chotibut, T; Kasanga, EA; McInnis, T; Meadows, S; Salvatore, MF | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Contin, M; Isaias, IU; Laguna, J; Pezzoli, G; Pozzi, NG | 1 |
| Asselta, R; Barbella, G; Benfante, R; Cereda, E; Cilia, R; Fornasari, D; Goldwurm, S; Marabini, L; Pezzoli, G; Vallauri, D | 1 |
| de Souza, A; de Souza, RJ | 1 |
| Bichon, A; Broussolle, E; Carnicella, S; Castrioto, A; Delpont, B; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Lüscher, C; Pélissier, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, S | 1 |
| Bezard, E; Carta, M; Cheng, LY; Ko, WKD; Li, Q; Morelli, M | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Muñoz, A; Napolitano, F; Rossi, F; Tronci, E; Usiello, A | 1 |
| Felt, L; Hauser, RA; Isaacson, SH; Johnson, R; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM | 1 |
| Espay, AJ; Verhagen Metman, L | 1 |
| Bezard, E; Calabresi, P; De Rosa, A; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Mellone, M; Minocci, D; Napolitano, F; Picconi, B; Racca, C; Stanic, J; Thiolat, ML; Usiello, A; Zianni, E | 1 |
| Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C | 1 |
| Avale, ME; Bernardi, MA; Bordone, MP; Damianich, A; Ferrario, JE; Gershanik, OS; Gomez, G; Hanger, DP; Isaja, L; Sanz-Blasco, S; Taravini, IR | 1 |
| Funamizu, Y; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T | 1 |
| Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG | 2 |
| Bourque, M; Di Paolo, T; Grégoire, L | 1 |
| Damier, P; Delval, A; Derkinderen, P; Destée, A; Meissner, WG; Negre-Pages, L; Perez-Lloret, S; Rascol, O; Tison, F | 1 |
| Abbruzzese, G; Antonini, A; Biundo, R; Calandra-Buonaura, G; Cortelli, P; Jori, MC; Lopiano, L; Marconi, R; Matinella, A; Morgante, F; Nicoletti, A; Tamburini, T; Tinazzi, M; Vorovenci, RJ; Weis, L; Zappia, M | 1 |
| Pagano, G; Politis, M; Yousaf, T | 1 |
| Aldrin-Kirk, P; Björklund, T; Davidsson, M; Heuer, A; Mattsson, B; Rylander Ottosson, D | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK | 1 |
| Carras, N; Choi, YY; Dhawan, V; Eidelberg, D; Feigin, A; Jourdain, VA; Ma, Y; Markowitz, D; Nardi, D; Nazem, A; Niethammer, M; Peng, S; Schindlbeck, KA; Tang, CC | 1 |
| Fox, SH; Li, MH; Mestre, TA; Taati, B | 3 |
| Asser, T; Kadastik-Eerme, L; Taba, N; Taba, P | 1 |
| Castello, J; Cenci, MA; Cortés, M; Flajolet, M; Friedman, E; Malave, L; Rebholz, H | 1 |
| Cicchetti, F; David, LS; Lamontagne-Proulx, J; Saint-Pierre, M | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF | 1 |
| Borgkvist, A; Lieberman, OJ; Sulzer, D | 1 |
| Olanow, CW; Stocchi, F | 4 |
| Bronstein, JM; Farrer, MJ; Guella, I; Kusters, CDJ; Paul, KC; Ritz, BR; Sinsheimer, JS | 1 |
| Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E | 1 |
| Calabresi, P; Hernández, LF; Obeso, JA; Picconi, B | 1 |
| Arcuri, L; Brambilla, R; Fasano, S; Frassineti, M; Journigan, BV; Mercatelli, D; Meyer, ME; Morari, M; Morella, I; Novello, S; Pisanò, CA; Polgar, WE; Zaveri, NT | 1 |
| Choi, H; Koh, SH | 1 |
| Bernardi, MA; Ferrario, JE; Gershanik, OS; Gomez, G; Saborido, MD; Taravini, IR | 1 |
| Francardo, V; Tronci, E | 1 |
| Bishop, C; Lanza, K | 1 |
| Chondrogiorgi, M; Giannakis, A; Konitsiotis, S; Tatsioni, A; Tsironis, C | 1 |
| Bhide, N; Bishop, C; George, JA; Goldenberg, AA; Ostock, CY | 1 |
| Gardoni, F; Mellone, M | 1 |
| Fisone, G; Spigolon, G | 1 |
| Morelli, M; Pinna, A; Serra, M; Simola, N | 1 |
| Bair-Marshall, CJ; Girasole, AE; Guenthner, CJ; Kreitzer, AC; Lum, MY; Luo, L; Nathaniel, D; Nelson, AB | 1 |
| Matarazzo, M; Perez-Soriano, A; Stoessl, AJ | 1 |
| Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z | 1 |
| Bendi, VS; Joy, S; Shou, J; Torres-Russotto, D | 1 |
| Koski, SK; Leino, S; Rannanpää, S; Salminen, O | 1 |
| Björklund, A; Carta, M | 1 |
| Cenci, MA; Crossman, AR | 1 |
| Calabresi, P; De Leonibus, E; Picconi, B | 1 |
| Bordia, T; Perez, XA; Quik, M | 1 |
| Beck, G; Chang, PL; Maehara, S; Papa, SM | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Alcázar, JP; Caro Aponte, PA; Guzmán, JC; Mayorga, EL; Otálora, CA; Turner, LF | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Baillargeon, J; Darlix, N; Lévesque, C; Lévesque, D; Maheux, J; Majeur, S; Paquet, B; Rouillard, C; St-Hilaire, M | 1 |
| Boi, L; Carta, AR; Fenu, S; Mulas, G; Pisanu, A; Spiga, S | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Bahroo, LB; Elkurd, MT; Pahwa, R | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC | 1 |
| Cenci, MA; Sebastianutto, I | 1 |
| Cenci, MA; Jörntell, H; Petersson, P | 1 |
| Pal, PK; Prasad, S | 1 |
| Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S | 1 |
| Bishop, C; Chambers, N; Conti, MM | 1 |
| Ayton, S; Bush, AI; Chung, SJ; Kim, J; Kim, K; Kim, MJ; Kim, MS; Lee, JY; Oh, SB; Ryu, HS | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Lacoste, AMB; Lang, AE; Visanji, NP | 1 |
| Bair-Marshall, C; Nelson, AB; Ryan, MB | 1 |
| Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T | 1 |
| Breger, LS; Cenci, MA; Fieblinger, T; Lockowandt, M; Lundberg, C; Quintino, L; Sebastianutto, I; Zanetti, L | 1 |
| Frei, K; Tran, TN; Truong, DD; Vo, TNN | 1 |
| Brusa, L; Caltagirone, C; Koch, G; Picazio, S; Ponzo, V | 1 |
| Antonelli, F; Cerquera, C; Ezquerra, M; Fernández-Santiago, R; Malagelada, C; Martí, MJ; Martín-Flores, N; Moreno, V | 1 |
| Choi, DH; Go, J; Han, PL; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Noh, JR; Park, HY; Rhee, M; Ryu, YK | 1 |
| Carta, M; Hirsch, E | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
| Chung, SJ; Jeong, HE; Kim, JS; Kim, SJ; Lee, HS; Lee, PH; Oh, JS; Sohn, YH; Yoo, HS | 1 |
| Ahn, S; Jeon, SH; Kim, J; Kim, YK; Lee, AR; Park, H; Park, HJ; Yoo, J | 1 |
| Cunha, RA; Prediger, RD; S Aguiar, A; Schamne, MG; Speck, AE | 1 |
| Alifirova, VM; Bokhan, NA; Fedorenko, OY; Freidin, MB; Ivanova, SA; Loonen, AJM; Mironova, YA; Osmanova, DZ; Pozhidaev, IV; Tiguntsev, VV; Wilffert, B; Zhukova, IA; Zhukova, NG | 1 |
| Keam, SJ; Paik, J | 1 |
| Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato, V; Thobois, S; Tremblay, L | 1 |
| Arnulfo, G; Canessa, A; Isaias, IU; Marotta, G; Olivieri, C; Palmisano, C; Pezzoli, G; Pozzi, NG; Turco, F; Volkmann, J | 1 |
| Lane, EL | 1 |
| Ba, M; Kong, M; Wang, Y; Yang, H; Yu, G; Yu, L | 1 |
| Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ | 1 |
| Bezard, E; Charvin, D; Conquet, F; Di Paolo, T; Duvey, G; Gregoire, L; Halldin, C; Medori, R; Pioli, E; Takano, A | 1 |
| Drucker-Colín, R; Enríquez-Traba, J; García-Montes, JR; Moratalla, R; Ruiz-DeDiego, I; Solís, O | 1 |
| Bezard, E; Calabresi, P; Campanelli, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Marino, G; Mellone, M; Picconi, B; Stanic, J; Thiolat, ML; Zianni, E | 1 |
| Brotchie, JM; Fox, SH | 2 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Azulay, JP; Benel, L; Boraud, T; Chaigneau, V; Cormier-Dequaire, F; Corvol, JC; Debilly, B; Dellapina, E; Durif, F; Eusebio, A; Galitzky, M; Guimarães-Costa, R; Haddad, R; Houot, M; Lacomblez, L; Mariani, LL; Meissner, WG; Rascol, O; Salis, A; Thalamas, C | 1 |
| Di Battista, ME; Fattapposta, F; Lucarelli, M; Meco, G; Moret, F; Pascale, E; Pierandrei, S; Purcaro, C; Rubino, A; Vanacore, N | 1 |
| Amato, N; Galati, S; Kaelin-Lang, A; Manconi, M; Möller, JC; Sarasso, S; Staedler, C; Stanzione, P | 1 |
| Bezard, E; Calabresi, P; Espay, AJ; Fasano, A; Fox, SH; Lang, AE; Marsili, L; Merola, A; Morgante, F; Picconi, B | 1 |
| Fidani, L; Kalinderi, K; Papaliagkas, V | 1 |
| Ahlskog, JE; Bower, JH; Cutsforth-Gregory, JK; Mielke, MM; Parisi, JE; Savica, R; Turcano, P | 1 |
| Dragašević-Mišković, N; Kostić, VS; Petrović, I; Stanković, I | 1 |
| Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K | 1 |
| Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J | 1 |
| Jenner, P | 7 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Kohtala, S; Koski, SK; Leino, S; Rannanpää, S; Rantamäki, T; Salminen, O | 1 |
| Chen, J; Li, M; Li, N; Luo, F; Lv, S; Wang, J; Wang, N; Wang, Q; Xie, Z; Zhang, W | 1 |
| Nambu, A; Sano, H | 1 |
| Benskey, MJ; Bishop, C; Chambers, N; Manfredsson, FP; Newman, JH; Sandoval, IM; Sellnow, RC; Steece-Collier, K; West, AR | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Ba, F; Nathoo, N; Sankar, T; Suchowersky, O | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Sohn, YH; Yoo, HS | 1 |
| Beck, G; Calabresi, P; Cardinale, A; Costa, C; de Iure, A; Durante, V; Ghiglieri, V; Mancini, A; Mazzocchetti, P; Megaro, A; Napolitano, F; Papa, SM; Picconi, B; Punzo, D; Quiroga Varela, A; Sciaccaluga, M; Tantucci, M; Tozzi, A; Usiello, A | 1 |
| Morris, GP; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Montes, S; Ríos, C | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Abdelkarim, AH; Alkanj, S; Aziz, MAE; Bahbah, EI; Diab, A; Ebada, M; Ebada, MA; Fayed, N; Negida, A; Soliman, AM | 1 |
| Martini, ML; Mocco, J; Panov, F | 1 |
| Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR | 1 |
| Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O | 1 |
| Graves, SM; Shen, W; Surmeier, DJ; Zhai, S | 1 |
| Del Bello, F; Giannella, M; Giorgioni, G; Piergentili, A; Quaglia, W | 1 |
| Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Kuhn, W; Möhr, JD; Müller, T | 1 |
| Elmer, LW; Hauser, RA; Howard, R; Johnson, R; Kreitzman, DL; Kremens, DE; Nguyen, JT; Patni, R; Walsh, RR | 1 |
| Bezard, E; Fernagut, PO; Li, Q | 1 |
| Buhmann, C; Jost, WH; Kassubek, J; Lingor, P; Schrag, A; Schwarz, J; Tönges, L | 1 |
| Bezard, E; Delamarre, A; Galitzky, M; Li, Q; Meissner, WG; Rascol, O; Tison, F | 1 |
| Kumar, PM; Lim, EC; Nadkarni, NV; Tan, EK; Wu, J | 1 |
| Baig, F; Barber, TR; Ben-Shlomo, Y; Hu, MT; Kelly, MJ; Klein, JC; Lawton, MA; Lo, C; Ruffmann, C | 1 |
| Bishop, C; Deak, T; Lanza, K; Perkins, AE | 1 |
| Ahmed, MR; Ahmed, MS; Jayakumar, M; Job, JK; Li, EH; Ohtsu, H; Pittenger, C; Rajadas, J; Tao, J; Zamaleeva, AI | 1 |
| Möhr, JD; Müller, T | 1 |
| Boi, L; Carboni, E; Carta, AR; Fenu, S; Greig, NH; Mulas, G; Pisanu, A; Scerba, MT; Spiga, S; Tweedie, D | 1 |
| Aristieta, A; Lafuente, JV; Miguelez, C; Paredes-Rodriguez, E; Ugedo, L; Vegas-Suarez, S | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M | 1 |
| Gago, B; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| da Silva, CA; de Aguiar, D; de Oliveira-Tavares, D; Del Bel, E; Ferreira, NR; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Bastide, M; Bézard, E | 1 |
| Boroojerdi, B; Giladi, N; Surmann, E | 1 |
| Carignan, B; Daneault, JF; Duval, C; Panisset, M; Sadikot, AF | 1 |
| Backer, F; Balachandran, A; Chandran, S; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Pradeep, S | 1 |
| Contini, A; De Deurwaerdère, P; Lagière, M; Navailles, S | 1 |
| Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R | 1 |
| Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Bordia, T; Campos, C; Jordan, K; Letchworth, S; McIntosh, JM; Quik, M; Strachan, JP; Zhang, J | 1 |
| Ivanova, SA; Loonen, AJ | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Lambrecht, C; Richter, A; Sander, SE | 1 |
| Emre, M; Kieburtz, K; Leinonen, M; Nissinen, H; Poewe, W; Rascol, O; Schapira, AH; Stocchi, F; Warren Olanow, C | 1 |
| Damier, P; Derkinderen, P | 1 |
| Factor, SA; Silver, M | 1 |
| Asselta, R; Cilia, R; Cohen, OS; Goldwurm, S; Greenbaum, L; Hassin-Baer, S; Inzelberg, R; Kohn, Y; Lerer, B; Lifschytz, T; Tesei, S; Yahalom, G; Zozulinsky, P | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Caramés, JM; Moratalla, R; Murer, MG; Solís, JM; Solís, O; Suárez, LM; Taravini, IR | 1 |
| Arabia, G; Cerasa, A; Gioia, CM; Morelli, M; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Brotchie, JM; Fox, SH; Graef, JD; Hill, MP; Huot, P; James, JW; Johnston, TH; Jordan, KG; Koprich, JB; Letchworth, SR; Szeliga, KT | 1 |
| Bézard, E; Obeso, JA; Olanow, CW | 1 |
| Anselmo-Franci, J; da-Silva, CA; Del-Bel, E; Guimaraes, FS; Padovan-Neto, FE; Raisman-Vozari, R; Romano-Dutra, AC; Szawka, RE | 1 |
| Ly, J; Mallela, A; Quik, M; Zhang, D | 1 |
| Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E | 1 |
| Mendoza-Elias, N; Meredith, GE; Rademacher, DJ; Steece-Collier, K; Tseng, KY; Zhang, Y | 1 |
| Destee, A; Gao, H; Graf, A; Hattori, N; Hauser, RA; Kenney, C; Lang, AE; Merschhemke, M; Nagel, J; Poewe, W; Rascol, O; Stacy, M; Stocchi, F; Tolosa, E; Trenkwalder, C | 1 |
| Fox, S | 1 |
| Coelho, M; Ferreira, JJ; Mestre, TA; Pita Lobo, P; Rosa, MM | 1 |
| Altieri, M; Berardelli, A; Bloise, M; Bologna, M; Fabbrini, G; Fasano, A; Latorre, A; Pietracupa, S; Sarchioto, M | 1 |
| Bencherif, M; Carroll, FI; Letchworth, S; Mallela, A; Quik, M; Sohn, D; Zhang, D | 1 |
| Halje, P; Petersson, P; Richter, U | 1 |
| Fox, SH | 1 |
| Andersson, M; Cenci, MA; Iderberg, H; Lees, AJ; Lindgren, HS; O'Sullivan, SS; Rylander, D; Williams, DR | 1 |
| Dunnett, SB; Heuer, A; Klein, A; Lane, EL; Smith, GA; Vinh, NN | 1 |
| Manson, A; Schrag, A; Stirpe, P | 1 |
| Björklund, A; Decressac, M | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Salat, D; Tolosa, E | 1 |
| Burack, MA; Giuffrida, JP; Mera, TO | 2 |
| Hashim, HZ; Nafisah, WY; Norlinah, MI; Raymond, AA; Tamil, AM; Tan, HJ | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P | 1 |
| Jackson, MJ; Jenner, P; Pearce, RK; Swart, T | 1 |
| Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E | 1 |
| Bertram, K; Bras, J; Cheshire, P; Foltynie, T; Halliday, G; Ling, H; McLean, C; O'Sullivan, SS; Storey, E; Williams, DR | 1 |
| Bimpisidis, Z; Cenci, MA; Iderberg, H; Rylander, D | 1 |
| Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
| Bastide, MF; Bézard, E; Charron, G; Dovero, S; Fernagut, PO; Gross, CE; Porras, G | 1 |
| Edwards, MJ; Rothwell, JC | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E | 1 |
| Bézard, E; Björklund, A; Carta, M; Li, Q; Muñoz, A; Pioli, EY; Porras, G; Tronci, E | 1 |
| Guo, JF; Liu, ZH; Lou, MX; Song, CY; Tang, BS; Xu, Q; Yan, XX; Yu, RH; Zhang, YH | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| González-Aparicio, R; Moratalla, R | 1 |
| Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H | 1 |
| Cenci, MA; Francardo, V | 1 |
| Chondrogiorgi, M; Konitsiotis, S; Reichmann, H; Tatsioni, A | 1 |
| Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V | 1 |
| Af Bjerkén, S; Gerhardt, GA; Nevalainen, N; Strömberg, I | 1 |
| Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M | 1 |
| Narayanan, NS; Rodnitzky, RL | 1 |
| Rajput, AH | 1 |
| Liu, Z; Song, L; Wei, J; Wu, N; Yang, X | 1 |
| Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L | 1 |
| Arai, A; Baba, M; Migita, K; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Kelsey, JE; Neville, C | 1 |
| Kieburtz, K; Olanow, CW; Stocchi, F | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Lewis, KD; Piggott, MJ; Reyes, MG | 2 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 2 |
| Bleickardt, C; Chitravanshi, VC; Cote, SR; Kuzhikandathil, EV; Sapru, HN | 1 |
| Loane, C; Niccolini, F; Politis, M | 1 |
| Chen, H; Chen, HB; Chen, SD; Chen, X; Li, L; Liu, YM; Liu, ZG; Qu, QM; Shao, M; Sun, SG; Wan, X; Wang, G; Wang, J; Wen, HB; Xu, Q; Zhang, BR; Zhang, ZX | 1 |
| Gan, J; Liu, ZG; Pan, JL; Xie, CL; Zhang, SF | 1 |
| Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Quik, M; Zhang, D | 1 |
| Burn, DJ; Crossman, AR; Kass-Iliyya, L; Kellett, MW; Kobylecki, C; Silverdale, MA | 1 |
| Bain, P; Brooks, DJ; Kiferle, L; Loane, C; Molloy, S; Piccini, P; Politis, M; Turkheimer, FE; Wu, K | 1 |
| Ding, Y; Kang, UJ; Singh, P; Won, L | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Bezard, E; Ko, WK; Li, Q | 1 |
| Arai, A; Baba, M; Funamizu, Y; Haga, R; Ichinohe, N; Kimura, T; Kon, T; Meguro, R; Migita, K; Miki, Y; Nishijima, H; Suzuki, C; Suzuki, S; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Calabresi, P; Picconi, B | 1 |
| Cenci, MA; Fenster, RJ; Francardo, V; Greengard, P; Heilbut, A; Heiman, M; Kolaczyk, ED; Kulicke, R; Mesirov, JP; Surmeier, DJ | 1 |
| Liu, J; Wang, HS; Wang, T; Wang, Y; Zhang, QJ | 1 |
| Chatterjee, S; Choudhury, S; Das, M; Ghosh, P; Gupta, A; Paul, P; Pradhan, R | 1 |
| Bezard, E; Dufour, A; Facheris, MF; Ko, WK; Li, Q; McGuire, S; Pioli, E; Sherer, TB | 1 |
| Dollé, F; Hantraye, P; Kirik, D; Lavisse, S; Ozgur, M; Rbah-Vidal, L; Sahin, G; Thompson, LH | 1 |
| Cakmur, R; Sayın, S; Uğurel, B; Uzunel, F; Yaka, E; Yener, GG | 1 |
| Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Laitman, Y; Milgrom, R; Rosset, S; Vituri, A; Yahalom, G | 1 |
| Corrigan, F; Hassall, MM; Thornton, E; Vink, R | 1 |
| Chase, A | 1 |
| Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH | 1 |
| Ham, JH; Hong, JY; Kim, JS; Lee, I; Lee, JE; Lee, PH; Oh, JS; Sohn, YH; Sunwoo, MK | 1 |
| Lewitt, PA; Mouradian, MM | 1 |
| Deutch, AY | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Bezard, E; De Deurwaerdère, P; Engeln, M; Fernagut, PO; Li, Q | 1 |
| Visanji, NP | 1 |
| Bishop, C; Goldenberg, AA; Kampton, E; Lindenbach, D; Ostock, CY | 1 |
| Bagetta, V; Brambilla, R; Calabresi, P; Cerovic, M; Fasano, S; Ghiglieri, V; Giampà, C; Hardingham, N; Heuer, A; Marchisella, F; Morella, I; Papale, A; Pendolino, V; Picconi, B | 1 |
| Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M | 1 |
| Bezard, E; Girard, F; Keywood, C; Li, Q; Mutel, V; Pioli, EY; Poli, SM; Rascol, O; Tison, F | 1 |
| Christensen, MS; Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Rowe, JB; Siebner, HR | 2 |
| Amalric, M; Beurrier, C; Chabbert, D; Concetta, L; Jaouen, F; Kerkerian-Le Goff, L; Langa, F; Marie, H; Melon, C; Révy, D; Salin, P; Tafi, E | 1 |
| Fang, X; Guo, L; Jia, J; Liu, Z; Lu, W; Yang, Z; Ye, N; Zhang, A; Zhao, B; Zhao, J; Zhao, R; Zhen, X; Zheng, L | 1 |
| Auladell, C; Beas-Zarate, C; Camins, A; Canudas, AM; de Lemos, ML; Folch, J; Lazarowski, A; Pallàs, M; Pedros, I; Petrov, D | 1 |
| Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Bandak, S; Docu-Axelerad, A; Hauser, RA; Kenney, C; Kieburtz, KD; Kozyolkin, O; Lew, M; Meya, U; Neale, A; Olanow, CW; Pourcher, E; Resburg, C | 1 |
| Antonini, A; Poewe, W | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 2 |
| Decker, MW; McGregor, M; Quik, M; Zhang, D | 1 |
| Adjei, P; Akassi, J; Akpalu, A; Amboni, M; Bonetti, A; Cereda, E; Cham, M; Cilia, R; Fabbri, M; Pezzoli, G; Sarfo, FS | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 2 |
| Amanzio, M; Geminiani, G; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M | 1 |
| Dostrovsky, JO; Hodaie, M; Hutchison, WD; Liu, LD; Lozano, AM; Prescott, IA | 1 |
| Bastide, MF; Bezard, E; Boué-Grabot, E; Bourdenx, M; Dehay, B; Doudnikoff, E; Engeln, M; Fernagut, PO; Gross, CE; Li, Q; Pisani, A; Toulmé, E | 1 |
| Al Dakheel, A; Beaulieu-Boire, I; Fox, SH | 1 |
| Fox, SH; Johnston, TM | 1 |
| Iravani, M; Jackson, M; Jenner, P; McCreary, AC; Papathanou, M; Rose, S; Stockwell, K; Strang, I; Zeng, BY | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A | 1 |
| Chung, BH; Han, PL; Hwang, JH; Kang, Y; Kang, YM; Kim, KS; Kim, MR; Kim, YH; Lee, CH; Nam, KH; Park, HY; Park, TS; Ryu, YK | 1 |
| Dyavarshetty, B; Greven, AC; Mouradian, MM; Papa, SM; Potts, LF; Uthayathas, S | 1 |
| Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R | 1 |
| Di Paolo, T; Elbast, W; Feuerbach, D; Gomez-Mancilla, B; Grégoire, L; Weiss, M | 1 |
| Berretta, N; Bonito-Oliva, A; Cappellacci, L; Fisone, G; Ledonne, A; Mango, D; Mercuri, NB; Nisticò, R; Petrelli, R | 1 |
| Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N | 1 |
| Tomiyama, M | 1 |
| Di Paolo, T; Morin, N | 1 |
| Caboche, J; Feyder, M; Fisone, G; Hansen, K; LaPlant, Q; Nestler, EJ; Santini, E; Södersten, E; Spigolon, G; Vialou, V; Watts, EL | 1 |
| Anselmo-Franci, J; Carolino, RO; Cavalcanti-Kiwiatkoviski, R; Del Bel, E; Padovan-Neto, FE | 1 |
| Chotibut, T; Fields, V; Salvatore, MF | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Linsalata, G; Mazzucchi, S; Nicoletti, V; Ripoli, A | 1 |
| Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Sharma, JC; Vassallo, M | 1 |
| Bilbe, G; Bouhelal, R; Desrayaud, S; Enz, A; Flor, PJ; Gasparini, F; Kuhn, R; McAllister, K; Ofner, S; Vranesic, I | 1 |
| Danysz, W; Dekundy, A; Hofmann, M; Mela, F | 1 |
| Berg, D; Pilotto, A; Schaeffer, E | 1 |
| Canela, EI; Canet-Pons, J; Casadó, V; Cortés, A; Dopeso-Reyes, IG; Farré, D; Franco, R; Labandeira-García, JL; Lanciego, JL; Lluís, C; Mallol, J; Moreno, E; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ | 1 |
| Augimeri, A; Brusa, L; Caltagirone, C; Cerasa, A; Donzuso, G; Koch, G; Mangone, G; Morelli, M; Passamonti, L; Picazio, S; Ponzo, V; Quattrone, A; Salsone, M; Stampanoni Bassi, M | 1 |
| Bastide, MF; Bézard, E; Boraud, T; de la Crompe, B; Doudnikoff, E; Fernagut, PO; Gross, CE; Mallet, N | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Ando, K; Inoue, T; Itoh, T | 1 |
| Borgkvist, A; Mosharov, EV; Sulzer, D | 1 |
| Bernardi, G; Castelli, V; Cavaliere, F; D'Angelo, V; Ferrazzoli, D; Giorgi, M; Martorana, A; Morrone, LA; Sancesario, G; Sica, F; Sorge, R | 1 |
| Berardelli, A; Bloise, MC; Colosimo, C; Defazio, G; Di Biasio, F; Fabbrini, G; Latorre, A | 1 |
| Di Luca, M; Gardoni, F | 1 |
| Amalric, M | 1 |
| Antonini, A; Pilleri, M | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
| Aquino, CC; Fox, SH | 1 |
| Aguiar, AS; Bortolanza, M; Del-Bel, E; Padovan-Neto, FE; Prediger, RD; Raisman-Vozari, R; Tumas, V | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH | 1 |
| Ba, M; Kong, M; Ma, G | 1 |
| Alcacer, C; Carpentier, W; Charbonnier-Beaupel, F; Corvol, JC; During, M; Girault, JA; Hervé, D; Malerbi, M; Tahiri, K; Wang, C; Worley, PF; Xu, D | 1 |
| Ba, M; Kong, M; Liu, C; Qiu, H; Zhang, H; Zhang, Y | 1 |
| Antonini, A; Konitsiotis, S; Stathis, P | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F | 1 |
| Baracchi, F; Bassetti, CL; Galati, S; Kaelin-Lang, A; Möller, JC; Pace, M; Salvadè, A; Sarasso, S; Städler, C; Stanzione, P | 1 |
| Obeso, JA; Rothwell, JC | 1 |
| Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Ayton, S; Bertram, KL; Cheshire, P; Finkelstein, DI; Halliday, GM; Li, A; Ling, H; McLean, C; O'Sullivan, SS; Revesz, T; Storey, E; Williams, DR | 1 |
| Hauser, RA; Isaacson, S; McClure, NL; Pahwa, R; Ruby, AE; Sethi, K; Stempien, MJ; Struck, L; Tanner, CM; Truong, D; Went, GT | 1 |
| Kenney, C; Landrian, A; Lenderking, WR; Mannix, S; Petrillo, J; Schrag, AE | 1 |
| Ding, Y; Hitchcock, SA; Kang, UJ; Lim, SAO; McGehee, DS; Ray, WJ; Won, L; Xia, R | 1 |
| Bezard, E; Carta, M | 2 |
| Af Edholm Arvidsson, K; Björklund, A; Keywood, C; Lowe, DA; Rosenblad, C; Shankar, B; Svenningsson, P; Wictorin, K; Widner, H | 1 |
| Niccolini, F; Politis, M; Rocchi, L | 1 |
| Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV; Kook, S; Zurkovsky, L | 1 |
| Fahn, S; Kestenbaum, M | 1 |
| Berg, D; Liepelt-Scarfone, I; Maetzler, W; Reilmann, R; Sass, C; Schaeffer, E | 1 |
| Aschermann, Z; Bereczki, D; Dézsi, L; Dibó, G; Klivényi, P; Komoly, S; Kovács, N; Nagy, H; Takáts, A; Tóth, A; Valikovics, A; Varannai, L; Vécsei, L; Zemlényi, G | 1 |
| Bubser, M; Cenci, MA; Conn, PJ; Hopkins, CR; Iderberg, H; Jones, CK; Lindsley, CW; Maslava, N; Niswender, CM; Thompson, AD | 1 |
| Abrams, MB; Galter, D; Gellhaar, S; Marcellino, D | 1 |
| Cenci, MA; Fieblinger, T | 1 |
| Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Di Paolo, T; Goodenowe, D; Grégoire, L; Miville-Godbout, E; Mochizuki, A; Senanayake, V; Smith, T | 1 |
| Deshmukh, R; Sharma, S; Sharma, V; Singh, S; Singh, VP | 1 |
| Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N | 1 |
| Braithwaite, SP; Dyavar Shetty, BL; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Voronkov, M; Woo, JM | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; George, JA; Lindenbach, D; Surrena, MA | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CR; Schneider Medeiros, M; Schumacher-Schuh, AF | 1 |
| Carlsson, T; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Oertel, WH; Schäfer, MK; Weihe, E | 1 |
| Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Bezard, E; Carta, M; Chuan, Q; Fidalgo, C; Ko, WK; Li, Q; Stancampiano, R; Tronci, E | 1 |
| Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM | 1 |
| Gan, J; Liu, Z; Qi, C | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; Del-Bel, E; Dos Santos-Pereira, M; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Newman-Tancredi, A | 1 |
| Counsell, CE; Macleod, AD; Scott, NW | 1 |
| Bäckman, CM; Cadet, JL; Chiang, YH; Diaz, O; Hoffer, BJ; Ladenheim, B; Olson, L; Shan, L; Zhang, Y | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Guan, R; Staisch, J; Towle, VL; Warnke, P; Xie, T | 1 |
| Chaote, P; Dewhurst, F; Dotchin, CL; Gray, WK; Massawe, J; Walker, RW | 1 |
| Calandra-Buonaura, G; Chiari, L; Contin, M; Cortelli, P; Lopane, G; Mellone, S | 1 |
| Chammas, C; Soghomonian, JJ; Zhang, K | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Alcacer, C; Angela Cenci, M; Bastide, MF; Bézard, E; Bourdenx, M; Brambilla, R; Carta, M; Crossman, AR; De Deurwaerdère, P; Ding, Y; Engeln, M; Fasano, S; Fernagut, PO; Feyder, M; Fisone, G; Fox, S; Francardo, V; Gardoni, F; Groc, L; Guehl, D; Gurevich, EV; Jon Stoessl, A; Kang, UJ; Ko, WK; Meissner, WG; Mellone, M; Morari, M; Morelli, M; Navailles, S; Picconi, B; Quik, M; Rodriguez, MC; Simola, N; Steece-Collier, K; Tison, F; Tronci, E | 1 |
| Wictorin, K; Widner, H | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M; Rajput, A; Rajput, AH | 2 |
| Chang, JW; Chang, WS; Jung, HH; Kim, JH | 1 |
| Arabia, G; Augimeri, A; Cerasa, A; Donzuso, G; Mangone, G; Morelli, M; Passamonti, L; Quattrone, A; Salsone, M | 1 |
| Ferreira, JJ; Perez-Lloret, S; Rascol, O | 1 |
| Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY | 1 |
| Feld, Y; Finberg, JP; Gross, RE; Gutekunst, CA; Mewes, K; Papa, SM; Singh, A; Uthayathas, S | 1 |
| Bloem, BR; Borm, GF; Haaxma, CA; Horstink, MW; Lemmens, WA; Zijlmans, JC | 1 |
| Daniels, WM; Mabandla, MV; Ndlovu, BC | 1 |
| Bastide, MF; Bézard, E; Bido, S; Duteil, N | 1 |
| Garcia-Montes, JR; González-Granillo, A; Moratalla, R; Solís, O; Xu, M | 1 |
| Brugnoli, A; Morari, M; Napolitano, F; Usiello, A | 1 |
| Fedorova, NV; Gubanova, ЕN; Kulua, TK | 1 |
| Altunbaev, RA; Yakovleva, LA; Zalyalova, ZA | 1 |
| Ardolino, G; Bianchi, M; Bocci, T; Borroni, B; Cogiamanian, F; Cortese, F; Di Fonzo, A; Ferrucci, R; Padovani, A; Pittera, D; Priori, A; Turrone, R; Vergari, M | 1 |
| Case, DT; Collier, TJ; Divito, CB; Edwards, RH; Rubio, ME; Seal, RP; Sortwell, CE; Stancati, JA; Steece-Collier, K; Sulzer, D; Williams, SP; Zhang, H; Zhi, L | 1 |
| Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Perez, XA; Quik, M; Zhang, D | 1 |
| Beaudoin-Gobert, M; Sgambato-Faure, V; Tremblay, L | 1 |
| Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB | 1 |
| Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Girasole, AE; Nelson, AB | 1 |
| Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z | 1 |
| Feng, Z; Gupta, DK; Hang, X; Hasan, A; Liu, R | 1 |
| Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A | 1 |
| Tan, LC; Zhang, J | 1 |
| Bartlett, MJ; Estevez, M; Falk, T; Heien, ML; Joseph, RM; Laude, ND; Lazarus, LB; LePoidevin, LM; Parent, KL; Sherman, SJ | 1 |
| Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L | 1 |
| Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E | 1 |
| Stoessl, AJ | 1 |
| Adams, JR; Boileau, I; Furukawa, Y; Guttman, M; Houle, S; Kish, SJ; Payer, DE; Rusjan, P; Tong, J; Wilson, AA | 1 |
| Alam, M; Jin, X; Krauss, JK; Schwabe, K | 1 |
| Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Carrault, G; Jalloul, N; L'Hostis, P; Porée, F; Viardot, G | 1 |
| Bonato, P; Daneault, JF; Golabchi, FN; Lee, SI; Paganoni, S; Patel, S; Shih, L | 1 |
| Brys, I; Halje, P; Ivica, N; Petersson, P; Richter, U; Tamtè, M | 1 |
| Carta, M; Cenci, MA | 1 |
| Nicoletti, A; Zappia, M | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Baeken, C; Cordenier, A; De Keyser, J; De Raedt, S; Flamez, A; Michiels, V; Parys, E; Smetcoren, S; Van Merhaegen-Wieleman, A | 1 |
| De Deurwaerdère, P; Miguelez, C; Navailles, S; Ugedo, L | 1 |
| Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT | 1 |
| Gurevich, EV | 1 |
| Benussi, A; Brusa, L; Caltagirone, C; Di Lorenzo, F; Koch, G; Picazio, S; Ponzo, V | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Fülöp, F; Majláth, Z; Toldi, J; Vécsei, L | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK | 1 |
| Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M | 1 |
| Barbon, A; Bono, F; Busi, C; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Piccini, P; Politis, M; Roussakis, AA; Towey, D | 1 |
| Bordia, T; Heiss, J; Perez, XA; Quik, M; Zhang, D | 1 |
| Cerasa, A; Dileone, M; Obeso, I; Quattrone, A | 1 |
| Azulay, JP; Boulamery, A; Eusebio, A; Gayraud, D; Simon, N; Viallet, F | 1 |
| Berg, D; Braatz, U; Ferreira, JJ; Graessner, H; Heger, T; Hobert, MA; Hucker, S; Maetzler, W; Manoli, Y; Meckler, S; Ramsperger, R; Serrano, JA; van Uem, J | 1 |
| Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Nielsen, SH; Siebner, HR | 1 |
| Hwang, E; Hwang, O; Jeon, SR; Lee, CJ; Min, J; Suh, JK; Yoon, HH | 1 |
| Arabia, G; Barone, P; Iliceto, G; Lamberti, P; Marconi, R; Morgante, L; Mostile, G; Nicoletti, A; Nicoletti, G; Quattrone, A; Zappia, M | 1 |
| Asensio, MJ; García-Sanz, P; Herranz, AS; Moratalla, R; Solís, O | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Azulay, JP; Berg, D; Broussolle, E; Ceballos-Baumann, A; Corvol, JC; Defebvre, L; Derkinderen, P; Di Paolo, T; Durif, F; Eggert, K; Espay, AJ; Feigin, A; Feuerbach, D; Geny, C; Gomez-Mancilla, B; Gostkowski, M; Hockey, HU; Houeto, JL; Jaeger, J; Jakab, A; Johns, D; Linazasoro, G; Maruff, P; Rascol, O; Rozenberg, I; Schwarz, J; Sovago, J; Stocchi, F; Storch, A; Tranchant, C; Trenkwalder, C; Weiss, M; Zhang, L | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF; Zhang, Y | 1 |
| Moustafa, YM; Teema, AM; Zaitone, SA | 1 |
| Dhall, R; Kreitzman, DL | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K | 1 |
| Aguilera, J; Candalija, A; Limón, ID; Mendieta, L; Palafox-Sánchez, V; Ramírez-García, G | 1 |
| Jankovic, J; Vijayakumar, D | 1 |
| Kanaya, Y; Kono, R; Kuriyama, M; Shiga, Y; Shimoe, Y; Takeshima, S | 1 |
| Dronamraju, N; Graf, A; Kenney, C; Poewe, W; Shah, A; Stocchi, F; Trenkwalder, C; von Raison, F | 1 |
| Bezard, E; Corvol, JC; Durif, F; Eggert, K; Goetz, CG; Isaacson, S; Keywood, C; Lew, M; Poli, SM; Rascol, O; Tison, F; Trenkwalder, C; Wakefield, M | 1 |
| Eskow Jaunarajs, KL; Figge, DA; Standaert, DG | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Schäfer, MK; Weihe, E | 1 |
| Alty, JE; Cosgrove, J; Jamieson, S; Lones, MA; Smith, SL; Trefzer, MA; Turner, AP; Tyrrell, AM | 1 |
| da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M; Guimarães, FS | 1 |
| Cao, X; Hou, D; Li, S; Ping, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Fiszer, U; Michałowska, M; Szatanowski, T | 1 |
| Chu, Y; Isacson, O; Kordower, JH; Redmond, DE; Vinuela, A | 1 |
| Bezard, E; Camus, SM; Ko, WKD; Li, Q; McGuire, S; Pioli, EY; Yang, J | 1 |
| Chiou, SM | 1 |
| Benitez-Rivero, S; Cheeran, B; Del-Olmo, MF; Hu, M; Jenkinson, N; Koch, G; Lago-Rodriguez, A; Ponzo, V | 1 |
| Brzuszkiewicz-Kuzmicka, G; Gorecki, W; Mossakowski, Z; Sobstyl, M; Zabek, M; Zaczynski, A | 1 |
| Cenci, MA; Hopkins, CR; Maslava, N; Sebastianutto, I | 1 |
| Aguado, C; Lujan, R; Moratalla, R; Solis, O; Suarez, LM | 1 |
| Ba, M; Guan, L; Kong, M; Yi, M; Zhang, H | 1 |
| Bariotto, K; Bortolanza, M; Del-Bel, E; Dos-Santos-Pereira, M; Raisman-Vozari, R | 1 |
| Hardy, GA; Lee, HJ; Schallert, T; Smith, ES | 1 |
| Hallett, M; Li, J; Li, X; Li, Y; Zhang, Y; Zhuang, P | 1 |
| Angius, F; Batetta, B; Carboni, E; Carta, AR; Cossu, G; Espa, E; Fenu, S; Giuffrida, A; Jadžić, D; Lecca, D; Mulas, G; Pillai, E; Simbula, G; Spiga, S; Spolitu, S | 1 |
| Choi, YY; Dhawan, V; Dresel, C; Eidelberg, D; Holtbernd, F; Jourdain, VA; Ma, Y; Tang, CC | 1 |
| Bonenfant, J; Drapier, S; Haegelen, C; Houvenaghel, JF; Naudet, F; Sauleau, P; Vérin, M | 1 |
| Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z | 1 |
| Alberico, SL; Kim, YC; Lence, T; Narayanan, NS | 1 |
| James, P; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Yahia-Cherif, L | 1 |
| Cohen, OS; Elincx-Benizri, S; Greenbaum, L; Hassin-Baer, S; Israeli-Korn, S; Shabat, C; Stein, E; Strauss, H; Warmann-Alaluf, N; Yahalom, G | 1 |
| Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P | 1 |
| Wang, Q; Zhang, W | 1 |
| Mizuno, Y; Origasa, H; Shimoda, S | 1 |
| Alonso-Frech, F; Catalán, MJ; Escribano, PM | 1 |
| Frouni, I; Gourdon, JC; Hamadjida, A; Harraka, MJ; Huot, P; Kwan, C; Nuara, SG; Sid-Otmane, L; Veyres, N | 1 |
| Abreu, D; Albuquerque, L; Carvalho, H; Cattoni, B; Coelho, M; Correia-Guedes, L; Domingos, J; Fabbri, M; Ferreira, AG; Ferreira, JJ; Freitas, V; Godinho, C; Lobo, PP; Pereira, JM; Reimão, S; Rosa, MM | 1 |
| Cicero, CE; Contrafatto, D; Dibilio, V; Luca, A; Mostile, G; Nicoletti, A; Raciti, L; Sciacca, G; Vasta, R; Zappia, M | 1 |
| Bezard, E; Fernagut, PO; Frank, MJ; Grace, AA; Napier, TC; Obeso, J; Rodriguez-Oroz, M; Sgambato-Faure, V; Voon, V | 1 |
| Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H | 1 |
| Herz, DM; Løkkegaard, A; Siebner, HR; Thomsen, BL | 1 |
| Bimpisidis, Z; Cenci, MA; Lundblad, C; Maslava, N; Öberg, CM | 1 |
| A Figge, D; Standaert, DG | 1 |
| Betz, AJ; Bibbiani, F; Chase, TN; Davis, RE; Kielaite, A; Salamone, JD; Vanover, KE; Weber, SM; Weiner, DM | 1 |
| Bishop, C; Dupre, KB; Eskow, KL; Klioueva, A; Lormand, L; Negron, GE; Park, JY; Steiniger, A | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A | 2 |
| Bourdeix, I; Damier, P; Rerat, K; Viallet, F; Ziegler, M | 1 |
| Bagetta, V; Barone, I; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C | 1 |
| Carta, AR; Frau, L; Morelli, M; Pinna, A; Pontis, S | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Busi, C; Fiorentini, C; Missale, C; Spano, P | 1 |
| Bordia, T; Campos, C; Huang, L; Quik, M | 1 |
| Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Morè, L; Nagel, J; Pietraszek, M | 1 |
| Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Brotchie, JM; Chuang, R; Fox, SH | 1 |
| Sethi, K | 1 |
| Kieburtz, K | 1 |
| Albanese, A; Del Sorbo, F | 1 |
| Ballerini, R; Hauser, RA; Mori, A; Roberts, JW; Shulman, LM; Sussman, NM; Trugman, JM | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Bezard, E; Gerfen, CR; Nadjar, A | 1 |
| Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ | 1 |
| Cardoso, F; Gomide, L; Kummer, A; Teixeira, AL | 1 |
| Bhatia, K; Filipović, SR; Rothwell, JC; van de Warrenburg, BP | 1 |
| Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C | 1 |
| Barker, RA; Bhatia, KP; Cheeran, B; Edwards, MJ; Foltynie, T; Rothwell, JC; Schneider, SA; Weinberger, D; Williams-Gray, CH | 1 |
| Caron, MG; Gainetdinov, RR; Hallett, PJ; Isacson, O; Patterson, M; Reske-Nielsen, C; Sotnikova, TD; Vinuela, A | 1 |
| Freeman, T; Godbold, J; Goetz, CG; Gracies, JM; Kordower, JH; Obeso, JA; Olanow, CW; Stoessl, AJ | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C | 1 |
| Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM | 1 |
| Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Fahn, S | 5 |
| Hattori, N; Ohizumi, H; Tanaka, S; Yoritaka, A | 1 |
| Murata, M | 2 |
| Buck, K; Ferger, B | 4 |
| Destée, A; Moreau, C | 1 |
| Pal, PK; Prashantha, DK | 1 |
| Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Bodenheimer, RE; Davis, TL; Dawant, BM; Li, R; Rao, AS; Voight, C | 1 |
| Bono, G; Garavaglia, P; Guidotti, M; Leva, S; Pianezzola, C; Raudino, F; Riboldazzi, G | 1 |
| Ben-Shlomo, Y; Morris, HR; Wickremaratchi, MM | 1 |
| García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| af Bjerkén, S; Cenci, MA; Gerhardt, GA; Lundblad, M; Pomerleau, F; Strömberg, I | 1 |
| Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P | 1 |
| Baker, WL; Coleman, CI; Patel, AA; Reinhart, K; Talati, R | 1 |
| Lyons, KE; Pahwa, R | 2 |
| Pisani, A; Shen, J | 1 |
| Bhidayasiri, R; Ling, H | 1 |
| Berger, SP; Brudney, EG; Foley, K; Johnson, SW; Meshul, CK; Paquette, MA | 1 |
| Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P | 1 |
| Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V | 1 |
| Barnum, CJ; Bishop, C; Dickinson, SO; Dupre, KB; Eskow, KL; Park, JY | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Mela, F; Recchia, A; Rylander, D | 1 |
| Berthet, A; Bezard, E; Bloch, B; Cador, M; Doudnikoff, E; Porras, G; Stark, H | 1 |
| Abbruzzese, G | 1 |
| Antonini, A; Odin, P; Wolters, E | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Vercammen, L | 1 |
| Collier, TJ; Maries-Lad, E; Soderstrom, KE; Sortwell, CE; Steece-Collier, K | 1 |
| García-Gutiérrez, MS; Ledent, C; Leiva, C; Leza, JC; Manzanares, J; Molina, JA; Pérez-Nievas, BG; Pérez-Rial, S | 1 |
| Durairajan, SS; Fong, WL; Gao, J; Kum, WF; Li, M; Lu, JH; Man, SC; Xie, LX | 1 |
| Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E | 1 |
| Astradsson, A; Brownell, AL; Choi, JK; Hallett, PJ; Isacson, O; Jenkins, BG; Levesque, MA; McDowell, JS; Spealman, RD | 1 |
| Edelstyn, NM; Ellis, SJ; Jenkinson, PM; Stephens, R | 1 |
| Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R | 1 |
| Montgomery, EB | 3 |
| Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N | 1 |
| Blond, S; Defebvre, L; Delval, A; Destée, A; Devos, D; Dujardin, K; Kreisler, A; Krystkowiak, P; Salleron, J; Simonin, C; Tir, M | 1 |
| Emre, M; Jenner, P; Poewe, W; Schapira, AH | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Klivényi, P; Vécsei, L | 1 |
| Brusa, L; Caltagirone, C; Carrillo, F; Koch, G; Lo Gerfo, E; Mir, P; Oliveri, M; Stanzione, P; Torriero, S | 1 |
| Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Scheller, D; Smith, LA; Stockwell, KA; Tayarani-Binazir, K | 1 |
| Fisone, G; Greengard, P; Heiman, M; Santini, E; Valjent, E | 1 |
| Bishop, C; Dupre, KB; Jaunarajs, KL; Kelly, C; Klioueva, A; Moore, A; Steiniger, A | 1 |
| Di Paolo, T; Gilbert, F; Grégoire, L; Lévesque, D; Mahmoudi, S; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P | 1 |
| Aguilar, E; Bonastre, M; Jiménez, A; Marin, C | 2 |
| Soghomonian, JJ; Yamamoto, N | 1 |
| Berardelli, A; Bloise, M; Colosimo, C; Defazio, G; Fabbrini, G; Suppa, A | 1 |
| Aguilar, E; Barbanoj, M; Kulisevsky, J; Marin, C; Pérez, V; Rubio, A | 1 |
| Brocco, M; Mela, F; Millan, MJ; Morari, M | 1 |
| Balfour, RH; Jackson, MJ; Jenner, P; Rose, S; Zeng, BY | 1 |
| Maertens de Noordhout, A | 1 |
| Barichella, M; Cereda, E; Pezzoli, G | 1 |
| Andree, TH; Hansard, M; Hoffman, DC; Hurtt, MR; Jackson, MJ; Jenner, P; Kehne, JH; Pitler, TA; Smith, LA; Stack, G | 1 |
| Bode, M | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Rose, S; Scheller, DK; Smith, LA; Stockwell, KA | 1 |
| Bezard, E; Brotchie, JM; Dunah, AW; Hallett, PJ; Kobylecki, C; Li, Q; Ravenscroft, P; Silverdale, MA | 1 |
| Chelaru, MI; Duval, C; Jog, M | 1 |
| Buck, K; Ferger, B; Voehringer, P | 2 |
| Baunez, C; Bezard, E; Fernagut, PO; Juncos, JL; Obeso, JA; Pavon, N; Rodriguez, M; Voon, V; Wickens, J | 1 |
| Di Rocco, A; Howard, J; Varanese, S | 1 |
| Di Paolo, T; Lévesque, D; Morissette, M; Samadi, P | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I | 1 |
| Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H | 1 |
| Bureau, G; Chagniel, L; Cyr, M; Lebel, M | 1 |
| Brodsky, MA; Nutt, JG; Park, BS | 1 |
| Adam, OR; Ferrara, JM; Ondo, WG | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N | 1 |
| Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S | 1 |
| Bonanni, L; Cossu, G; Manca, D; Onofrj, M; Stocchi, F; Thomas, A | 1 |
| Cenci, MA; Ohlin, KE; Rylander, D | 1 |
| Bezard, E; Guigoni, C | 1 |
| Stocchi, F | 3 |
| Antonini, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P | 1 |
| Cenci, MA; Ohlin, KE | 1 |
| Berthet, A; Bezard, E | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Huot, P; Johnston, T; Reyes, G; Visanji, N | 1 |
| Auff, E; Haubenberger, D; Hochschorner, G; Katzenschlager, R; Kloiber, I; Ott, E; Poewe, W; Ransmayr, G; Schwingenschuh, P; Seppi, K; Wolf, E | 1 |
| Bordia, T; Campos, C; McIntosh, JM; Quik, M | 1 |
| Duval, C; Edwards, R; Jog, M; Mann, RK; Zhou, J | 1 |
| Chung, KA; Horak, F; Lobb, BM; McNames, J; Nutt, JG | 1 |
| Chung, KA; Holford, NH; Nutt, JG | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; McIldowie, MJ; Piggott, MJ | 1 |
| Gil, S; Koh, H; Lee, J; Park, C | 1 |
| Lewitt, PA | 2 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B | 1 |
| Glass, GA; Ku, S | 1 |
| Fukaya, C; Katayama, Y; Kobayashi, K; Nishikawa, Y; Ogasawara, K; Ogawa, A; Oshima, H; Yamamoto, T | 1 |
| Marconi, S; Stocchi, F | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Adams, B; Earl, NL; Gray, AM; Hauser, RA; Lyons, KE; Olanow, W; Pahwa, R; Sethi, K; Stern, M; Watts, RL | 1 |
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
| Nodel', MR | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 2 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Winkelmolen, L | 1 |
| Kleiner-Fisman, G; Lang, AE; Lozano, A; Moro, E; Poon, YY | 1 |
| Fisone, G; Santini, E; Valjent, E | 2 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Mink, JW; Zinner, SH | 1 |
| Kirik, D; Sahin, G; Ulusoy, A | 1 |
| Calabresi, P; Ghiglieri, V; Picconi, B | 2 |
| Belujon, P; Grace, AA; Lodge, DJ | 1 |
| Chen, CC; Chen, RS; Grattan-Smith, P; Jung, SM; Lai, SC; Lang, AE; Lin, YW; Lu, CS; Sugo, E; Wu-Chou, YH | 1 |
| Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Alken, RG; Cenci, MA; Malmlöf, T; Rylander, D; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Adeli, GM; Arenovich, T; Fox, SH; Hung, SW; Lang, AE | 1 |
| Espay, AJ; Metman, LV; O'Sullivan, JD; Paviour, DC; Revilla, FJ; Schmidt, RE | 1 |
| Bateup, HS; Birnbaum, S; Fisone, G; Greengard, P; Nestler, EJ; Santini, E; Shen, W; Surmeier, DJ; Valjent, E | 1 |
| Cenci, MA; Konradi, C | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Parent, A; Rose, S; Zeng, BY | 1 |
| Koch, G | 1 |
| Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H | 1 |
| Aceves, J; Erlij, D; Florán, B; Lopéz-Santiago, LM; Rangel-Barajas, C; Silva, I | 1 |
| Kaczmarska, J; Konradi, C; Luksik, AS; Naydenov, AV; Vassoler, F | 1 |
| Grählert, X; Löhle, M; Reichmann, H; Schneider, C; Schwanebeck, U; Schwarz, J; Storch, A; Strecker, K; Wolz, M | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Antonini, A; Burkhard, PR; Poewe, W; Vingerhoets, F; Zijlmans, JC | 1 |
| Inoue, T; Koyama, M; Ogata, A; Tani, Y | 1 |
| Calabresi, P; Di Filippo, M; Ghiglieri, V; Picconi, B; Tambasco, N | 1 |
| Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D | 1 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Cho, J; Jeon, BS; Lee, EK; Lee, JY; Park, SS | 1 |
| Bartolini, WP; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Milne, GT; Pearson, JP; Sykes, KA; Wakefield, JD | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Winkelmolen, L | 1 |
| Alegre, M; Artieda, J; Garcia-Garcia, D; Guridi, J; López-Azcárate, J; Obeso, JA; Rodriguez-Oroz, MC; Toledo, J; Valencia, M | 1 |
| Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Hametner, E; Poewe, W; Seppi, K | 1 |
| Cantuti-Castelvetri, I; Crittenden, JR; Graybiel, AM; Hernandez, LF; Hollingsworth, ZR; Keller-McGandy, CE; Kett, LR; Landy, A; Nillni, EA; Saka, E; Standaert, DG; Young, AB | 1 |
| da-Silva, CA; Del Bel, EA; Novaretti, N; Padovan-Neto, FE; Tumas, V | 1 |
| Bougia, P; Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tzallas, AT | 1 |
| Chapman, J; Cohen, OS; Hassin-Baer, S; Katzav, A; Korczyn, AD; Molchadski, I; Nitzan, Z | 1 |
| Bezard, E; Brambilla, R; Cenci, MA; Cerovic, M; D'Antoni, A; Doveró, S; Fasano, S; Francardo, V; Indrigo, M; Qin, L | 1 |
| Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH | 1 |
| Bagetta, V; Calabresi, P; Di Filippo, M; Fusco, FR; Ghiglieri, V; Giampà, C; Paillè, V; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A | 1 |
| Bogdanov, RR; Kotov, SV; Kunitsyna, AN; Turbina, LG | 1 |
| Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ | 1 |
| Hu, WD; Huang, YX; Li, D; Liu, CF; Luo, WF | 1 |
| Daly, CS; Dunnett, SB; Lane, EL; Smith, GA | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Rascol, O | 4 |
| Andersson, D; Cenci, MA; Francardo, V; Nissbrandt, H; Popovic, N; Recchia, A | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Johns, D; Morin, N; Ouattara, B; Sahasranaman, S; Vranesic, I | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Brotchie, JM; Fahana, N; Johnston, TH; Khademullah, CS; Lam, D; Lo, C; Nash, JE; Talwar, S; Thiele, SL; Warre, R | 1 |
| Ahmed, I; Bose, SK; Brooks, DJ; Hammers, A; Hotton, G; Pavese, N; Ramlackhansingh, A; Turkheimer, F | 1 |
| Del-Bel, E; Lazzarini, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Arabia, G; Cerasa, A; Lanza, P; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Aquilonius, SM; Askmark, H; Nyholm, D | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY | 1 |
| Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G | 1 |
| Duker, AP; Espay, AJ; Gartner, M; Revilla, FJ; Sahay, A; Shukla, R; Vaughan, JE | 1 |
| Dotchin, C; Jusabani, A; Walker, R | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Abi-Saab, W; Berg, D; Cooke, K; Csoti, I; Di Paolo, T; Eggert, K; Gasparini, F; Godau, J; Gomez-Mancilla, B; Hariry, S; Huber, H; Johns, D; Morelli-Canelo, M; Ries, V; Schneider, C; Stamelou, M; Storch, A; Trenkwalder, C; Vandemeulebroecke, M; Wolz, M | 1 |
| Lee, MS; Lyoo, CH | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G | 1 |
| Barroso-Chinea, P; Conte-Perales, L; Gómez-Bautista, V; Lanciego, JL; Luquin, N; Rico, AJ; Roda, E; Sierra, S | 1 |
| Cohen, OS; Efrati, L; Hassin-Baer, S; Korczyn, AD; Kozlova, E; Molchadski, I; Nitzan, Z; Tunkel, O | 1 |
| Af Bjerkén, S; Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK | 1 |
| Bloem, BR; Hovestadt, A; van Laar, T; Vlaar, A | 1 |
| Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 2 |
| Ahmed, I; Bose, SK; Brooks, DJ; Pavese, N; Ramlackhansingh, AF; Turkheimer, FE | 1 |
| Bishop, C; Dupre, KB; George, J; Jaunarajs, KL; Krolewski, D; Ostock, CY; Walker, PD; Walters, H | 1 |
| Grady, SR; Huang, LZ; Quik, M | 1 |
| Irie, S; Kanazawa, N; Mochizuki, H; Nomura, Y; Ryoh, M; Segawa, M | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE | 1 |
| Bido, S; Marti, M; Morari, M | 1 |
| Chen, RS; Chuang, WL; Huang, YZ; Lu, CS; Rothwell, JC | 1 |
| Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM | 1 |
| Calabresi, P; Di Luca, M; Gardoni, F; Pendolino, V; Picconi, B; Sgobio, C | 1 |
| Ballinari, P; Kaelin-Lang, A; Kipfer, S; Schüpbach, WM; Stephan, MA | 1 |
| Cai, XY; Fang, Q; Kong, XM; Ning, P; Xu, YJ; Xue, SR; Zhang, B | 1 |
| McKeown, MJ; Oishi, MM; Stevenson, JK; Talebifard, P; Ty, E | 1 |
| Fernandez, HH; Foote, KD; Hwynn, N; Iyer, SS; Jacobson, CE; Malaty, IA; Okun, MS; Oyama, G; Rodriguez, RL; Zeilman, P | 1 |
| Iravani, MM; Jenner, P | 1 |
| Johnston, TH; Lane, EL | 1 |
| Bezard, E; Fisone, G | 1 |
| Brotchie, J; Jenner, P | 1 |
| Lozano, AM; Sankar, T | 1 |
| Brusa, L; Ceravolo, R; Iani, C; Kiferle, L; Koch, G; Monteleone, F; Schillaci, O; Stanzione, P | 1 |
| Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E | 1 |
| Dunnett, SB; Heuer, A; Lane, EL; Smith, GA | 1 |
| Brotchie, JM; Visanji, NP | 1 |
| Crossman, AR; Hill, MP; Kobylecki, C; Ravenscroft, P | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Espay, AJ; Giuffrida, JP; Heldman, DA; Mera, TO; Payne, M | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Bido, S; Cenci, MA; Marti, M; Mela, F; Morari, M | 1 |
| Ondo, WG | 1 |
| Chagniel, L; Cyr, M; Lebel, M; Robitaille, C | 1 |
| Becker, N; Munhoz, RP; Teive, HA | 1 |
| Arbelo, JM; del Val, JL; Sesar, A | 1 |
| Gerlach, M; Riederer, P; Scheller, D | 1 |
| Arabia, G; Cerasa, A; Gioia, MC; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Jann, MW | 1 |
| Alstrup, AK; Doudet, DJ; Gjedde, A; Høltzermann, M; Jakobsen, S; Landau, AM; Møller, A; Nahimi, A; Simonsen, M; Vang, K; Wegener, G | 1 |
| Iravani, MM; Jenner, P; McCreary, AC | 1 |
| Barrow, R; Errico, F; Kim, S; Mealer, RG; Napolitano, F; Shahani, N; Snyder, SH; Subramaniam, S; Tyagi, R; Usiello, A | 1 |
| Giuffrida, A; Macheda, T; Martinez, A; Morgese, MG; Trabace, L | 1 |
| Barroso-Chinea, P; Baufreton, J; Berthet, A; Bezard, E; Bloch, B; Dehay, B; Fasano, S; Giros, B; Li, Q; Martin-Negrier, ML; Martinez, A; Nosten-Bertrand, M; Porras, G; Thiolat, ML | 1 |
| Cheshire, PA; Williams, DR | 1 |
| Bronzova, J; Hauser, RA; Lang, AE; Rascol, O; Sampaio, C; Theeuwes, A; van de Witte, SV | 1 |
| Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lim, SY | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Aron, AR; Obeso, J | 1 |
| Duval, C; Edwards, R; Fenney, A; Jog, M; Mann, RK; Zhou, J | 1 |
| Djaldetti, R; Gad, A; Khlebtovsky, A; Melamed, E; Rigbi, A; Steiner, I; Ziv, I | 1 |
| Ago, Y; Hiramatsu, N; Matsuda, T; Ota, Y; Takahashi, T; Takuma, K; Tanaka, T | 1 |
| Björklund, A; Carta, M; Shin, E; Tronci, E | 1 |
| Francardo, V; Iderberg, H; Pioli, EY | 1 |
| Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tsouli, S; Tzallas, AT | 1 |
| Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA | 1 |
| Ardouin, C; Aya Kombo, M; Benabid, AL; Bichon, A; Bosson, JL; Broussolle, E; Carnicella, S; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Polo, G; Quesada, JL; Schmitt, E; Seigneuret, E; Thobois, S; Xie, J | 1 |
| Alcacer, C; Gaven, F; Girault, JA; Hervé, D; Santini, E; Valjent, E | 1 |
| Eidelberg, D; Feigin, A; Niethammer, M | 1 |
| De Deurwaerdère, P; Navailles, S | 1 |
| Adamaszek, M; Beck, J; Ohm, S; Schwarz, J; Strecker, K; Wegner, F | 1 |
| Billet, F; Costentin, J; Dourmap, N | 1 |
| Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Balachandran, A; Joseph, T; Kishore, A; Meunier, S; Popa, T; Velayudhan, B | 1 |
| Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R | 1 |
| Mallya, U; Pahwa, R; Suh, DC | 1 |
| Balbi, P; Bertotti, G; Boveri, N; Comi, C; Felicetti, G; Frazzitta, G; Leva, S; Maestri, R; Morelli, M; Pelosin, E; Riboldazzi, G; Turla, M | 1 |
| Sabetay, S; Schwartz, M | 1 |
| Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G | 1 |
| Tarsy, D | 2 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 2 |
| Debicki, D; Jog, M | 1 |
| Chen, R; Elahi, B; Phielipp, N | 1 |
| Arabia, G; Augimeri, A; Cerasa, A; Gioia, MC; Morelli, M; Novellino, F; Quattrone, A; Salsone, M | 1 |
| Derkinderen, P; Lebouvier, T; Pouclet, H | 1 |
| Coppard, N; Hauser, RA; Leinonen, M; Lewitt, PA; Lu, M; Nicholas, AP; Savola, JM; Weiner, W | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Fischer, K; Lettfuss, NY; Pichler, BJ; Sossi, V; von Ameln-Mayerhofer, A | 1 |
| Al Hadithy, AF; Alifirova, VM; Brouwers, JR; Fedorenko, OY; Freidin, MB; Govorin, NV; Ivanova, SA; Loonen, AJ; Pechlivanoglou, P; Rudikov, EV; Semke, AV; Sorokina, VA; Wilffert, B; Zhukova, IA | 1 |
| Daragon, A; Derrey, S; Lefaucheur, R; Maltête, D; Nicolau, J; Verdet, M | 1 |
| Aristieta, A; Azkona, G; Miguelez, C; Ruiz-Ortega, JÁ; Sagarduy, A; Sanchez-Pernaute, R; Ugedo, L | 1 |
| Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Brotchie, JM; Damude, S; Fox, SH; Huot, P; Johnston, TH; Jones, SW; Rusche, JR | 1 |
| Broussolle, E; Castrioto, A; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, SC | 1 |
| Barbin, L; Damier, P; Leux, C; Meyniel, C; Nguyen, JM; Pereon, Y; Sauleau, P | 1 |
| Bordia, T; Chin, M; Mallela, A; McIntosh, JM; Perez, XA; Quik, M | 1 |
| Berthet, A; Bezard, E; Bloch, B; Boué-Grabot, E; Choquet, D; Chuan, Q; Dehay, B; Doudnikoff, E; Dovero, S; Groc, L; Ladepeche, L; Li, Q; Martin-Négrier, ML; Martinez, A; Normand, E; Porras, G | 1 |
| Breger, LS; Dunnett, SB; Lane, EL | 1 |
| Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M; Parent, M | 1 |
| Duty, S | 1 |
| Bhatia, KP; Filipović, SR; Rothwell, JC | 1 |
| Bezard, E; Brambilla, R; Calabresi, P; Fasano, S; Guerrini, R; Li, Q; Marti, M; Morari, M; Morella, I; Rodi, D; Simonato, M; Tozzi, A | 1 |
| Altmann, V; Callegari-Jacques, SM; Fagundes, PT; Francisconi, CL; Hutz, MH; Monte, TL; Rieck, M; Rieder, CR; Schumacher-Schuh, AF | 1 |
| Calleja-Castillo, J; Cervantes-Arriaga, A; Corona, T; Morales-Briceño, H; Rodríguez-Violante, M | 1 |
| Cenci, MA; Halje, P; Mohammed, M; Petersson, P; Richter, U; Tamtè, M | 1 |
| Bodenheimer, RE; Davis, T; Dawant, BM; Fang, J; Hedera, P; Li, R; Phibbs, F; Rao, AS | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Arai, A; Baba, M; Kimura, T; Migita, K; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Wakabayashi, K; Yamada, J | 1 |
| Brotchie, JM; Fox, SH; Hill, MP; Huot, P; Johnston, TH; Koprich, JB; Snoeren, T | 1 |
| Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Jarvie, K; Koprich, JB; Lang, AE; Seeman, P | 1 |
| Fukushima, FB; Valle, AP; Vidal, EI; Villas Boas, PJ | 1 |
| Barbon, A; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Chen, JF; Eberly, S; Kamp, C; Lang, AE; McDermott, MP; Messing, S; Oakes, D; Schwarzschild, MA; Tanner, CM; Tennis, M; Togasaki, D; Wills, AM | 1 |
| Li, L; Zhou, FM | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Bordia, T; McIntosh, JM; Quik, M | 1 |
| Hong, JY; Kim, KM; Lee, PH; Sohn, YH; Sunwoo, MK | 1 |
| Berger, SP; Bhide, N; Bishop, C; Goldenberg, AA; Lindenbach, D; Paquette, MA; Surrena, MA | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Artuch, R; Cormand, B; Dinopoulos, A; Garzía-Cazorla, A; Orfanou, I; Ormazabal, A; Pons, R; Serrano, M; Syrengelas, D; Youroukos, S | 1 |
| Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Antic, R; Rice, JE; Thompson, PD | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Calon, F; Di Paolo, T | 1 |
| Cheetham, SC; Hansard, MJ; Jackson, MJ; Jenner, P; Smith, LA | 2 |
| Coelho, C; Goberman, AM | 2 |
| Collins, DR; Wanklyn, P | 1 |
| Bonhomme, C; Braceras, R; Chezaubernard, C; Del Signore, S; Hansard, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA; Tel, BC | 1 |
| Choe, GY; Choi, YL; Jeon, BS; Kim, JM; Lee, KH | 1 |
| Cenci, MA | 3 |
| Chase, TN; Oh, JD | 1 |
| Verhagen Metman, L | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Katzenschlager, R; Lees, AJ | 1 |
| Kondo, T | 1 |
| Djaldetti, R; Melamed, E | 1 |
| Ohye, C; Shibazaki, T | 1 |
| Benabid, AL; Esselink, RJ; Moro, E; Pollak, P | 1 |
| Bibbiani, F; Chase, TN; Oh, JD | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Grégoire, L; Grondin, R; Hadj Tahar, A | 1 |
| Widner, H | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV | 1 |
| Onofrj, M; Stocchi, F; Vacca, L | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Brotchie, JM; Nicholson, SL | 1 |
| Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M | 1 |
| Kempster, PA; McColl, CD; Reardon, KA; Shiff, M | 1 |
| Lees, AJ; Manson, AJ; Turner, K | 1 |
| Al-Barghouthy, G; Jackson, M; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, L; Zeng, BY | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Bonnet, AM; Houeto, JL | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Gielen, SC; Horstink, MW; Keijsers, NL | 2 |
| Cho, IS; Ha, JH; Im, JH; Lee, MC | 1 |
| Lang, AE; Marras, C | 1 |
| Zegers de Beyl, D | 1 |
| Bernardini, S; Bonuccelli, U; Dell'Agnello, G; Gambaccini, G; Lucetti, C; Petrozzi, L; Rossi, G | 1 |
| Bergamasco, B; Bosticco, E; Lanotte, M; Lopiano, L; Perozzo, P; Rizzone, M; Tavella, A; Torre, E | 1 |
| Albin, RL; Frey, KA | 1 |
| Gordin, A; Larsen, JP; Leinonen, M; Reinikainen, K; Sidén, A; Worm-Petersen, J | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Morissette, M; Rajput, AH | 1 |
| Gerlach, M; Riederer, P | 1 |
| Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Fisone, G; Greengard, P; Håkansson, K; Picconi, B | 1 |
| Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Bordet, R; Destée, A | 1 |
| Derkinderen, P; Vidailhet, M | 1 |
| Brefel-Courbon, Ch; Ferreira, JJ; Montastruc, JL; Payoux, P; Rascol, O | 1 |
| Dunnett, S | 1 |
| Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA | 1 |
| Burke, MA; Fernandez, HH; Friedman, JH; Jacques, C; Trieschmann, ME | 1 |
| Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY | 1 |
| Bézard, E; Boraud, T; Ferry, S; Gross, C; Leriche, L; Mach, U; Sokoloff, P; Stark, H | 1 |
| Calandrella, D; Martignoni, E; Riboldazzi, G; Riva, N | 1 |
| Brockmöller, J; Gasser, T; Grapengiesser, A; Hofer, A; Kaiser, R; Kupsch, A; Roots, I | 1 |
| Love, R | 1 |
| Brotchie, JM; Crossman, AR; Engstrom, M; Fox, SH; Hill, M; McGuire, SG; Merivuori, H; Savola, JM; Wurster, S | 1 |
| Chassain, C; Durif, F; Eschalier, A | 1 |
| Hauser, RA; Hubble, JP; Truong, DD | 1 |
| Nakatsuka, A; Nomoto, M | 1 |
| Barone, P | 1 |
| Olanow, CW | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Cao, X; Sun, S; Xu, Y | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA | 1 |
| Baron, MS; Dalton, WB | 1 |
| Decamp, E; Gonczi, H; Schneider, JS | 1 |
| Bédard, PJ; Grégoire, L; Samadi, P | 1 |
| Ardouin, C; Batir, A; Benabid, AL; Benazzouz, A; Chabardes, S; Fraix, V; Koudsie, A; Krack, P; LeBas, JF; Limousin, PD; Pollak, P; Van Blercom, N | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Chan, DK | 1 |
| Standaert, DG | 1 |
| Ongini, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Agid, Y; Bonnet, AM; Cornu, P; Duyckaerts, C; Hauw, JJ; Houeto, JL; Jarraya, B | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH | 1 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Koller, WC; Tse, W | 1 |
| LeWitt, PA; Nyholm, D | 1 |
| Evans, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Watt, H | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Argyriou, AA; Chroni, E; Ellul, J; Papapetropoulos, S | 1 |
| Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A | 1 |
| Borg, M; Broussolle, E; Debilly, B; Durif, F; Galitzky, M; Morand, D; Rascol, O; Thobois, S; Viallet, F | 1 |
| Calne, DB; de la Fuente-Fernández, R; Mak, E; Schulzer, M; Stoessl, AJ | 1 |
| Foster, HD; Hoffer, A | 1 |
| Kostić, VS | 1 |
| Bédard, PJ; Bézard, E; Grondin, R; Gross, CE; Hadj Tahar, A | 1 |
| Pagni, CA; Zeme, S; Zenga, F | 1 |
| Burbaud, P; Coman, I; Cuny, E; Gin, H; Guehl, D; Macia, F; Perlemoine, C; Rigalleau, V; Tison, F | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Swope, DM | 1 |
| Ando, T; Itoh, M; Nakajima, T; Nimura, T; Shirane, R; Tominaga, T; Yamaguchi, K | 1 |
| Lasa, A; Linazaroso, G; van Blercom, N | 1 |
| Bonuccelli, U; Del Dotto, P | 1 |
| Marciani, MG; Placidi, F; Romigi, A | 1 |
| Di Paolo, T; Fenton, ME; Hornykiewicz, O; Pifl, C; Rajput, AH; Sitte, H | 1 |
| Brotchie, J; Crossman, A; Davies, R; Fletcher, N; Fox, S; Kellett, M; Silverdale, M; Steiger, M | 1 |
| Fellows, SJ; Noth, J | 1 |
| Bain, PG; Carroll, CB | 1 |
| Fisone, G; Håkansson, K; Lindskog, M; Pozzi, L; Usiello, A | 1 |
| Cenci, MA; Lindgren, H; Lundblad, M; Picconi, B | 1 |
| Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P | 1 |
| Bogousslavsky, J; Burkhard, PR; Combrement, P; Ghika, J; Russmann, H; Villemure, JG; Vingerhoets, FJ | 1 |
| Linazasoro, G | 5 |
| Hamani, C; Lozano, A; Toda, H | 1 |
| Follett, KA | 1 |
| Alterman, RL; Gudesblatt, M; Shils, JL; Tagliati, M | 1 |
| Lo, TC; Thanvi, BR | 1 |
| Calne, DB; de la Fuente-Fernández, R; Furtado, S; Huang, Z; Lu, JQ; Ruth, TJ; Sossi, V; Stoessl, AJ | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Agid, Y; Albanese, A; Bonuccelli, U; Bonucelli, U; Damier, P; De Yebenes, J; Gershanik, O; Grandas, F; Guttman, M; Hallett, M; Hornykiewicz, O; Jenner, P; Katzenschlager, R; Langston, WJ; LeWitt, P; Melamed, E; Mena, MA; Michel, PP; Mizuno, Y; Mytilineou, C; Obeso, JA; Olanow, CW; Poewe, W; Quinn, N; Raisman-Vozari, R; Rajput, AH; Rascol, O; Sampaio, C; Stocchi, F | 1 |
| Chapuis, S; Durif, F; Gerbaud, L; Metz, O; Ouchchane, L | 1 |
| Filiano, JJ; Furukawa, Y; Kish, SJ | 1 |
| Annesi, F; Annesi, G; Bellesi, M; Candiano, IC; Capecci, M; Carrideo, S; Ceravolo, MG; Civitelli, D; De Marco, EV; Iacoangeli, M; Passamonti, L; Provinciali, L; Quattrone, A; Ricciuti, R; Scerrati, M; Tarantino, P; Zappia, M | 1 |
| Mizusawa, H; Nishina, K | 1 |
| Carta, M; Cenci, MA; Dekundy, A; Eaton, ME; Konradi, C; Kuter, K; Lundblad, M; Westin, JE | 1 |
| Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA | 1 |
| Aubert, I; Barthe, N; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Fisone, G; Gross, CE; Guigoni, C; Håkansson, K; Li, Q | 1 |
| Fukaya, C; Hashimoto, T; Itakura, T; Katayama, Y; Kobayashi, K; Tanaka, K; Yamamoto, T; Yokoyama, T | 1 |
| Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA | 1 |
| Brotchie, JM; Crossman, AR; Nicholson, SL; Silverdale, MA | 1 |
| Brotchie, JM; Lee, J; Venderova, K | 1 |
| Braga-Neto, P; da Silva-Júnior, FP; Monte, FS; Nobre E Souza, MÂ; Sales de Bruin, VM | 1 |
| Chang, S; Davis, M; Eunson, L; Graham, E; Horta, W; Johnson, JO; Khan, NL; Lees, AJ; Singleton, A; Wood, NW | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J | 1 |
| Björklund, A; Burger, C; Carlsson, T; Cenci, A; Kirik, D; Mandel, RJ; Muzyczka, N; Winkler, C | 1 |
| Aquilonius, SM; Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Jansson, R; Nilsson Remahl, AI; Nyholm, D | 1 |
| Alvarez, E; Alvarez, L; DeLong, MR; Guridi, J; Juncos, JL; Koller, W; Litvan, I; Lopez, G; Macias, R; Maragoto, C; Obeso, JA; Pavon, N; Rodriguez-Oroz, MC; Tolosa, ES; Vitek, J | 1 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Pisani, A | 1 |
| Di Monte, DA; Langston, JW; Protell, P; Quik, M; Tan, LC; Togasaki, DM | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q | 2 |
| Ross, IN; Sharma, JC; Vassallo, M | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Kurlan, R | 1 |
| Jech, R; Mecír, P; Roth, J; Růzicka, E; Urgosík, D; Vladyka, V; Vymazal, J | 1 |
| De Reuck, J; De Weweire, M; Santens, P; Van Maele, G | 1 |
| Metman, LV; O'Leary, ST | 1 |
| Waters, C | 1 |
| Widnell, K | 1 |
| Jankovic, J | 2 |
| Jankovic, J; Olanow, CW | 1 |
| Di Rocco, A; Huang, N; Marinelli, L; Mazzella, L; Moshier, E; Yahr, MD | 1 |
| Annesi, F; Annesi, G; Arabia, G; Carrideo, S; Cirò-Candiano, IC; Civitelli, D; De Marco, EV; Gambardella, A; Messina, D; Nicoletti, G; Pugliese, P; Quattrone, A; Spadafora, P; Tarantino, P; Zappia, M | 1 |
| Bain, PG; Carroll, CB; Liu, X; Wang, SY; Zajicek, J | 1 |
| Cook, R; Garrick, R; Halliday, GM; Huang, Y; Morris, J; O'Sullivan, D | 1 |
| Aubert, I; Benovic, JL; Bezard, E; Bioulac, BH; Bloch, B; Ferry, S; Fisone, G; Gross, CE; Guigoni, C; Gurevich, EV; Gurevich, VV; Håkansson, K; Leriche, L; Li, Q; Mach, U; Sokoloff, P; Stark, H | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Matsunaga, M; Tomiyama, M | 1 |
| Brotchie, JM; Crossman, AR; Di Marzo, V; Fox, SH; Hill, M; Petrosino, S; van der Stelt, M | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Barone, I; Bernardi, G; Bonsi, P; Calabresi, P; Centonze, D; Picconi, B; Pisani, A | 1 |
| Subramanian, T; Tousi, B | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Hauser, RA; Maldonado, JL; Sullivan, KL; Tatum, WO; Zesiewicz, TA | 1 |
| Agid, Y; Albanese, A; Benabid, AL; Bonnet, AM; Contarino, MF; Fraix, V; Gironell, A; Guridi, J; Hariz, MI; Houeto, JL; Kulisevsky, J; Lang, AE; Lozano, AM; Molet, J; Obeso, JA; Pascual-Sedano, B; Pidoux, B; Pollak, P; Quinn, NP; Rehncrona, S; Rodriguez-Oroz, MC; Romito, L; Saint-Cyr, J; Scerrati, M; Speelman, JD; Van Blercom, N; Volkmann, J; Xie, J; Zamarbide, I | 1 |
| Wedekind, S | 1 |
| Brotchie, JM | 4 |
| Brown, P; Di Lazzaro, V; Insola, A; Mazzone, P; Oliviero, A; Silberstein, P | 1 |
| Bishop, C; Taylor, JL; Walker, PD | 1 |
| Hurley, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA | 1 |
| Brown, P; Di Lazzaro, V; Fogelson, N; Insola, A; Kühn, AA; Kupsch, A; Limousin, P; Mazzone, P; Pogosyan, A; Quartarone, A; Speelman, H; Tijssen, M; van Bruggen, G | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q | 1 |
| Agostino, R; Bagnato, S; Berardelli, A; Dinapoli, L; Modugno, N | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 2 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Braga-Neto, P; da Silva-Júnior, FP; de Bruin, VM; Sueli Monte, F | 1 |
| Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E | 1 |
| Al-Bargouthy, G; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Obeso, JA; Zeng, BY | 1 |
| Bédard, PJ; Bélanger, N; Di Paolo, T; Grégoire, L | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Kitagawa, M; Tashiro, K | 1 |
| Borek, LL; Friedman, JH | 1 |
| Ransmayr, G | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH | 1 |
| Dunnett, SB; Monville, C; Torres, EM | 1 |
| Goto, S; Kaji, R; Kuratsu, J; Yamada, K | 1 |
| Caroff, SN; Duda, JE; Eisa, M; Gallop, R; Kleiner-Fisman, G; Lorry, A; Martine, R; Stern, MB | 1 |
| Bontempi, S; Busi, C; Collo, G; Fiorentini, C; Missale, C; Rizzetti, MC; Spano, P | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Winkler, C | 1 |
| Dalvi, A; Gartner, M; Gong, J; Revilla, FJ; Sahay, A; Samaha, FJ; Strong, JA; Welge, JA; Yu, L; Yue, X | 1 |
| Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH | 1 |
| Cannas, A; Floris, G; Solla, P; Tacconi, P | 1 |
| Chen, R; Espay, AJ; Gunraj, C; Lang, AE; Morgante, F | 1 |
| Adams, J; de la Fuente-Fernández, R; Schulzer, M; Sossi, V; Stoessl, J | 1 |
| Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA; Weigand, S | 1 |
| Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R | 1 |
| Apaydin, H; Benbir, G; Delil, S; Erginöz, E; Ozekmekçi, S | 1 |
| Morelli, M; Pinna, A; Pontis, S | 1 |
| Konitsiotis, S; Tsironis, C | 1 |
| Duval, C; Edwards, R; Ghassemi, M; Jog, M; Lemieux, S | 2 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; Manrique, M; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M; Zamarbide, I | 1 |
| Kulkantrakorn, K; Pongchaiyakul, C; Pulkes, T; Tiamkao, S | 1 |
| Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A | 1 |
| Hatano, T; Hattori, N; Izawa, N; Kagohashi, M; Mizuno, Y; Mochizuki, H; Mori, H; Nishioka, K; Sato, K; Yamashiro, K | 1 |
| Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD | 1 |
| Corvol, JC; Girault, JA; Hervé, D | 1 |
| Obeso, JA; Olanow, CW; Stocchi, F | 2 |
| Bernardi, G; Brusa, L; Centonze, D; Iani, C; Koch, G; Stanzione, P; Versace, V | 1 |
| Fukaya, C; Kano, T; Katayama, Y; Kobayashi, K; Oshima, H; Yamamoto, T | 1 |
| Bédard, PJ; Rouillard, C; Samadi, P | 1 |
| Chung, EJ; Ki, CS; Kim, IS; Kim, JY; Lee, WY | 1 |
| Carminati, P; Jackson, MJ; Jenner, P; Johnson, L; Rose, S; Smith, LA; Stockwell, K | 1 |
| Hasoon, M; Macnamara, L; Ross, I; Sharma, JC; Vassallo, M | 1 |
| Carta, AR; Morelli, M; Pinna, A | 1 |
| Cenci, MA; Lundblad, M | 2 |
| Abdalla, M; Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O | 1 |
| Chu, WB; Iravani, MM; Jackson, MJ; Jenner, P; Tayarani-Binazir, K | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE | 1 |
| Hauser, RA | 1 |
| Evans, AH; Katzenschlager, R; Lees, AJ; Silveira-Moriyama, L | 1 |
| Aljanati, R; Buzó, R; Chouza, C; de Medina, O; Dieguez, E; Gomensoro, J; Lisanti, N; Romero, S; Scaramelli, A | 1 |
| Clissold, BG; Kempster, PA; McColl, CD; Reardon, KR; Shiff, M | 1 |
| Cohen, HS; Gracies, JM; MacDougall, HG; Moore, ST; Ondo, WG | 1 |
| Alves, R; Barbosa, E; Scaff, M | 1 |
| Di Rocco, A; Nasser, S; Werner, P | 1 |
| Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H | 1 |
| Al-Barghouthy, G; Jackson, MJ; Jenner, P; Rose, S; Smith, LA | 1 |
| Avila, I; Bibbiani, F; Chase, TN; Collins, MA; Oh, JD; Smith, CP | 1 |
| Chaná C, P; Juri C, C | 1 |
| Mash, DC; Papapetropoulos, S | 1 |
| Barker, RA; Kuan, WL; Lin, R; Tyers, P | 1 |
| Agid, Y; Blau, N; Remy, P; Ribeiro, MJ; Saudubray, JM; Sedel, F | 1 |
| Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH | 1 |
| Harn, HJ; Lin, JJ; Lin, SZ; Liu, JT; Yueh, KC | 1 |
| Cao, X; Chen, Z; Guan, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Bartalucci, A; Biagioni, F; Ferrucci, M; Fornai, F; Fulceri, F; Galli, V; Lazzeri, G; Paparelli, A; Ruggieri, S | 1 |
| Enokizono, J; Hagihara, K; Iida, K; Kashima, H; Kurokawa, M; Nonaka, H; Shimada, J; Uchida, S | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Lundblad, M | 1 |
| Angel, MJ; Chen, R; Enjati, M; Gunraj, C; Lang, AE; Wagle-Shukla, A; Zadikoff, C | 1 |
| Chen, L; Cox, H; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM | 1 |
| Bezard, E; Bloch, B; Doudnikoff, E; Guigoni, C; Li, Q | 1 |
| Carlson, NE; Carter, JH; Nutt, JG | 1 |
| Grandas, F; Hernández, B | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M | 1 |
| Fiddian-Green, RG | 1 |
| Tetrud, JW | 1 |
| Brotchie, JM; Fabbrini, G; Goetz, CG; Grandas, F; Nomoto, M | 1 |
| Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, LA | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; James, P; Krogh, M; Lundblad, M; Quack, G; Valastro, B | 1 |
| Lo, N; Robinson, T; Thanvi, B | 1 |
| Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X | 1 |
| Choi, JK; Iris Chen, YC; Isacson, O; Jenkins, BG; Sánchez-Pernaute, R | 1 |
| Borgkvist, A; Carta, M; Fisone, G; Girault, JA; Greengard, P; Hervé, D; Santini, E; Usiello, A; Valjent, E | 1 |
| Karamanakos, PN; Marselos, M; Pappas, P | 1 |
| Hurley, MJ; Jackson, MJ; Jenner, P; Patel, PH; Rose, S; Smith, LA | 1 |
| Hauser, RA; Sullivan, KL; Zesiewicz, TA | 1 |
| Cao, X; Factor, S; Greenamyre, JT; Griffith, DA; Hadcock, JR; Iredale, PA; Liang, L; Menniti, FS; Papa, SM | 1 |
| Jankovic, J; Stacy, M | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Winkler, C | 1 |
| Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB | 1 |
| Cenci, MA; Konradi, C; Strome, EM; Vercammen, L; Westin, JE | 1 |
| Duval, C; Edwards, R; Ghassemi, M; Gour, J; Jog, M; Lemieux, S | 1 |
| Calon, F; Di Paolo, T; Morelli, M; Schwarzschild, MA; Wardas, J; Xiao, D | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Hauser, RA; Schapira, AH; Simonson, W | 1 |
| Guan, Q; He, Y; Tan, L; Zhan, Q | 1 |
| di Poggio, AB; Fornai, F; Paparelli, A; Pellegrini, A; Ruggieri, S | 1 |
| Dunnett, S; Lane, E | 1 |
| Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG | 1 |
| Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G | 1 |
| Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M | 1 |
| Tse, W | 1 |
| Chang, LJ; Furukawa, Y; Guttman, M; Hornykiewicz, O; Kish, SJ; Rajput, A; Tong, J | 1 |
| Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M | 1 |
| Liou, HH; Liu, HM; Su, PC; Tseng, HM; Yen, RF | 1 |
| Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P | 1 |
| Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B | 1 |
| Brown, P; Eusebio, A | 1 |
| Bédard, PJ; Bélanger, N; Calon, F; Di Paolo, T; Dridi, M; Grégoire, L; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Haeger, DA; Hock, K; Mueller, T; Russ, H; Woitalla, D | 1 |
| Duval, C; Fenney, A; Jog, MS | 1 |
| Baláz, M; Pulkrábek, J; Rektor, I | 1 |
| Barker, RA; Kuan, WL; Zhao, JW | 1 |
| Jeon, BS; Kim, DG; Kim, HJ; Kim, JY; Lee, JY; Paek, SH | 1 |
| Alvarez-Erviti, L; Barroso-Chinea, P; Blesa, FJ; Guridi, J; Lanciego, JL; Obeso, JA; Rodríguez-Oroz, MC; Smith, Y | 1 |
| Agid, Y; Brice, A; Durr, A; Fraix, V; Houeto, JL; Krack, P; Laine, S; Lesage, S; Lohmann, E; Mesnage, V; Pollak, P; Tanguy, ML; Welter, ML | 1 |
| Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Doudnikoff, E; Fälth, M; Guigoni, C; Kultima, K; Li, Q; Scholz, B; Sköld, K; Svensson, M | 1 |
| Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB | 1 |
| Cenci, MA; Lindgren, HS | 1 |
| Brooks, D; Rascol, O; Ross, IN; Sharma, JC | 1 |
| Gardoni, F | 1 |
| Guridi, J; Lozano, AA; Manrique, M; Obeso, JA; Rodriguez-Oroz, MC | 1 |
| Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S | 1 |
| Clarke, C; Ferreira, J; Gray, R; Hawker, RJ; Ives, NJ; Shah, L; Stowe, RL; van Hilten, J; Wheatley, K | 1 |
| Evangelou, A; Konitsiotis, S; Marselos, M; Tsironis, C | 1 |
| Encarnacion, EV; Hauser, RA | 1 |
| Horstink, MW | 1 |
| Lakke, JP; Staal-Schreinemachers, A; van Weerden, TW | 1 |
| Bjørndal, N; Casey, D; Gerlach, J | 1 |
| Itoh, H | 1 |
| Bathien, N; Koutlidis, RM; Rondot, P | 1 |
| Lloyd, KG; Worms, P | 1 |
| Jeste, DV; Wyatt, RJ | 2 |
| Hunter, KR | 1 |
| Rosal-Greif, VL | 1 |
| Weiner, M | 1 |
| Ananth, J | 1 |
| Hellemans, J; Hens, L | 1 |
| Bjørndal, N; Casey, DE; Gerlach, J | 1 |
| Alpert, M; Diamond, F; Friedhoff, AJ | 1 |
| Shoulson, I | 1 |
| Hardie, RJ; Lees, AJ; Stern, GM | 1 |
| Jeste, DV; Karson, CN; LeWitt, PA; Wyatt, RJ | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Bitton, V; Melamed, E | 1 |
| Andrade, LA; Bertolucci, PH; Pereira, JS | 1 |
| Still, CN | 1 |
| Yung, CY | 1 |
| Bartholini, G | 2 |
| Mejer Nielsen, B | 1 |
| Giampietro, AC; Karniol, IG; Moura, DS; Oliveira, MA; Vilela, WA; Zuardi, AW | 1 |
| Nakajima, Y; Narabayashi, H; Yokochi, F | 1 |
| Coffey, CE; Massey, EW; Olanow, CW; Ross, DR | 1 |
| Blair, RD; Lang, AE | 1 |
| Ludin, HP | 1 |
| Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y | 1 |
| Burns, R | 1 |
| Morris, JG | 2 |
| Katsuki, T; Mizuno, Y; Shimizu, N | 1 |
| Mutani, R; Sechi, GP; Tanda, F | 1 |
| Klawans, HL | 2 |
| Reilly, DK; Rivera-Calimlim, L | 1 |
| Jacob, RG; Szekely, BC; Turner, SM | 1 |
| Matsumoto, Y; Miyamoto, T; Nakamura, S; Ohmoto, T | 1 |
| Kucharski, LT; Unterwald, EM | 1 |
| Agnoli, A; Baldassarre, M; Bocola, V; Del Roscio, S; Denaro, A; Ruggieri, S | 1 |
| Broekkamp, CL | 1 |
| Hirayama, K; Yamada, T | 1 |
| Parkes, JD | 1 |
| Haas, JA; Lakke, JP | 1 |
| Ando, K; Mano, Y; Muramoto, O; Riku, S | 1 |
| Calne, DB | 1 |
| Meerwaldt, JD; Staal, A | 1 |
| Calne, DB; Karson, CN; LeWitt, PA; Wyatt, RJ | 1 |
| Goetz, CG; Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
| Carvey, P; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Bergsrud, D; Elton, RL; Racy, A; Teychenne, PF; Vern, B | 1 |
| Gil Núñez, A; Giménez-Roldán, S; Mateo, D | 1 |
| Korein, J | 1 |
| McKenna, P; Pratt, RT; Stern, GM; Ward, C | 1 |
| Lees, AJ; Shaw, KM; Stern, GM | 2 |
| Dostrovsky, JO; Duff, J; Galvez-Jimenez, N; Hutchinson, WD; Lang, AE; Lozano, AM; Miyasaki, J | 1 |
| Agid, Y; Blin, J; Bonnet, AM; Durif, F; Vidailhet, M | 1 |
| Cardoso, F | 1 |
| Kempster, PA; Shif, M | 1 |
| Lunn, V; Northcott, C; Yatham, LN | 1 |
| Brown, LK | 1 |
| Winn, P | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Martel, JC; Piercey, MF | 1 |
| Crossman, AR; Page, RD; Sambrook, MA | 1 |
| Hamamoto, M; Ishikura, N; Miyazaki, T; Ohtsubo, K | 1 |
| Kaur, S; Starr, BS; Starr, MS | 1 |
| Bédard, PJ; Blanchet, P; Britton, DR; Kebabian, JW | 1 |
| Chouinard, G; Miller, R | 1 |
| Caligiuri, MP | 1 |
| Arnold, G; Oertel, WH; Schwarz, J; Trenkwalder, C | 1 |
| Radwany, SM; Rich, MW | 1 |
| Agid, Y; Bonnet, AM; Gouider-Khouja, N; Marconi, R; Vidailhet, M | 1 |
| Bédard, PJ; Blanchet, PJ; Boucher, R | 1 |
| Bennett, JP; Dietrich, S; Landow, ER; Schuh, LA | 1 |
| Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R | 1 |
| Nutt, JG | 4 |
| Bennett, JP; Landow, ER; Schuh, LA | 1 |
| Koller, WC; Pahwa, R | 1 |
| Kondo, T; Mizuno, Y; Mori, H | 1 |
| Martí, MJ; Tolosa, ES; Valldeoriola, F | 1 |
| Poewe, WH | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM | 1 |
| Poewe, W; Schelosky, L | 1 |
| Bédard, PJ; Gomez-Mancilla, B | 3 |
| Caligiuri, MP; Peterson, S | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Lefebvre-Caparros, D; Marconi, R; Vidailhet, M | 1 |
| Mendis, L | 1 |
| Bonifati, V; Cipriani, R; Fabrizio, E; Meco, G; Vanacore, N | 1 |
| Deffond, D; Dordain, G; Durif, F; Tournilhac, M | 1 |
| Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR | 1 |
| Kurisaki, H; Mizuno, T | 1 |
| Poewe, W | 1 |
| Akiguchi, I; Nakamura, S | 1 |
| Lang, AE; Riley, DE | 1 |
| Chase, TN; Dambrosia, JM; Peppe, A | 1 |
| Gash, DM; Kurlan, R; McDermott, M; Smith, RD; Zhang, Z | 1 |
| Blond, S; Caparros-Lefebvre, D; Guieu, JD; Pécheux, N; Petit, H; Vermersch, P | 1 |
| Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W | 1 |
| Kabel, JF; Kerkhof, GA; Kramer, CG; Middelkoop, HA; Roos, RA; van Hilten, JJ | 1 |
| Caligiuri, MP; Lohr, JB | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Marconi, R; Serre, I | 1 |
| Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C | 1 |
| Di Rocco, A; Kollmeier, B; Molinari, SP; Yahr, MD | 1 |
| Holford, NH; Nutt, JG | 1 |
| Chase, TN; Papa, SM | 1 |
| Narabayashi, H | 3 |
| Facca, A; Sanchez-Ramos, J | 1 |
| Andrade, LA; Borges, V; Ferraz, HB; Rocha, MS | 1 |
| Hirato, M; Horikoshi, S; Ishihara, J; Ohye, C; Shibazaki, T | 1 |
| Iacono, RP; Kuniyoshi, S; Lonser, RR; Maeda, G; Mandybur, G; Warner, D; Yamada, S | 1 |
| Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Smith, L | 1 |
| Bédard, PJ; Blanchet, PJ; Grondin, R | 1 |
| Goto, I; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N | 2 |
| Giron, LT; Koller, WC | 1 |
| Blümner, E; Danielczyk, W; Gerlach, M; Kaiser, HJ; Kraus, PH; Letzel, H; Przuntek, H; Riederer, P; Uberla, K; Welzel, D | 1 |
| Gerlach, M; Klotz, P; Kuhn, W; Müller, T; Przuntek, H | 1 |
| Brotchie, JM; Henry, B | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Gachoud, JP; Gasser, U; Ghika, J | 1 |
| Chase, TN; Mouradian, MM | 1 |
| Kołodziejczyk, K; Maj, J; Rogóz, Z; Skuza, G | 1 |
| Emerich, DF; Francis, JM; Lindner, MD; Plone, MA | 1 |
| Hariz, MI | 1 |
| Alterman, RL; Beric, A; Eidelberg, D; Fazzini, E; Kelly, P; Perrine, K; Sterio, D | 1 |
| Dostrovsky, JO; Gross, RE; Hutchison, WD; Lang, AE; Lozano, AM; Tasker, RR | 1 |
| Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K | 1 |
| Grandas, F; López-Ariztegui, N | 1 |
| Jiménez-Jiménez, FJ; Molina, JA | 1 |
| Bioulac, B; Boraud, T; Gross, C; Guehl, D; Julien, J; Rougier, A | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Tolosa, E; Valldeoriola, F | 1 |
| Marsden, CD | 2 |
| Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J | 1 |
| Bosch, DA; de Bie, RM; Schuurman, PR; Speelman, JD | 1 |
| Brooks, DJ; Piccini, P; Weeks, RA | 1 |
| Busenbark, K; Hubble, J; Koller, WC; Lyons, K; McGuire, D; Michalek, D; Miyawaki, E; Pahwa, R; Smith, D; Tröster, AI | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Alessandri, A; Bonifati, V; Fabrizio, E; Meco, G; Vanacore, N | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Stanzione, P; Stefani, A; Vangelista, T | 1 |
| Banerji, T; Jenner, P; Marsden, CD; Pearce, RK | 1 |
| Mark, MH; Murphy, J; Sage, JI; Syed, N; Zimmerman, T | 1 |
| Branston, NM; Brooks, DJ; Caputo, E; Lees, AJ; Marsden, CD; Quinn, NP; Rothwell, JC; Samuel, M; Scaravilli, T; Schrag, A; Thomas, DG | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P; Xie, J | 1 |
| Brefel, C; Celsis, P; Chollet, F; Fabre, N; Montastruc, JL; Rai, S; Rascol, O; Sabatini, U; Senard, JM; Viallard, G | 1 |
| de la Fuente-Fernández, R | 1 |
| Seeman, P; Tallerico, T | 1 |
| Kulisevsky, J | 1 |
| Chase, TN | 1 |
| Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G | 1 |
| Chase, TN; Del Dotto, P; Fang, J; Mouradian, MM; van den Munckhof, P; Verhagen Metman, L | 1 |
| Colzi, A; Lees, AJ; Turner, K | 1 |
| Adipietro, A; Fattapposta, F; Pierelli, F; Pozzessere, G; Scoppetta, C; Soldati, G | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Koller, WC; Tolosa, E | 1 |
| Capildeo, R | 1 |
| Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P | 1 |
| Blasko, J; Burkhart, WA; Goiney, RC; Grimm, P; Posewitz, A; Shumway-Cook, A; Vermeulen, SS; Young, RF | 1 |
| Horstink, MW; Praamstra, P | 1 |
| Harper, J; Vieira, B | 1 |
| Wills, AJ | 1 |
| Chouinard, G; Looper, KJ | 1 |
| Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, LA; Perlmutter, JS; Stambuk, MK | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S | 1 |
| Galvez-Jimenez, N; Kumar, R; Lang, AE; Rajput, A; Rajput, AH; Uitti, RJ | 1 |
| Björklund, A; Cenci, MA; Lee, CS | 1 |
| Ardouin, C; Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P | 1 |
| Onofrj, M; Paci, C; Thomas, A | 2 |
| Rinne, UK; Ruottinen, HM | 1 |
| Standaert, D | 1 |
| Ben-Shlomo, Y; Brown, R; Marsden, CD; Quinn, N; Schrag, A | 1 |
| Dillon, LC; Hoffman, M; Hughes, AJ; O'Sullivan, JD; Said, CM | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Papadopoulos, S; Pidoux, B; Vidailhet, M | 1 |
| Bassi, A; Bernardi, G; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Castro García, A; Sesar Ignacio, A | 1 |
| Giladi, N; Melamed, E | 1 |
| Agid, Y; Debilly, B; Durif, F; Vidailhet, M | 1 |
| Bédard, PJ; Hadj Tahar, A | 1 |
| Broussolle, E | 1 |
| Britton, DR; Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Shiosaki, K | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Ziv, I | 1 |
| Klockgether, T; Löschmann, PA; Spieker, S | 1 |
| Caparros-Lefebvre, D; Lannuzel, A; Strobel, M; Tiberghien, F | 1 |
| Benabid, AL; Benazzouz, A; Deuschl, G; Krack, P; Limousin, P; Pollak, P | 1 |
| Tedroff, JM | 1 |
| Marin, C; Tolosa, E | 1 |
| Brefel-Courbon, C; Descombes, S; Montastruc, JL; Rascol, O | 1 |
| Grossman, R; Jankovic, J; Krauss, J; Lai, EC | 1 |
| Damier, P | 1 |
| Carlson, JD; Iacono, RP; Kuniyoshi, SM; Mohamed, AS | 1 |
| Sunohara, N | 1 |
| Benabid, AL; Blond, S; Caparros-Lefebvre, D; Feltin, MP; Pollak, P | 2 |
| King, DB | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Whittemore, ER; Woodward, RM; Zhou, ZL | 1 |
| Vale, S | 1 |
| Agid, Y; Bonnet, AM; Durif, F; Marconi, R; Vidailhet, M | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; DiPaolo, T; Doucet, JP; Falardeau, P; Gomez-Mancilla, B; Goulet, M; Grondin, R; Lévesque, D; Morissette, M; Robertson, GS; Soghomonian, JJ | 1 |
| Goetz, CG | 1 |
| Pearce, RK | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Clavier, I; Damier, P; Jaillon, C | 1 |
| Defer, GL; Widner, H | 1 |
| Nutt, J | 1 |
| Giduz, T; Pact, V | 1 |
| Ben-Arie, L; Grossman, R; Jankovic, J; Krauss, JK; Lai, E | 1 |
| Aguglia, U; Andreoli, V; Annesi, G; Branca, D; Cittadella, R; Civitelli, D; Gambardella, A; Montesanti, R; Nicoletti, G; Oliveri, RL; Pasqua, AA; Quattrone, A; Spadafora, P; Zappia, M | 1 |
| Andringa, G; Cools, AR; Stoof, JC | 1 |
| Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
| Chase, TN; Del Dotto, P; Fang, J; Konitsiotis, S; LePoole, K; Metman, LV | 1 |
| Gottwald, MD | 1 |
| Ahlskog, JE | 2 |
| Anderson, VC; Burchiel, KJ; Favre, J; Hammerstad, JP | 1 |
| Finken, MJ; Ramaker, C; van de Beek, WJ; van Hilten, BJ | 1 |
| Asselman, P; Brown, P; Buckwell, D; Lees, AJ; Manson, AJ; O'Sullivan, JD | 1 |
| Galiano, ML; Grandas, F; Tabernero, C | 1 |
| Guridi, J; Linazasoro, G; Obeso, JA; Ramos, E; Rodriguez-Oroz, MC | 1 |
| Ben-Aire, L; Contant, C; Grossman, R; Jankovic, J; Lai, E; Ondo, WG | 1 |
| Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P | 1 |
| Shulman, LM | 1 |
| Weiner, WJ | 2 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Damier, P; Féger, J; Hirsch, EC; Tremblay, L | 1 |
| Iakovidou, E; Lees, AJ; Manson, AJ | 1 |
| Chin, S; Dhawan, V; Eidelberg, D; Fahn, S; Frucht, S | 1 |
| Kumar, R; Lang, AE; Lozano, AM; Saint-Cyr, JA; Trépanier, LL | 1 |
| Ferrer, E; Molinuevo, JL; Nobbe, FA; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Philippon, J; Pidoux, B; Yelnik, J | 1 |
| Sealfon, SC | 1 |
| DeLong, MR; Obeso, JA; Olanow, CW; Rodriguez, M; Rodriguez-Oroz, MC | 1 |
| Filion, M | 1 |
| Canales, JJ; Graybiel, AM | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Giacomini, P | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
| Di Monte, DA; Jakowec, M; Langston, JW; Petzinger, G; Quik, M | 1 |
| Hirsch, EC | 1 |
| Hallett, M | 1 |
| Brooks, DJ; Piccini, P; Samuel, M; Turjanski, N | 1 |
| Obeso, JA; Olanow, CW | 1 |
| Benabid, AL; Benazzouz, A; Koudsie, A; Krack, P; Limousin, P; Piallat, B; Pollak, P | 1 |
| Lang, AE | 1 |
| Jenner, P; MacKenzie, GM; Pearce, RK; Zeng, BY | 2 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L | 1 |
| Iacono, RP; Nahab, FB; Nahab, FH | 1 |
| Andringa, G; Cools, AR; Drukarch, B; Lubbers, L; Stoof, JC | 1 |
| Clarke C, E; Speller J, M | 2 |
| Finken, MJ; Ramaker, C; Van de Beek, WJ; van Hilten, JJ | 1 |
| Clarke, CE; Speller, JM | 2 |
| Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Damier, P; Demeret, S; Houeto, JL | 1 |
| Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O | 1 |
| Di Monte, DA; Janson, AM; Langston, WJ; McCormack, A; Petzinger, G; Quik, M | 1 |
| Blasucci, LM; Goetz, CG; Stebbins, GT | 1 |
| Stoessl, AJ; Van Kampen, JM | 1 |
| Björklund, A; Cenci, MA; Lee, CS; Schulzer, M | 1 |
| Bangassoro, E; Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Ferrer, E; Molinuevo, JL; Roldan, H; Rumia, J; Tolosa, E; Valldeoriola, F; Valls-Sole, J | 1 |
| Becker, G; Berg, D; Reiners, K | 1 |
| Busek, P; Jech, R; Roth, J; Růzicka, E | 1 |
| Lees, AJ; Manson, AJ; Schrag, A | 1 |
| Earnhart, M; Hiner, BC | 1 |
| Frucht, S | 1 |
| Yamamoto, T | 1 |
| Factor, SA; Weiner, WJ | 1 |
| Jenner, P; Smith, LA; Treseder, SA | 1 |
| Bösch, S; Luginger, E; Poewe, W; Wenning, GK | 1 |
| Emre, M; Hanağasi, HA; Kaptanoglu, G; Sahin, HA | 1 |
| Nomoto, M | 1 |
| Fung, VS; Hely, MA; Morris, JG | 1 |
| Quinn, N; Schrag, A | 1 |
| Cersósimo, MG; Micheli, FE; Scorticati, MC | 1 |
| Nutt, JG; Obeso, JA; Olanow, CW | 1 |
| Artieda, J; Gonzalo, N; Lanciego, JL; Obeso, JA; Olanow, CW; Rodríguez, M; Rodríguez-Oroz, MC | 1 |
| Bernardi, G; Calabresi, P; Centonze, D | 1 |
| Canales, JJ; Capper-Loup, C; Graybiel, AM | 1 |
| Brooks, DJ | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Doucet, JP; Goulet, M; Grondin, R; Hadj Tahar, A; Morissette, M; Nestler, E; Robertson, GS | 1 |
| Nutt, JG; Obeso, JA; Stocchi, F | 1 |
| Olanow, W; Rascol, O; Schapira, AH | 1 |
| Kanazawa, I; Momose, Y; Murata, M | 1 |
| Saiki, H; Takeuchi, J; Yamagami, T | 1 |
| Katayama, Y | 1 |
| Itakura, T; Nakao, N; Uematsu, Y | 1 |
| Kuno, S | 1 |
| Namba, H; Sugiyama, K; Yokoyama, T | 1 |
| Balakrishnan, S; Joseph, S; Kishore, A; Panikar, D; Sarma, S | 1 |
| Gielen, CC; Hoff, JI; Horstink, MW; Keijsers, NL; van Hilten, JJ | 1 |
| Benabid, AL; Fraix, V; Koudsie, A; Krack, P; Pollak, P; Van Blercom, N; Xie, J | 2 |
| Lachenmayer, L; Reichmann, H | 1 |
| Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J | 1 |
| Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC | 1 |
| Blin, O; Carter, JH; Currie, LJ; Fabre, N; Giardina, WW; Goetz, CG; Nutt, JG; Rascol, O; Soubrouillard, C; Thalamas, C; Trugman, JM; Wright, S | 1 |
| Baas, H | 1 |
| Hoff, JI; van den Plas, AA; van Hilten, JJ; Wagemans, EA | 1 |
| Hobart, J; Katzenschlager, R; Lees, AJ; Manson, AJ | 1 |
| Clarke, CE; Deane, KH | 1 |
| Clarke, CE; Deane, KD | 1 |
| Ashby, P; Dostrovsky, JO; Levy, R; Tasker, RR; Wu, YR | 1 |
| Andersson, KE; Andersson, M; Cenci, MA; Johansson, PA | 1 |
| Ahlskog, JE; Muenter, MD | 1 |
| Bernardini, S; Bonuccelli, U; Chase, TN; Del Dotto, P; Gambaccini, G; Metman, LV; Pavese, N | 1 |
| Le Pen, C; Lilliu, H; Maurel, F | 1 |
| Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A | 1 |
| Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Peggs, D | 1 |
| Agid, Y; Arnulf, I; Bejjani, B; Bonnet, AM; Brefel-Courbon, C; Descombes, S; Fabre, N; Montastruc, JL; Peyro-Saint Paul, H; Rascol, O; Thalamas, C; Vidailhet, M | 1 |
| Bezard, E; Brotchie, JM; Gross, CE | 1 |
| Heikkilä, M; Jenner, P; Lindén, IB; Pearce, RK | 1 |
| Di Monte, DA; Langston, JW; Protell, P; Quik, M; Tan, L; Togasaki, DM | 1 |
| Benabou, R; Cubo, E; Goetz, CG; Gracies, JM; Leurgans, S; Olanow, CW; Raman, R | 1 |
| Hamada, I; Hasegawa, N; Okiyama, R; Takahashi, H; Taniguchi, M; Yokochi, F | 1 |
| Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ | 1 |
| Becker, G; Berg, D; Naumann, M; Reiners, K | 1 |
| Brotchie, JM; Crossman, AR; Dick, JP; Fox, SH; Hill, M; Sieradzan, KA | 1 |
| Ohye, C | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Albanese, A; Bentivoglio, AR; Cortelli, P; Elia, A; Ferraris, A; Ialongo, T; Montagna, P; Valente, EM | 1 |
| Kostić, VS; Marinković, J; Przedborski, S; Stefanova, E; Svetel, M | 1 |
| Ding, Y; Li, Y; Shao, M; Zhao, G | 1 |
| Bareš, M; Hortová, H; Kanovský, P; Kubová, D; Rektor, I; Streitová, H; Znojil, V | 1 |
| Bédard, PJ; Birdi, S; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH | 1 |
| Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C | 1 |
| Boesch, SM; Poewe, W; Ransmayr, G; Wenning, GK | 1 |
| Mazzoni, P | 1 |
| Deuschl, G; Herzog, J; Klebe, S; Krack, P; Lorenz, D; Pohle, S; Wenzelburger, R; Wilms, H; Zhang, BR | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I | 1 |
| Burgunder, JM; Krauss, JK; Loher, TJ; Pohle, T; Sommerhalder, R; Weber, S | 1 |
| Defebvre, L; Krystkowiak, P | 1 |
| Dill, RE; Dorris, RL; Phillips-Thonnard, I | 1 |
| Carroll, BJ; Curtis, GC; Kokmen, E | 1 |
| Lloyd, KG | 1 |
| Ringwald, E | 1 |
| Costentin, J | 1 |
| Marsden, CD; Parkes, JD; Price, P | 1 |
| Jiang, Y; Liu, D | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Sears, ES | 1 |
| Goetz, C; Klawans, HL; Nausieda, PA; Weiner, WJ | 2 |
| Casey, DE | 2 |
| Bédard, P; Langlier, P; Villeneuve, A | 1 |
| Klawans, HL; Moskovitz, C; Nausieda, PA; Weiner, WJ | 1 |
| Cotzias, GC; Tang, LC | 1 |
| Godwin-Austen, RB | 1 |
| Marsden, CD; Parkes, JD; Price, PA | 1 |
| Lakke, JP; Lindeboom, SF | 1 |
| Lance, JW; Mackenzie, RA | 1 |
| Gerlach, J | 2 |
| Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Casey, DE; Denney, D | 1 |
| Hirayama, K; Kondo, T; Kuruma, I; Narabayashi, H; Yokochi, M | 1 |
| Lander, CM; Lees, AJ; Stern, GM | 1 |
| List, SJ; Seeman, P | 1 |
| Bathien, N; Rondot, P | 1 |
| Asano, T; Matsumoto, Y; Mimura, Y; Mino, S; Nishimoto, A; Ohmoto, T; Yoshimura, Y | 1 |
| Durocher, AM; Graux, P | 1 |
| Cotzias, GC; Lazarus, CB; Papavasiliou, PS; Tolosa, ES | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Murphy, MJ | 1 |
| Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M | 3 |
| Ando, K | 1 |
| Cotzias, GC; McDowell, FH; Papavasilliou, PS; Rosal, VL; Sheehan, PJ | 1 |
| Granérus, AK | 1 |
| Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Bédard, P; Marsden, CD; Parkes, JD | 1 |
| Agid, Y; Lhermitte, F; Signoret, JL | 1 |
| Bonnet, K; Friedhoff, AJ; Rosengarten, H | 1 |
| Bianchine, JR; Shaw, GM | 1 |
| Comoy, E; Lhermitte, F; Rosa, A | 1 |
| Galea-Debono, A; Jenner, P; Marsden, CD; Parkes, JD; Tarsy, D; Walters, J | 1 |
| Bala, SP; Cohen, B; Mendoza, M; Shimizu, N; Yahr, MD | 1 |
| Agid, Y; Lhermitte, F; Signoret, JL; Studler, JM | 1 |
| Davis, JM; Frohman, LA; Pandey, G; Smith, RC; Tamminga, CA | 1 |
| Mano, T | 1 |
| Ohtomo, E | 1 |
| Debono, AG; Marsden, CD; Parkes, JD | 1 |
| Johnels, B; Karlsson, S; Persson, M | 1 |
| Sandyk, R | 1 |
| Anninos, PA; Derpapas, K; Sandyk, R; Tsagas, N | 1 |
| Deleu, D | 1 |
| Mark, MH; Sage, JI | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Baronti, F; Brughitta, G; Chase, TN; Conant, KE; Giuffra, M; Mouradian, MM | 1 |
| Heinz, A; Klewin, I; Klotz, P; Kuhn, W; Przuntek, H; Suchy, I | 1 |
| Koller, WC | 1 |
| Rodnitzky, RL | 1 |
| Bédard, PJ; Blanchette, P; Di Paolo, T; Gagnon, C; Mancilla, BG | 1 |
| Page, RD | 1 |
| Chen, S | 1 |
| Lees, AJ; Turjanski, N | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| de Saint Victor, JF; Gervason, CL; Perret, J; Pollak, P | 1 |
| Arts, N; Horstink, M; Tacke, T; van de Vlasakker, C | 1 |
| Lu, CS; Tsai, CH | 1 |
| Fahn, S; Flaster, E; Giladi, N; Guillory, S; Kostic, V; McMahon, D; Przedborski, S | 1 |
| Jamieson, PW | 1 |
| Campbell, N; Evans, C; Franco, K; Pentz, J; Tamburrino, M | 1 |
| Chaná, P; Díaz, F | 1 |
| Carey, RJ | 1 |
| Friedman, A; Sienkiewicz, J | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
| Haba, K; Mizukawa, K; Ogawa, N; Sato, H | 1 |
| Crossman, AR | 1 |
| Flaster, E; Kostic, V; Przedborski, S; Sternic, N | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ | 1 |
| Cedarbaum, JM; Gandy, SE; McDowell, FH | 1 |
| Baronti, F; Brughitta, G; Davis, TL; Mouradian, MM | 1 |
| Kleedorfer, B; Lees, AJ; Stern, GM | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 3 |
| Bergen, M; Hening, WA; McHale, D; Sage, JI; Walters, AS | 1 |
| Cedarbaum, JM | 1 |
| Montastruc, JL; Rascol, A; Rascol, O | 1 |
| Dickey, W; Morrow, JI | 1 |
| Genitrini, S; Giovannini, P; Girotti, F; Piccolo, I; Scigliano, G; Suchy, I; Testa, D | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, M | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Jansen, EN; van Laar, T | 1 |
| Cedarbaum, JM; Kutt, H; Silvestri, M | 1 |
| Ludatscher, JI | 1 |
| Schneider, JS | 1 |
| Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ | 1 |
| Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA | 1 |
| Artieda, J; Grandas, F; Lera, G; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Rodriguez, ME; Vaamonde, J | 1 |
| Le, W | 1 |
| Chacon, J; Chaparro, P; Iriarte, LM; Madrazo, J; Vadillo, J | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 1 |
| Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM | 1 |
| Greer, M | 1 |
| Fog, R | 1 |
| Bossi, L; Fournier, V; Morselli, PL; Musch, B | 1 |
| Rajput, AH; Uitti, RJ | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Critchley, P; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Casabona, J; Jankovic, J | 1 |
| Engstrom, FW | 1 |
| Bathien, N; Fournier, V; Morselli, PL; Rondot, P; Ziegler, M | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM | 1 |
| Ohmoto, T | 1 |
| García, S; Gershanik, OS; Scipioni, O | 1 |
| Agid, Y; Bonnet, AM; Javoy-Agid, F; Ruberg, M | 1 |
| Sandyk, R; Snider, SR | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD | 1 |
| Caradoc-Davies, TH | 1 |
| Mondal, BK; Mondal, KN | 1 |
| Delwaide, PJ; Maertens de Noordhout, A | 1 |
| Albani, C; Asper, R; Baumgartner, G | 1 |
| Gershanik, OS; Luquin, MR; Obeso, JA; Scipioni, O | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mohr, E; Mouradian, MM; Schlegel, J | 1 |
| Bartko, JJ; Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Schlegel, J | 1 |
| Martí, MJ; Tolosa, E | 1 |
| Wermuth, L | 1 |
| Gibb, WR; Lees, AJ | 1 |
| Lieberman, AN | 1 |
| Bhatia, R; Weinrich, M | 1 |
| Clarke, CE; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Critchley, P; Marsden, CD; Quinn, N | 1 |
| el-Awar, M; Freedman, M; Goldenberg, L; Little, J; Seeman, P; Solomon, P | 1 |
| Diamond, SG; Markham, CH | 1 |
| Indo, T; Takahashi, A | 1 |
| von Kummer, R | 1 |
| Jankovic, J; Nour, F | 1 |
| Luquin, MR; Martínez Lage, JM; Obeso, JA | 2 |
| Gopinathan, G; Lieberman, AN; Neophytides, A | 1 |
| Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Friedman, A | 1 |
| Bulpitt, CJ; Clifton, P; Davies, JB; Reid, JL; Shaw, K; Stern, G | 1 |
| Arlazoroff, A; Barber, Y; Bleicher, Z; Flechtir, S; Goldexberg, E | 1 |
| Espadaler Medina, JM | 1 |
| Kondo, T; Nakajima, Y; Narabayashi, H | 1 |
393 review(s) available for levodopa and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease | 2021 |
The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Topics: Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Practice Guidelines as Topic | 2021 |
GOCOVRI
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Longitudinal Studies | 2022 |
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2022 |
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life | 2022 |
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Serotonin 5-HT
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin | 2023 |
Role of P11 through serotonergic and glutamatergic pathways in LID.
Topics: Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
5-HT
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2023 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate | 2023 |
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Xerostomia | 2019 |
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Levodopa; Parkinson Disease | 2019 |
Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Drug Delivery Systems; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2019 |
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Cannabidiol; Cannabinoids; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2020 |
Opicapone for the treatment of Parkinson's disease: an update.
Topics: Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2019 |
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patents as Topic | 2019 |
MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease | 2020 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats | 2020 |
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Biological; Molecular Targeted Therapy; Oxidative Stress; Parkinson Disease; Proto-Oncogene Proteins c-fyn | 2021 |
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonin | 2021 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease | 2021 |
New insights into pathogenesis of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: Connecting the dots in a multicomponent network.
Topics: Cerebellum; Connectome; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Cortex; Neuronal Plasticity; Parkinson Disease | 2017 |
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Design; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease | 2017 |
Levodopa treatment and dendritic spine pathology.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dendritic Spines; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Putamen | 2018 |
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Positron-Emission Tomography | 2017 |
Synaptic plasticity may underlie l-DOPA induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2018 |
Levodopa: A new look at an old friend.
Topics: Age Factors; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2018 |
Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; beta Catenin; Dopamine; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3; Humans; Levodopa; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease | 2018 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats | 2018 |
Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists | 2018 |
Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
Topics: Antiparkinson Agents; Causality; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Regression Analysis | 2018 |
Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; GABAergic Neurons; Gene Expression; Humans; Levodopa; Receptors, Dopamine D1; Signal Transduction | 2018 |
Role of adenosine A
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2018 |
Dyskinesias and levodopa therapy: why wait?
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonergic Neurons | 2018 |
Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary | 2018 |
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity | 2018 |
The striatal cholinergic system in L-dopa-induced dyskinesias.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Parkinson Disease | 2018 |
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Receptors, N-Methyl-D-Aspartate | 2018 |
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Tumor Necrosis Factor-alpha | 2018 |
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2018 |
On the neuronal circuitry mediating L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Levodopa; Neural Pathways | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cholinergic Neurons; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2018 |
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Risk Factors | 2018 |
Amantadine Extended-Release (GOCOVRI
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
L-DOPA for Parkinson's disease-a bittersweet pill.
Topics: Animals; Antiparkinson Agents; Cell Transplantation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Pharmacogenetics and levodopa induced motor complications.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pharmacogenetics | 2019 |
Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
Topics: Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Neurosurgical Approaches to Levodopa-Induced Dyskinesia.
Topics: Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Transcranial Magnetic Stimulation | 2019 |
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Dopaminergic modulation of striatal function and Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Neurotransmitter | 2019 |
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2019 |
Dyskinesia in multiple system atrophy and progressive supranuclear palsy.
Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Supranuclear Palsy, Progressive | 2019 |
Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease; Serotonergic Neurons | 2019 |
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2019 |
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
Topics: Animals; Disease Management; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills; Parkinson Disease; Recovery of Function; Signal-To-Noise Ratio | 2013 |
Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Microdialysis; Neostriatum; Parkinson Disease; Rats; Serotonergic Neurons; Serotonin | 2013 |
New insights into the mechanism of drug-induced dyskinesia.
Topics: Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Humans; Levodopa; Neural Pathways; Thalamus | 2013 |
[Specificities of the treatment of Parkinson's disease in the elderly].
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
Mechanisms underlying cortical resonant states: implications for levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2013 |
Non-dopaminergic treatments for motor control in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Mesencephalon; Molecular Targeted Therapy; Monoamine Oxidase Inhibitors; Neurons; Off-Label Use; Parkinson Disease; Serotonin Antagonists; Tremor | 2013 |
Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.
Topics: Antiparkinson Agents; Disease Management; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Quality of Life; Risk Factors | 2012 |
Levodopa in the treatment of Parkinson's disease: current status and new developments.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2013 |
Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Multimerization; Receptors, N-Methyl-D-Aspartate | 2013 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2014 |
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials.
Topics: Databases, Bibliographic; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2014 |
Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography | 2014 |
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ganglionic Stimulants; Levodopa; Nicotine; Parkinsonian Disorders | 2014 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
Mavoglurant as a treatment for Parkinson's disease.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life; Receptor, Metabotropic Glutamate 5 | 2014 |
Emerging drugs for levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Design; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine; Signal Transduction | 2014 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primates | 2015 |
Adenosine receptors and dyskinesia in pathophysiology.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1 | 2014 |
Prognostic significance of weight changes in Parkinson's disease: the Park-weight phenotype.
Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Energy Intake; Female; Humans; Levodopa; Male; Nutritional Status; Parkinson Disease; Quality of Life; Sex Factors; Smell; Thinness; Treatment Outcome; Weight Loss | 2014 |
Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2014 |
Presynaptic effects of levodopa and their possible role in dyskinesia.
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Presynaptic Terminals | 2015 |
Targeting glutamatergic synapses in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Ionotropic Glutamate; Synaptic Transmission | 2015 |
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate | 2015 |
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
Topics: Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; GABA Antagonists; Humans; Levodopa; Parkinson Disease; Serotonin Antagonists; Serotonin Receptor Agonists | 2015 |
Clinical spectrum of levodopa-induced complications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Nitric oxide, a new player in L-DOPA-induced dyskinesia?
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitric Oxide; Parkinson Disease | 2015 |
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time | 2015 |
Molecular imaging of levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Receptors, Dopamine | 2015 |
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease | 2015 |
L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum | 2015 |
Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Neurons | 2015 |
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Topics: Animals; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Central Nervous System; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
New treatments for levodopa-induced motor complications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2015 |
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum; Parkinsonian Disorders; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2 | 2016 |
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Kynurenine; Levodopa; Molecular Structure; Parkinson Disease | 2016 |
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Topics: Animals; Antiparkinson Agents; Astrocytes; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Neurons; Parkinson Disease | 2016 |
Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Cortex; Neuronal Plasticity | 2016 |
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2017 |
Involvement of the serotonin system in L-dopa-induced dyskinesias.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonin | 2008 |
Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinsonian Disorders; Protein Transport; Receptors, N-Methyl-D-Aspartate; Synapses | 2008 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Gene Expression Regulation; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Molecular; Oxidopamine; Parkinson Disease; Protein Subunits; Rats; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2008 |
Molecular mechanisms of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease | 2008 |
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
Topics: Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin | 2008 |
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Topics: Animals; Basal Ganglia; Clinical Trials as Topic; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Isoforms; Receptors, Serotonin; Serotonin | 2008 |
Levodopa unresponsive symptoms in Parkinson disease.
Topics: Antiparkinson Agents; Anxiety; Depression; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Sweating; Xerostomia | 2008 |
Therapeutic strategies to prevent motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
Levodopa-induced dyskinesias and their management.
Topics: Antiparkinson Agents; Chorea; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2008 |
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Risk Factors; Treatment Outcome | 2008 |
Levodopa in the early treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 2009 |
The effect of onset age on the clinical features of Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenotype; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Levodopa-related wearing-off in Parkinson's disease: identification and management.
Topics: Antiparkinson Agents; Cost of Illness; Disabled Persons; Disease Progression; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Health Surveys; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Surveys and Questionnaires; Time Factors | 2009 |
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Thailand | 2009 |
Optimising levodopa therapy.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2008 |
Levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
[Management of Parkinson's disease in 2009].
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primary Dysautonomias; Prognosis; Risk Factors | 2009 |
[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2009 |
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
Topics: Antiparkinson Agents; Automatism; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gambling; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Sexual Behavior | 2009 |
Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinsonian Disorders; Polyneuropathies | 2009 |
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain-Derived Neurotrophic Factor; Dyskinesia, Drug-Induced; Humans; Levodopa; Microvessels; Neuronal Plasticity; Parkinson Disease; Serotonin | 2009 |
Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Biological; Protein Transport; Receptors, Dopamine D1; Signal Transduction | 2009 |
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.
Topics: Administration, Oral; Clinical Protocols; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Treatment Outcome | 2010 |
Rodent models of treatment-induced motor complications in Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Motor Skills Disorders; Parkinson Disease; Rats | 2009 |
Dopamine receptors and L-dopa-induced dyskinesia.
Topics: Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2009 |
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors | 2010 |
Entacapone.
Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease | 2010 |
rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
Topics: Animals; Antiparkinson Agents; Cerebellum; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Prefrontal Cortex; Transcranial Magnetic Stimulation | 2010 |
L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2010 |
The clinical spectrum of levodopa-induced motor complications.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2011 |
Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
Topics: Animals; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Models, Neurological; Motor Activity; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Signal Transduction; Synaptic Transmission | 2011 |
The treatment of early Parkinson's disease: levodopa rehabilitated.
Topics: Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2011 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Rats; Serotonergic Neurons; Serotonin | 2011 |
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Neurotransmitter Agents; Parkinson Disease; Signal Transduction | 2011 |
Molecular mechanisms of l-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate-Early; Humans; Levodopa; Neurons; Parkinson Disease; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Signal Transduction; Sirolimus | 2011 |
New approaches to therapy.
Topics: Animals; Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, Biogenic Amine | 2011 |
Surgical approach to l-dopa-induced dyskinesias.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgery; Parkinson Disease | 2011 |
Motor complications in Parkinson's disease.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Levodopa; Parkinson Disease | 2011 |
Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?".
Topics: Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Dyskinesia, Drug-Induced; Goals; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2011 |
Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality-Adjusted Life Years; Secondary Prevention | 2011 |
Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2012 |
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin | 2012 |
Animal models of L-DOPA-induced dyskinesia: an update on the current options.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Reproducibility of Results | 2012 |
Functional neuroimaging in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Diseases, Metabolic; Cognition Disorders; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Functional Neuroimaging; Humans; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Positron-Emission Tomography; Psychomotor Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2012 |
What can we expect from the serotonergic side of L-DOPA?
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonergic Neurons; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Synaptic Transmission | 2012 |
An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2012 |
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Severity of Illness Index | 2012 |
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, AMPA; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2012 |
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2013 |
Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Enkephalins; Humans; Levodopa; Protein Precursors; Receptors, GABA | 2002 |
Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Risk Factors; Speech Acoustics; Speech Disorders; Speech Production Measurement; Speech Therapy; Treatment Outcome | 2002 |
Acoustic analysis of parkinsonian speech II: L-Dopa related fluctuations and methodological issues.
Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Severity of Illness Index; Speech Acoustics; Speech Production Measurement; Speech Therapy; Treatment Outcome | 2002 |
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Motor Activity; Parkinson Disease; Receptors, Cell Surface | 2002 |
Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2002 |
Treatment of Parkinson's disease: levodopa as the first choice.
Topics: Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2002 |
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2002 |
New drugs in the future treatment of Parkinson's disease.
Topics: Animals; Antioxidants; Antipsychotic Agents; Dopamine Agonists; Drug Therapy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Psychotic Disorders | 2002 |
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine | 2003 |
Strategies to modify levodopa treatment.
Topics: Antiparkinson Agents; Drug Interactions; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2003 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2003 |
Are there clinically significant differences between dopamine agonists.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Disorders of Excessive Somnolence; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2003 |
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Delivery Systems; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Agents | 2002 |
Measuring motor complications in clinical trials for early Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Risk | 2003 |
Should levodopa be used anymore?
Topics: Antiparkinson Agents; Brain; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2002 |
Initial agonist treatment of Parkinson disease: a critique.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2003 |
[Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
[Dyskinesia caused by L-DOPA].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
[Management of levodopa-induced dyskinesia].
Topics: Algorithms; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2002 |
Motor complications of Parkinson's disease.
Topics: Drug Resistance; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease; Treatment Failure | 2003 |
[Various kinds of antiparkinson agents and their characteristics].
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System Diseases; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors | 2003 |
[Therapy for patients with progressive Parkinson's disease].
Topics: Antiparkinson Agents; Disease Progression; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Style; Parkinson Disease | 2003 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates | 2003 |
Clinical strategies to prevent and delay motor complications.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Present and future directions in the management of motor complications in patients with advanced PD.
Topics: Antiparkinson Agents; Chronic Disease; Disease Management; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinson Disease | 2003 |
Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
Topics: Animals; Basal Ganglia; Dopamine Agonists; Dyskinesia, Drug-Induced; Efferent Pathways; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Unmet medical needs in Parkinson's disease.
Topics: Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2004 |
New developments in levodopa therapy.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug | 2004 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats | 2004 |
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
Topics: Animals; Antiparkinson Agents; Area Under Curve; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2004 |
Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Depression; Dyskinesia, Drug-Induced; Forecasting; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Psychoses, Substance-Induced | 2004 |
[Pathophysiology and therapy of L-Dopa-induced dyskinesia].
Topics: Animals; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Glutamate; Receptors, Opioid; Receptors, Purinergic P1 | 2003 |
Rapid treatment of "wearing off" in Parkinson's disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease; Salvage Therapy; Time Factors | 2004 |
[Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
Topics: Adult; Antiparkinson Agents; Behavior, Addictive; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Reward; Visual Cortex | 2004 |
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2003 |
DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia.
Topics: Animals; Cyclic AMP; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Nerve Tissue Proteins; Phosphoproteins; Signal Transduction | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure | 2004 |
Deep brain stimulation in the treatment of dyskinesia and dystonia.
Topics: Dyskinesia, Drug-Induced; Dyskinesias; Dystonic Disorders; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Molecular Chaperones; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome | 2004 |
Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Dyskinesias; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Organ Specificity; Parkinson Disease; Subthalamic Nucleus; Thalamus; Treatment Outcome | 2004 |
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Forecasting; Humans; Levodopa; Parkinson Disease | 2004 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2004 |
[Medical treatment of dyskinesia].
Topics: Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa | 2004 |
Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Treatment Outcome | 2004 |
["How I do it" no. 8, dopa-resistant Parkinson's disease].
Topics: Adult; Antiparkinson Agents; Brain; Drug Resistance; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Tomography, X-Ray Computed | 2004 |
Levodopa-induced dyskinesia in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2005 |
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Learning; Levodopa; Motor Skills; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Rats; Synapses | 2005 |
Role of surgery in the treatment of motor complications.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Thalamus | 2005 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
Pathophysiology of motor fluctuations in Parkinson's disease.
Topics: Adaptation, Physiological; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Hypokinesia; Levodopa; Muscle Rigidity; Neural Pathways; Parkinson Disease; Receptors, Neurotransmitter; Thalamus; Tremor | 2005 |
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index | 2005 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2005 |
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Denervation; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neostriatum; Neuronal Plasticity; Parkinson Disease; Parkinson Disease, Secondary; Rats; Synapses | 2005 |
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2005 |
New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Pharmacogenetics | 2005 |
Optimising levodopa therapy for the management of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2005 |
Advances in the delivery of treatments for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; Drug Delivery Systems; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Forecasting; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2005 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2006 |
[Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].
Topics: Antiparkinson Agents; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; GTP-Binding Proteins; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2006 |
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease; Receptors, Dopamine | 2006 |
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dopamine Agents; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Motor Skills; Parkinsonian Disorders; Stereotyped Behavior | 2006 |
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Blood-Brain Barrier; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Synapses; Synaptic Transmission | 2006 |
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease | 2006 |
Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Levodopa; Parkinson Disease | 2006 |
[Levodopa for Parkinson's disease: What have we learned?].
Topics: Antiparkinson Agents; Chile; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2006 |
Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Synapses | 2007 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Neuronal Plasticity; Neurons; Parkinson Disease | 2007 |
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Quality of Life; Risk Factors | 2007 |
Levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; PubMed; Quality of Life; Review Literature as Topic | 2007 |
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2007 |
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2007 |
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2007 |
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate | 2007 |
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index | 2007 |
Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Locus Coeruleus; Neurons; Norepinephrine; Parkinson Disease; Receptors, Adrenergic; Receptors, Dopamine | 2007 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics | 2008 |
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 2006 |
Paradoxes of functional neurosurgery: clues from basal ganglia recordings.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Essential Tremor; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease | 2008 |
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2007 |
Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
Topics: Animals; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Signal Transduction | 2008 |
Advances in understanding L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Synaptic Transmission | 2007 |
MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Chronic Disease; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Glutamic Acid; Guanylate Kinases; Humans; Huntington Disease; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Pain; Protein Subunits; Receptors, N-Methyl-D-Aspartate; Stroke; Synapses | 2008 |
L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2008 |
Dopamine agonist therapy in early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2008 |
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Quality of Life; Receptors, Glutamate; Severity of Illness Index | 2008 |
Drug-induced tardive dyskinesia.
Topics: Aging; Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Psychotic Disorders; Racial Groups; Sex Factors | 1981 |
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Muscular Diseases; Schizophrenia | 1981 |
Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Topics: Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurotransmitter Agents; Receptors, Dopamine | 1981 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
Current psychopathological theories of tardive dyskinesia and their implications for future research.
Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Estrogens; Female; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Norepinephrine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Tyrosine 3-Monooxygenase | 1982 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
Movement disorders with neuroleptic drug treatment.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Neuroleptic Malignant Syndrome; Parasympatholytics; Parkinson Disease, Secondary; Receptors, Dopamine; Time Factors; Tourette Syndrome | 1984 |
[Tardive dyskinesia: I. Physiopathology and treatment].
Topics: Animals; Antipsychotic Agents; Baclofen; Binding Sites; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Receptors, Dopamine; Receptors, GABA-A; Reserpine | 1984 |
Involuntary movement disorders.
Topics: Brain; Chorea; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Meige Syndrome; Movement Disorders; Parasympatholytics; Parkinson Disease | 1984 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
GABA system, GABA receptor agonists and dyskinesia.
Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Movement Disorders; Receptors, Cell Surface; Receptors, GABA-A | 1983 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Pyridines; Receptors, Dopamine; Time Factors | 1984 |
[Dyskinesia (author's transl)].
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Hypersensitivity, Delayed; Levodopa; Movement Disorders; Psychotropic Drugs | 1980 |
Adverse effects of antiparkinsonian drugs.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Hypotension; Levodopa; Mental Disorders; Parasympatholytics; Vomiting | 1981 |
The management of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Nausea; Parasympatholytics; Parkinson Disease | 1982 |
[Treatment of Parkinson disease].
Topics: Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Treatment Failure | 1995 |
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
Topics: Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Cholinergic; Receptors, Dopamine; Schizophrenia | 1993 |
Respiratory dyskinesia. An underrecognized phenomenon.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Phenothiazines; Prevalence; Respiration Disorders; Risk Factors; Trifluoperazine | 1994 |
Treating motor fluctuations with controlled-release levodopa preparations.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1994 |
Various aspects of motor fluctuations and their management in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1994 |
New and emerging strategies for improving levodopa treatment.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1994 |
Clinical aspects of motor fluctuations in Parkinson's disease.
Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors | 1994 |
Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease | 1993 |
Clinical and pathophysiologic aspects of late levodopa failure.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors; Treatment Failure | 1993 |
[Oral dyskinesis, facial dystonia].
Topics: Dyskinesia, Drug-Induced; Dystonia; Face; Female; Humans; Levodopa; Male; Meige Syndrome; Mouth; Movement Disorders; Receptors, Dopamine D1; Sulpiride; Tiapamil Hydrochloride; Trihexyphenidyl | 1993 |
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Topics: Circadian Rhythm; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Time Factors | 1996 |
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Nervous System; Parkinson Disease | 1995 |
Methods of managing levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa | 1996 |
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Topics: Dyskinesia, Drug-Induced; Genetic Therapy; Humans; Levodopa; Parkinson Disease | 1997 |
Controversies in pallidal surgery.
Topics: Brain Mapping; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques | 1997 |
[Physiopathology of the dyskinesias induced by L-dopa].
Topics: Age of Onset; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1997 |
[Pharmacological therapy of complicated Parkinson's disease].
Topics: Antiparkinson Agents; Ascorbic Acid; Combined Modality Therapy; Diet Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 1997 |
Mid-stage parkinsonism with mild motor fluctuations.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1994 |
Problems with long-term levodopa therapy for Parkinson's disease.
Topics: Cognition Disorders; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Parkinson Disease; Speech Disorders; Time Factors | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
Topics: Antipsychotic Agents; Binding, Competitive; Cholinergic Antagonists; Clozapine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Ligands; Limbic System; Nerve Tissue Proteins; Parkinson Disease, Secondary; Protein Binding; Psychoses, Substance-Induced; Psychotic Disorders; Radioligand Assay; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Recurrence; Serotonin Antagonists; Tomography, Emission-Computed | 1998 |
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1998 |
Effective strategies in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills Disorders; Parkinson Disease; Time Factors | 1998 |
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Rats | 1998 |
Stereotactic surgery and Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Thalamus | 1998 |
COMT inhibition in the treatment of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
Topics: Adrenergic Antagonists; Animals; Antiparkinson Agents; Cannabinoids; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Narcotic Antagonists; Neurons; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1998 |
[Long-term complications of treatment with levodopa].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 1998 |
[Understanding and treating levodopa-induced dyskinesias].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1998 |
[Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Free Radicals; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors | 1999 |
Functional consequences of dopaminergic degeneration in Parkinson's disease.
Topics: Adaptation, Physiological; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Receptors, Dopamine D2 | 1999 |
Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
Topics: Amino Acids; Animals; Antiparkinson Agents; Brain; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Synaptic Transmission | 1999 |
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1999 |
Surgical treatment of levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Thalamus | 1999 |
New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group.
Topics: Animals; Antiparkinson Agents; Brain; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation; Humans; Levodopa; Neurology; Parkinson Disease | 1999 |
[Toxic and adverse neurological effects of anti-parkinsonian drugs].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Cholinergic Antagonists; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Psychoses, Substance-Induced; Substance-Related Disorders | 1999 |
Parkinson's disease--levodopa complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Parkinson Disease | 1999 |
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Narcotics; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin | 1999 |
Pathophysiology of L-dopa-induced dyskinesias.
Topics: Animals; Binding, Competitive; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Haplorhini; Humans; Levodopa; Neural Pathways; Neurons; Protein Isoforms; Proto-Oncogene Proteins c-fos; Receptors, GABA; Substantia Nigra | 1999 |
Rating scales for dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
L-dopa and dyskinesias in normal monkeys.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haplorhini; Levodopa | 1999 |
Quantitative assessment of dyskinesias in subhuman primates.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Diagnosis, Differential; Dronabinol; Dyskinesia, Drug-Induced; Haplorhini; Idazoxan; Levodopa; Primates; Severity of Illness Index | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2000 |
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors | 2000 |
The spectrum of levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Dopamine receptors and locomotor responses: molecular aspects.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Ion Channel Gating; Levodopa; Locomotion; Parkinson Disease; Receptors, Dopamine | 2000 |
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
Topics: Basal Ganglia; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Physiologic basis of dyskinesia.
Topics: Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Patterns of gene expression and behavior induced by chronic dopamine treatments.
Topics: Brain Chemistry; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease | 2000 |
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2000 |
Molecular basis of levodopa-induced dyskinesias.
Topics: Animals; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease | 2000 |
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Primates | 2000 |
Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; MPTP Poisoning; Primates | 2000 |
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
Topics: Cell Communication; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease | 2000 |
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
Topics: Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Substantia Nigra | 2000 |
Clinical physiology of dopa dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease | 2000 |
Neuroimaging of dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed | 2000 |
Clinical pharmacology of levodopa-induced dyskinesia.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Preventing levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Medical treatment of levodopa-induced dyskinesias.
Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Dyskinesias and the subthalamic nucleus.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2000 |
Surgery for levodopa-induced dyskinesias.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Pergolide for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide | 2000 |
Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide | 2000 |
Bromocriptine for levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 2000 |
Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease | 2000 |
Lisuride for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease | 2000 |
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
[Tardive dyskinesia and the therapeutic agents].
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa | 2000 |
Treatment of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Anxiety; Catechol O-Methyltransferase Inhibitors; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease | 2000 |
Levodopa motor complications in Parkinson's disease.
Topics: Age of Onset; Antiparkinson Agents; Brain; Cost of Illness; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 2000 |
Pathophysiology of the basal ganglia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neurons; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine | 2000 |
Electrophysiology of dopamine in normal and denervated striatal neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease | 2000 |
Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neuronal Plasticity; Stereotypic Movement Disorder | 2000 |
PET studies and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Fluorine Radioisotopes; Humans; Levodopa; Neural Pathways; Opioid Peptides; Parkinson Disease; Pulse Therapy, Drug; Putamen; Receptors, Opioid; Tomography, Emission-Computed | 2000 |
Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index | 2000 |
Continuous dopamine-receptor stimulation in early Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index | 2000 |
Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
[Treatment of advanced Parkinson's disease].
Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Severity of Illness Index | 2000 |
[Details and indications of pallidotomy and thalamotomy for Parkinson's disease].
Topics: Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Stereotaxic Techniques; Thalamus; Tremor | 2000 |
[Deep brain stimulation(DBS) therapy for parkkinson,s disease].
Topics: Clinical Trials as Topic; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Subthalamic Nucleus; Tremor; Ventral Thalamic Nuclei | 2000 |
[Cell transplantation therapy for Parkinson's disease].
Topics: Cell Transplantation; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Ganglia, Sympathetic; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Transplantation, Autologous | 2000 |
[Medical treatment of L-dopa induced dyskinesia].
Topics: Antiparkinson Agents; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
[Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson's disease patients].
Topics: Antiparkinson Agents; Brain Tissue Transplantation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Thalamus | 2000 |
Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
Topics: Corpus Striatum; Drug Therapy; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Neural Pathways; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2000 |
[Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Dyskinesias; Globus Pallidus; Humans; Levodopa; Models, Animal; Models, Neurological; Motor Skills; Neurons; Parkinsonian Disorders; Subthalamic Nucleus; Thalamus | 2001 |
Cabergoline for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Australia; Canada; Drug Tolerance; Dyskinesia, Drug-Induced; Europe; Humans; Hypokinesia; Levodopa; Middle Aged; Parkinson Disease; Prevalence; Risk; Time Factors; United States | 2001 |
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
Motor fluctuations and dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Movement; Parkinson Disease | 2001 |
Use of selective thalamotomy for various kinds of movement disorder, based on basic studies.
Topics: Antiparkinson Agents; Cerebral Hemorrhage; Chorea; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Muscle Rigidity; Paresthesia; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Surgery, Computer-Assisted; Thalamic Nuclei; Tomography, X-Ray Computed; Treatment Outcome; Tremor | 2000 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Mental Disorders; Neural Pathways; Neurons; Neurotransmitter Agents; Norepinephrine; Parasympathetic Nervous System; Parkinson Disease; Serotonin | 1978 |
In search of treatment for tardive dyskinesia: review of the literature.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Methylphenidate; Parasympatholytics; Parasympathomimetics; Patient Dropouts; Research Design | 1979 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Striatum; Dogs; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Hypothermia; Levodopa; Memory; Mice; Opioid-Related Disorders; Parkinson Disease; Psychotic Disorders; Rats; Receptors, Dopamine; Sleep; Stereotyped Behavior; Substantia Nigra; Synapses; Synaptic Transmission | 1979 |
Deanol in the management of involuntary movement disorders: a review.
Topics: Acetylcholine; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Models, Neurological; Movement Disorders; Parkinson Disease; Physostigmine; Research Design; Time Factors | 1977 |
The treatment of Parkinson's disease.
Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1977 |
Clinical pharmacokinetics of levodopa in parkinson's disease.
Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gastric Mucosa; Gastrointestinal Diseases; Homovanillic Acid; Humans; Intestinal Absorption; Kinetics; Levodopa; Mental Disorders; Parkinson Disease; Pyridoxine; Stimulation, Chemical; Time Factors | 1976 |
The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Intravenous; Levodopa; Parkinson Disease; Substantia Nigra | 1992 |
Pharmacokinetics and pharmacodynamics of levodopa.
Topics: Administration, Oral; Aromatic-L-Amino-Acid Decarboxylases; Blood; Brain; Digestive System; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine | 1992 |
Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haplorhini; Humans; Levodopa; MPTP Poisoning | 1992 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus | 1992 |
Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors | 1990 |
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Topics: Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1990 |
Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1990 |
Drug-induced neurological disorders.
Topics: Antihypertensive Agents; Aspirin; Brain Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Nervous System Diseases; Neuromuscular Diseases | 1990 |
Levodopa-induced dyskinesia: review, observations, and speculations.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine | 1990 |
Medical treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1989 |
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Topics: Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Psychoses, Substance-Induced | 1989 |
Tardive dyskinesia: epidemiologic factors as a guide for prevention and management.
Topics: Age Factors; Animals; Antipsychotic Agents; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Haplorhini; Humans; Levodopa; Parasympatholytics; Reserpine; Risk | 1985 |
Psychiatric side effects during the treatment of Parkinson's disease.
Topics: Dreams; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Mental Disorders; Paranoid Disorders; Parkinson Disease; Serotonin; Severity of Illness Index; Sleep Wake Disorders | 1988 |
Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Facial Muscles; Female; Humans; Levodopa; Meige Syndrome | 1988 |
Drug treatment of hyperkinetic movement disorders.
Topics: Benzodiazepines; Botulinum Toxins; Dopamine; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Levodopa; Movement Disorders; Parasympathomimetics | 1987 |
159 trial(s) available for levodopa and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels.
Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Theta Rhythm; Transcranial Magnetic Stimulation | 2020 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Rats | 2020 |
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2021 |
Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
Topics: Affect; Aged; Antiparkinson Agents; Drug Therapy, Combination; Duloxetine Hydrochloride; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2017 |
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects; Quinidine | 2017 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; North America; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Motor Activity; Mucuna; Parkinson Disease; Phytotherapy; Powders; Seeds; Treatment Outcome | 2017 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naphthoquinones; Parkinson Disease; Treatment Outcome | 2019 |
Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
Topics: Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording | 2018 |
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prevalence | 2019 |
The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Singapore; Treatment Outcome | 2019 |
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Survival Analysis; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Parkinson Disease; Predictive Value of Tests; Time Factors | 2013 |
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; International Cooperation; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors | 2013 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fructose; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Topiramate | 2014 |
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Raclopride; Radionuclide Imaging; Radiopharmaceuticals; Serotonergic Neurons; Serotonin 5-HT1 Receptor Agonists; Synapses; Treatment Outcome | 2014 |
Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome; Video Recording | 2014 |
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Internationality; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2015 |
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines | 2015 |
Memantine and reduced time with dyskinesia in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease | 2016 |
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Oxadiazoles; Parkinson Disease | 2016 |
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Antiparkinson Agents; Azabicyclo Compounds; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines | 2016 |
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5 | 2016 |
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2008 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Medical Records; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Transcranial Magnetic Stimulation; Treatment Outcome | 2009 |
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
Topics: Antiparkinson Agents; Cell Transplantation; Double-Blind Method; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Substantia Nigra; Videotape Recording | 2009 |
Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Time Factors; Treatment Outcome | 2009 |
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Pilot Projects; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Treatment Outcome | 2009 |
Role of an electronic armband in motor function monitoring in patients with Parkinson's disease.
Topics: Arm; Basal Metabolism; Diet, Protein-Restricted; Dyskinesia, Drug-Induced; Electronics; Energy Metabolism; Humans; Levodopa; Monitoring, Ambulatory; Motor Activity; Movement; Parkinson Disease | 2010 |
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Brain; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome | 2010 |
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2010 |
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2010 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
Patient perception of dyskinesia in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Health Knowledge, Attitudes, Practice; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Perception | 2010 |
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome | 2010 |
[Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam; Treatment Outcome | 2011 |
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
Topics: Aged; Antiparkinson Agents; Botulinum Toxins, Type A; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Male; Neuromuscular Agents; Parkinson Disease; Treatment Outcome | 2011 |
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Treatment Outcome | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Piracetam; Severity of Illness Index; Time Factors; Video Recording | 2011 |
Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Muscle Contraction; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation | 2011 |
Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome | 2011 |
Feasibility of home-based automated Parkinson's disease motor assessment.
Topics: Algorithms; Antiparkinson Agents; Computers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Patient Compliance; Software | 2012 |
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
Topics: Adult; Aged; Antiparkinson Agents; Benzoxazoles; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Piperazines; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease.
Topics: Adult; Aged; Dopamine; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2012 |
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Severity of Illness Index; Treatment Outcome | 2012 |
Psychostimulant effect of levodopa: reversing sensitisation is possible.
Topics: Anxiety; Basal Ganglia; Deep Brain Stimulation; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Subthalamic Nucleus | 2013 |
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease; Pilot Projects; Sample Size | 2013 |
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin | 2013 |
Caffeine consumption and risk of dyskinesia in CALM-PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Caffeine; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Retrospective Studies; Risk | 2013 |
Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Monitoring, Physiologic; Motion; Parkinson Disease; Wireless Technology | 2012 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
Topics: Adult; Antiparkinson Agents; Dose-Response Relationship, Drug; Down-Regulation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Subthalamic Nucleus; Treatment Outcome | 2002 |
[Pergolide: a useful agonist for the treatment of Parkinson disease].
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 2002 |
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Topics: Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Treatment Outcome | 2003 |
Amantadine in Huntington's disease: open-label video-blinded study.
Topics: Aged; Amantadine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease; Hyperkinesis; Levodopa; Male; Receptors, N-Methyl-D-Aspartate; Time Factors | 2002 |
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor | 2003 |
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome | 2003 |
Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate | 2003 |
Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate | 2004 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
Topics: Aged; Antiparkinson Agents; Clozapine; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Serotonin Receptor Agonists; Treatment Outcome | 2004 |
Further experience with extradural motor cortex stimulation for treatment of advanced Parkinson's disease. Report of 3 new cases.
Topics: Aged; Deglutition Disorders; Dura Mater; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Electrodes, Implanted; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Cortex; Muscle Rigidity; Parkinson Disease; Treatment Outcome; Tremor | 2003 |
The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, sigma; Severity of Illness Index; Tomography, Emission-Computed | 2004 |
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease; Videotape Recording | 2004 |
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Suspensions; Videotape Recording | 2005 |
Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Cohort Studies; Dyskinesia, Drug-Induced; Female; Human Development; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Smoking; Time Factors | 2005 |
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cohort Studies; DNA Mutational Analysis; DNA Repeat Expansion; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Levodopa; Male; Multivariate Analysis; Parkinson Disease; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Dopamine D2; Sex Characteristics | 2005 |
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2005 |
Neither simple nor sequential arm movements are bradykinetic in parkinsonian patients with peak-dose dyskinesias.
Topics: Aged; Antiparkinson Agents; Arm; Biomechanical Phenomena; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Placebos; Treatment Outcome | 2005 |
Treatment of levodopa-induced dyskinesias with donepezil.
Topics: Aged; Antiparkinson Agents; Donepezil; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Male; Middle Aged; Nootropic Agents; Piperidines | 2006 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Levodopa induced motor complications in Thai Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Thailand | 2006 |
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome | 2006 |
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome | 2006 |
Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome | 2006 |
Clinical features and gene analysis in Korean patients with early-onset Parkinson disease.
Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Female; Humans; Korea; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Protein Kinases; Ubiquitin-Protein Ligases | 2006 |
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Weight Loss | 2006 |
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
Topics: Antiparkinson Agents; Confidence Intervals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Longitudinal Studies; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Survival Analysis | 2006 |
Longitudinal study of the motor response to levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease | 2006 |
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Time Perception; Tremor; Walking | 2007 |
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Early Diagnosis; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Time; Time Factors; Treatment Outcome | 2007 |
Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine | 1983 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
Tiapride in levodopa-induced involuntary movements.
Topics: Aged; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Tiapamil Hydrochloride | 1983 |
[A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Placebos; Psychotic Disorders | 1983 |
Dyskinesias associated with lithium therapy in parkinsonism.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Random Allocation | 1984 |
Bromocriptine: low-dose therapy in Parkinson disease.
Topics: Aged; Bromocriptine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tremor | 1982 |
Effect of GPi pallidotomy on motor function in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Stereotaxic Techniques; Tremor; Videotape Recording | 1995 |
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease | 1994 |
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Topics: Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies | 1994 |
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Topics: Adult; Brain; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Oxindoles; Parkinson Disease; Pyridines; Receptors, Dopamine | 1993 |
Buspirone in levodopa-induced dyskinesias.
Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1995 |
Parkinson's disease: progression and mortality in the L-DOPA era.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cause of Death; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Survival Analysis | 1996 |
Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Neurons; Parkinson Disease; Prospective Studies; Time Factors | 1996 |
Sustained-release of levodopa: single dose study of a new formulation.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Patient Dropouts; Psychomotor Agitation | 1997 |
The effects of pallidotomy on Parkinson's disease: study design and assessment techniques.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Complications; Single-Blind Method; Stereotaxic Techniques; Video Recording | 1997 |
Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Individuality; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Time Factors | 1997 |
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
Risperidone in levodopa induced dyskinesiae.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Risperidone; Serotonin Antagonists; Severity of Illness Index | 1998 |
[Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 1998 |
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Clozapine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 1998 |
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Antitussive Agents; Dextromethorphan; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1998 |
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index | 1999 |
[The effect of thalamic stimulation on levodopa induced dyskinesias--evaluation of a new target: the center parafascicular median].
Topics: Aged; Cerebral Ventriculography; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Female; Humans; Levodopa; Male; Middle Aged; Retrospective Studies; Stereotaxic Techniques; Thalamic Nuclei | 1999 |
Dyskinesias assessment in Phase II studies.
Topics: Biological Transport; Brain; Clinical Protocols; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Sensitivity and Specificity | 1999 |
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Severity of Illness Index | 1999 |
Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study.
Topics: Adult; Aged; Double-Blind Method; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Subthalamic Nucleus; Treatment Outcome | 1999 |
An ambulatory dyskinesia monitor.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index | 2000 |
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Failure | 2000 |
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Topics: Aged; Antiparkinson Agents; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Risk Factors | 2000 |
Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2000 |
Low-dose olanzapine for levodopa induced dyskinesias.
Topics: Aged; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Olanzapine; Pirenzepine | 2000 |
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2000 |
Evidence of functional somatotopy in GPi from results of pallidotomy.
Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Neurologic Examination; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Severity of Illness Index; Treatment Outcome | 2000 |
[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol].
Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Treatment Outcome | 2000 |
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Pyridines; Receptors, Dopamine D1; Tetrahydronaphthalenes | 2001 |
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Remission Induction | 2001 |
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome | 2001 |
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome | 2001 |
Morphine in tardive and idiopathic dystonia (short communication).
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Middle Aged; Morphine; Neostriatum; Pain; Parkinson Disease; Pilot Projects; Receptors, Dopamine; Treatment Outcome | 2001 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug | 2001 |
The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Muscle Rigidity; Parkinson Disease; Sex Characteristics; Tremor | 2002 |
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease | 2002 |
Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2002 |
[Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
Topics: Antipsychotic Agents; Bromocriptine; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine; Schizophrenia; Time Factors; Trihexyphenidyl | 1978 |
Sodium valproate in the treatment of levodopa-induced dyskinesia.
Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valerates; Valproic Acid | 1978 |
Baclofen in Parkinson's disease.
Topics: Aged; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 1978 |
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Topics: Aged; Clinical Trials as Topic; Deanol; Double-Blind Method; Drug Evaluation; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physostigmine; Placebos | 1978 |
An evaluation of bromocriptine in the treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 1978 |
Pharmacological characterization of tardive dyskinesia.
Topics: Adult; Benztropine; Clinical Trials as Topic; Deanol; Dopamine; Droperidol; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Physostigmine; Placebos; Time Factors | 1977 |
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
Topics: Adult; Apomorphine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Single-Blind Method | 1992 |
[Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Prospective Studies; Psychomotor Disorders; Randomized Controlled Trials as Topic | 1990 |
Stable remission of tardive dyskinesia by L-dopa.
Topics: Adult; Aged; Antipsychotic Agents; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Schizophrenia | 1989 |
[Clinical study on the treatment of dyskinesia by L-stepholidine].
Topics: Aged; Berberine; Berberine Alkaloids; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Multicenter Studies as Topic; Tourette Syndrome | 1989 |
Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Electromyography; gamma-Aminobutyric Acid; Humans; Levodopa | 1985 |
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Placebos | 1987 |
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors | 1988 |
1286 other study(ies) available for levodopa and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide | 2021 |
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Ketamine; Levodopa; Male; Microglia; Parkinson Disease; Phagocytosis; Rats; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2021 |
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides | 2021 |
Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Alleles; Biomarkers; Disease Susceptibility; Dyskinesia, Drug-Induced; Exome Sequencing; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Symptom Assessment | 2021 |
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; White Matter | 2022 |
Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
Topics: Animals; Antiparkinson Agents; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Ligands; Parkinsonian Disorders; Primates; Protein Structure, Secondary; Quinpirole; Receptors, Dopamine D3 | 2022 |
Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2022 |
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.
Topics: Analgesics, Opioid; Animals; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Mice; Nociceptin; Rats; Receptors, Opioid; Signal Transduction | 2023 |
Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.
Topics: Antiparkinson Agents; Chromatography, Liquid; Dyskinesia, Drug-Induced; Humans; Levodopa; Metabolome; Neuroinflammatory Diseases; Parkinson Disease; Tandem Mass Spectrometry | 2022 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetron; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonin; Subthalamic Nucleus | 2022 |
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2022 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5 | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Neurons; Oxidopamine | 2022 |
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Disabled Persons; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease; Phosphoric Diester Hydrolases; Primates | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Human Embryonic Stem Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2022 |
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tetrabenazine | 2022 |
Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Topics: Antiparkinson Agents; Anxiety; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease | 2023 |
Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.
Topics: Animals; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Parkinson Disease | 2022 |
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome.
Topics: Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Dystonia; Dystonic Disorders; Humans; Hypoventilation; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones | 2022 |
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Thalamus | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |
Discovery of levodopa-induced dyskinesia-associated genes using genomic studies in patients and Drosophila behavioral analyses.
Topics: Animals; Drosophila; Dyskinesia, Drug-Induced; Genome-Wide Association Study; Genomics; Levodopa; Parkinson Disease | 2022 |
Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia.
Topics: Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Rats; Rodentia | 2023 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate | 2022 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Psychotic Disorders; Quality of Life; Rats; Rats, Sprague-Dawley | 2023 |
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley | 2023 |
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
Topics: Antiparkinson Agents; Cross-Cultural Comparison; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2023 |
Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Drug-Induced; Levodopa; Male; Neurosteroids; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Glucagon-Like Peptide-1 Receptor; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
The Dynamics of Dopamine D
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D2 | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease | 2023 |
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease | 2023 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Rats; RNA, Messenger | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Motor Cortex; Piperazines; Rats; Serotonin Receptor Agonists | 2023 |
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Primates; Quality of Life | 2023 |
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.
Topics: Antiparkinson Agents; Double-Blind Method; Doxycycline; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2023 |
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; Levodopa; Oxidopamine; Parkinson Disease | 2023 |
Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; GABAergic Neurons; Halorhodopsins; Levodopa; Mice; Parkinson Disease; Pars Reticulata; Substantia Nigra | 2023 |
BDNF/TrkB pathway activation in D1 receptor-expressing striatal projection neurons plays a protective role against L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Transgenic; Oxidopamine; Receptor, trkB; Receptors, Dopamine D2 | 2023 |
Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Microglia; Rats | 2023 |
Effect of the mGlu
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders; Rats | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2023 |
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinson Disease | 2023 |
Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.
Topics: Animals; Brain; Carbon Radioisotopes; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins | 2020 |
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2019 |
Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
Topics: Antiparkinson Agents; China; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Risk Factors | 2020 |
Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neostriatum; Parkinson Disease; Protein Isoforms; Proto-Oncogene Proteins c-fos; Up-Regulation | 2019 |
Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Tyrosine 3-Monooxygenase | 2020 |
Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Topics: Adenoviridae; Animals; Antiparkinson Agents; beta-Arrestin 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Gene Deletion; Genetic Therapy; Genetic Vectors; Levodopa; Male; MAP Kinase Signaling System; Neostriatum; Parkinson Disease, Secondary; Phosphoproteins; Rats; Rats, Sprague-Dawley; Recovery of Function; Transcription Factors | 2019 |
Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.
Topics: Aged; Deep Brain Stimulation; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus | 2019 |
Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Brain; Case-Control Studies; Cerebral Cortex; Connectome; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Thalamus; White Matter | 2019 |
Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies | 2019 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2 | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol | 2020 |
The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia.
Topics: Adult; Age of Onset; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease | 2019 |
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2020 |
Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cytokines; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Nervous System Diseases; Tumor Necrosis Factor-alpha | 2019 |
Dyskinesia matters.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar | 2020 |
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; GABA Modulators; Levodopa; Male; MPTP Poisoning; Parkinson Disease; Psychoses, Substance-Induced; Pyridines; Receptors, Metabotropic Glutamate; Sulfonamides | 2020 |
Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide | 2020 |
White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Comorbidity; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Leukoaraiosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Risk | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease; Receptors, Dopamine D5 | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, Drug-Induced; Electrophysiology; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley | 2020 |
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Morphine; Narcotic Antagonists; Nociception; Rats, Sprague-Dawley; Receptors, Opioid, mu | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Synaptic Transmission; Up-Regulation | 2020 |
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Sprague-Dawley | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate | 2020 |
L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Substantia Nigra | 2020 |
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials | 2020 |
Predicting levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Analysis of factors associated with brittle response in patients with Parkinson's disease.
Topics: Adult; Body Mass Index; Body Weight; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Time Factors | 2020 |
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Genotype; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Phenotype; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Rats, Inbred Lew | 2020 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger | 2020 |
Dyskinesia Matters: But Not as Much as It Used to.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; DNA-Binding Proteins; Dyskinesia, Drug-Induced; Guanine Nucleotide Exchange Factors; Humans; Levodopa; Mammals; Parkinson Disease; TOR Serine-Threonine Kinases | 2020 |
Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid | 2020 |
High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Pain; Parkinson Disease | 2020 |
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Synaptic Transmission | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced | 2020 |
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Dendritic Spines; Depression; Drug Repositioning; Dyskinesia, Drug-Induced; Ketamine; Levodopa; Male; MAP Kinase Signaling System; Neurons; Rats; Rats, Sprague-Dawley; TOR Serine-Threonine Kinases | 2020 |
Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Gene Regulatory Networks; Inhibin-beta Subunits; Levodopa; Male; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Signal Transduction; Tachykinins; Tissue Inhibitor of Metalloproteinase-1; Transcriptome; Transforming Growth Factor beta1; Up-Regulation | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca fascicularis; Microglia; Parkinson Disease | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia.
Topics: Aged; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neostriatum; Neurodegenerative Diseases; Presynaptic Terminals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes | 2020 |
Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease.
Topics: Activities of Daily Living; Aged; Cross-Sectional Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Social Participation | 2020 |
Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias.
Topics: Antiparkinson Agents; Chromatography, High Pressure Liquid; Dyskinesia, Drug-Induced; Endocannabinoids; Humans; Levodopa; Parkinson Disease | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
Angiotensin AT
Topics: Animals; Calcium; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Mice; Phosphorylation; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Signal Transduction; Substantia Nigra | 2020 |
Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors | 2020 |
GraphNet-based imaging biomarker model to explain levodopa-induced dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Biomarkers; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases | 2020 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Embryo, Mammalian; Gene Knock-In Techniques; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Sympatholytics; Vesicular Glutamate Transport Protein 2 | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2021 |
Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Genetic Therapy; Hydroxydopamines; Levodopa; Male; MicroRNAs; Neostriatum; Psychomotor Performance; Rats; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2021 |
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists | 2021 |
Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort.
Topics: Aged; Attention; Cognitive Dysfunction; Cohort Studies; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Proportional Hazards Models; Severity of Illness Index | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2021 |
Bilateral subthalamic nucleus deep brain stimulation is an effective treatment for diphasic dyskinesia.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Subthalamic Nucleus; Treatment Outcome | 2021 |
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mass Spectrometry | 2021 |
Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Brain; Dyskinesia, Drug-Induced; Female; Gray Matter; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors | 2021 |
Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
Topics: Animals; Basal Ganglia; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Motor Activity; Synaptic Transmission | 2021 |
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gamma Rhythm; Ketamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2021 |
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; Interferon-gamma; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders | 2021 |
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Rats | 2021 |
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Doxycycline; Dyskinesia, Drug-Induced; Levodopa; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Oxidopamine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Tetracyclines | 2021 |
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; Motivation; Motor Activity; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2021 |
Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Wearable Electronic Devices | 2021 |
Differential roles of two isoforms of dopamine D2 receptors in l-dopa-induced abnormal involuntary movements in mice.
Topics: Animals; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Protein Isoforms; Quinpirole; Receptors, Dopamine D2; Salicylamides | 2021 |
Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2021 |
Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2021 |
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Hypoglycemic Agents; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Growth Factor | 2021 |
Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction | 2021 |
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease.
Topics: Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease | 2021 |
Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes.
Topics: Animals; Corpus Striatum; DNA Methylation; Dyskinesia, Drug-Induced; Levodopa; Rats; Rats, Wistar; Riluzole | 2021 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Biomarkers; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Fibers; Odds Ratio; Parkinson Disease; Temporal Lobe; White Matter | 2021 |
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson's disease.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Genetic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests | 2021 |
Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease.
Topics: COVID-19; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; RNA, Messenger; RNA, Viral; SARS-CoV-2; Vaccines | 2021 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2 | 2017 |
A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease.
Topics: Aged; Awareness; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Regression Analysis; Theory of Mind | 2017 |
A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
Topics: Antiparkinson Agents; Computer Communication Networks; Dyskinesia, Drug-Induced; Health Resources; Humans; Levodopa; Parkinson Disease | 2017 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P | 2017 |
What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2017 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Septal Nuclei | 2017 |
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene Expression; Isoxazoles; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Zonisamide | 2017 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Positron-Emission Tomography; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Sympatholytics | 2017 |
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Denmark; Dyskinesia, Drug-Induced; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Parkinson Disease; Signal Transduction; Single-Blind Method | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2017 |
Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Pharmacogenomic Variants; Receptors, Opioid, kappa; Time Factors | 2018 |
Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
Topics: Aged; Antiparkinson Agents; Demyelinating Diseases; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Osmosis; Parkinsonian Disorders | 2017 |
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
Topics: Aged; Behavior, Addictive; Central Nervous System Stimulants; Depressive Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Substance-Related Disorders | 2017 |
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Piperazines; Time Factors | 2017 |
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Gene Expression; HEK293 Cells; Humans; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons | 2017 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Topics: Aged; Amantadine; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Treatment Outcome | 2017 |
Teaching Video Neuro
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Videotape Recording | 2017 |
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca mulatta; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Post-Synaptic Density; Protein Binding; Rabphilin-3A; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques; Vesicular Transport Proteins | 2017 |
The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Topics: Animals; Benzodioxoles; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Movement; Neostriatum; Parkinson Disease; Phosphorylation; Protein Subunits; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2018 |
The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Second-Generation; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; MPTP Poisoning; Psychotic Disorders; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Plasmalogens; Time Factors | 2018 |
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2017 |
Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
Topics: Aged; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum.
Topics: Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Interneurons; Levodopa; Locomotion; Male; Parkinson Disease; Rats, Long-Evans; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2018 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Metformin; Mice, Inbred C57BL; Parkinson Disease; Signal Transduction | 2018 |
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hypercapnia; Levodopa; Male; Middle Aged; Neuroimaging; Parkinson Disease; Putamen; Sensorimotor Cortex | 2017 |
Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Machine Learning; Parkinson Disease | 2017 |
Factors associated with motor complications in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Long Term Adverse Effects; Male; Middle Aged; Parkinson Disease; Time-to-Treatment; Treatment Outcome | 2017 |
CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Topics: Animals; Casein Kinase II; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Gene Expression; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neurons; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2017 |
The effects of cysteamine in a mouse model of levodopa-induced dyskinesias.
Topics: Animals; Cysteamine; Cystine Depleting Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice | 2018 |
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidative Stress; Parkinson Disease; Poly(ADP-ribose) Polymerases; Rats; Reactive Oxygen Species; Substantia Nigra; Thioctic Acid | 2018 |
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2017 |
Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
Topics: Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Community Health Planning; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Association Studies; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Retrospective Studies | 2018 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens | 2018 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agents; Corpus Striatum; Cricetinae; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Nociceptin Receptor; Oxidopamine; Phosphorylation; Piperidines; Radioligand Assay; Rats; Receptors, Opioid | 2018 |
Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fyn; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2018 |
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Excessive Somnolence; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Serotonin Receptor Agonists; Trazodone | 2018 |
Striatal norepinephrine efflux in l-DOPA-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Rats; Rats, Sprague-Dawley | 2018 |
Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Neurons; Receptors, Glutamate | 2018 |
A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Neural Pathways; Neurons; Optogenetics; Parkinson Disease | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged | 2018 |
Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Nicotine; Nicotinic Agonists; Synaptosomes | 2018 |
A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Organic Chemicals; Phosphodiesterase Inhibitors | 2018 |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Knockout Techniques; Levodopa; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar | 2018 |
Levodopa-Induced Dyskinesia: "TRAP"ping the Culprit.
Topics: Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons | 2018 |
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Image Interpretation, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Reported Outcome Measures; Sensitivity and Specificity; Severity of Illness Index; Video Recording | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon | 2018 |
Association of metals with the risk and clinical characteristics of Parkinson's disease.
Topics: Aged; Copper; Dyskinesia, Drug-Induced; Female; Humans; Iron; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Sex Characteristics | 2018 |
Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia.
Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurons; Optogenetics; Parkinsonian Disorders; Receptors, Dopamine | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger | 2018 |
Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Mice; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Striatonigral Degeneration | 2018 |
Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Impulsive Behavior; Levodopa; Male; Motor Activity; Parkinson Disease; Reaction Time | 2018 |
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
Topics: Alleles; Dyskinesia, Drug-Induced; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide; Retrospective Studies; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Fos-Related Antigen-2; Gene Expression Regulation; Histone Acetyltransferases; Histone Code; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Specific Pathogen-Free Organisms; Substantia Nigra; Terpenes | 2018 |
Dyskinesia in Parkinson's disease: a clinical complication and an open scientific question.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies | 2018 |
Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Topics: Acupuncture Therapy; Animals; Aphakia; Dyskinesia, Drug-Induced; Gene Expression Regulation; Homeodomain Proteins; Hypothalamic Hormones; Hypothalamus; Levodopa; Melanins; Mice, Inbred C57BL; Neostriatum; Oxidopamine; Pituitary Hormones; Reproducibility of Results; RNA, Messenger; Transcription Factors; Up-Regulation | 2019 |
Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; Tyrosine 3-Monooxygenase | 2019 |
Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Regression Analysis | 2018 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles | 2018 |
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Macaca fascicularis; MPTP Poisoning; Multimodal Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Fibers; Parkinson Disease, Secondary; Positron-Emission Tomography; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2018 |
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Peptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; src-Family Kinases | 2019 |
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Binding; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sulfonamides | 2018 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats | 2018 |
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Metabotropic Glutamate; Time Factors | 2018 |
Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.
Topics: Allosteric Regulation; Animals; Aphakia; Biomarkers; Corpus Striatum; Down-Regulation; Dyskinesia, Drug-Induced; Female; Gene Knockdown Techniques; Levodopa; Male; Mice, Inbred C57BL; Models, Biological; Neurons; Nicotine; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1 | 2019 |
NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses | 2019 |
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
Topics: Animals; Drug Development; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Translational Research, Biomedical | 2019 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Alleles; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Italy; Levodopa; Male; Minisatellite Repeats; Parkinson Disease; Polymorphism, Genetic; Prevalence | 2019 |
Levodopa-induced dyskinesia in Parkinson disease: Sleep matters.
Topics: Actigraphy; Adult; Aged; Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Psychiatric Status Rating Scales; Sleep Wake Disorders; Statistics, Nonparametric | 2018 |
Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2018 |
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2018 |
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole | 2019 |
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wave.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Rats; Serotonin; Vilazodone Hydrochloride | 2018 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Brain-Derived Neurotrophic Factor; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Furans; Levodopa; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Quinuclidines; Random Allocation | 2018 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Piperazines; Rats; Substantia Nigra; Theta Rhythm | 2019 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide | 2019 |
Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Topics: Animals; Autoreceptors; Dopamine; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Ectopic Gene Expression; HEK293 Cells; Humans; Levodopa; Male; Rats, Inbred F344; Receptors, Dopamine D2; Serotonergic Neurons; Synaptic Transmission | 2019 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Risk Factors; Time Factors | 2019 |
Striatal spreading depolarization: Possible implication in levodopa-induced dyskinetic-like behavior.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiparkinson Agents; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Neurons; Nitrogen Mustard Compounds; Parkinsonian Disorders; Prednisolone; Procarbazine; Rats; Rats, Wistar; Synaptic Transmission; Vincristine | 2019 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure | 2019 |
Chronic administration of the histamine H
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar; Receptors, Histamine H3; Substantia Nigra | 2019 |
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra | 2019 |
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders | 2019 |
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Biomarkers; Creatine Kinase; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2019 |
Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Cohort Studies; Depression; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index | 2019 |
Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.
Topics: Aging; Animals; Dyskinesia, Drug-Induced; Gene Expression; Inflammation; Interleukin-1beta; Interleukin-6; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred F344; Risk Factors | 2019 |
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinase 3; Histamine H2 Antagonists; Levodopa; MAP Kinase Signaling System; Mice, Inbred C57BL; Parkinson Disease; Proto-Oncogene Proteins c-fos; Ranitidine; Receptors, Histamine H2 | 2019 |
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunologic Factors; Interleukin-10; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha | 2019 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome | 2013 |
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Movement; Neurons; Oxidopamine; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2013 |
Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Microinjections; Motor Activity; Nitric Oxide Synthase Type I; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar | 2013 |
A cup of coffee a day keeps dyskinesia away?
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Benzothiazoles; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Pramipexole | 2013 |
[PSD-95 expression controls L-Dopa dyskinesia].
Topics: Animals; Disks Large Homolog 4 Protein; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Models, Genetic; Parkinson Disease; Protein Transport; Receptors, Dopamine D1 | 2013 |
Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients.
Topics: Adult; Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electromyography; Evoked Potentials, Motor; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Transcranial Magnetic Stimulation | 2014 |
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal | 2013 |
NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; Blotting, Western; Corpus Striatum; Down-Regulation; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Statistics, Nonparametric | 2013 |
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Azabicyclo Compounds; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nerve Tissue Proteins; Neurons; Nicotinic Agonists; Parkinson Disease; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Synaptosomes | 2013 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
The K(V)7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Benzamides; Dyskinesia, Drug-Induced; Female; Ion Channel Gating; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2013 |
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Valproic Acid | 2013 |
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
Topics: Aged; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Israel; Italy; Jews; Levodopa; Male; Middle Aged; Polymorphism, Single Nucleotide | 2013 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2014 |
Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neurodegenerative Diseases; Normal Distribution; Parkinson Disease; Substantia Nigra | 2013 |
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Topics: Amantadine; Animals; Azabicyclo Compounds; Cyclopropanes; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Nicotinic Agonists | 2013 |
Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration.
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Levodopa | 2013 |
Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2014 |
Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Cotinine; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Parkinson Disease, Secondary; Saimiri | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2013 |
Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Levodopa; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Synapses; Thalamus | 2013 |
Commentary.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinsonian Disorders; Substantia Nigra | 2013 |
Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
Topics: Aged; Antiparkinson Agents; Craniocerebral Trauma; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiography; Substantia Nigra; Tomography Scanners, X-Ray Computed | 2013 |
Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms.
Topics: Aged; Aged, 80 and over; Awareness; Diagnostic Self Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording | 2013 |
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Saimiri | 2013 |
Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Autoradiography; Basal Ganglia; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Postmortem Changes; Proto-Oncogene Proteins c-fos; Putamen; Up-Regulation | 2011 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Stereotyped Behavior | 2012 |
mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Tremor; Wrist | 2013 |
Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Malaysia; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Factors; Severity of Illness Index | 2014 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Benzamides; Brain; Case-Control Studies; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin; Sulfonamides; Thiazoles | 2013 |
Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric | 2014 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2013 |
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide; Prevalence; Time Factors | 2014 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine D1; Serotonin Receptor Agonists; Thiazoles | 2013 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |
Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain; Cytoskeletal Proteins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Fos-Related Antigen-2; Immediate-Early Proteins; Levodopa; Male; Nerve Tissue Proteins; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2014 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists | 2014 |
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists | 2013 |
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2013 |
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; In Situ Hybridization; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2013 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oleic Acids; Oxidopamine; Parkinson Disease; TRPV Cation Channels | 2014 |
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction | 2014 |
Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Levodopa; Nerve Fibers; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Plasma Membrane Transport Proteins | 2014 |
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2014 |
Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male | 2014 |
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; beta-Arrestins; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Female; G-Protein-Coupled Receptor Kinases; Immunohistochemistry; Levodopa; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2013 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Rats; Rats, Wistar; Telencephalon | 2014 |
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Forelimb; Kainic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Long-Evans | 2014 |
Initiating levodopa therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male | 2014 |
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzodioxoles; Callithrix; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Mental Disorders; Methylamines; Molecular Structure; Motor Activity; Parkinsonian Disorders; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzopyrans; Corpus Striatum; Dependovirus; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Genetic Vectors; Green Fluorescent Proteins; Immunohistochemistry; Levodopa; Mastication; Motor Activity; Neurons; Oxazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Transfection | 2014 |
Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Asian People; China; Cross-Sectional Studies; Cultural Characteristics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Treatment Outcome | 2014 |
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotinic Agonists; Pyridines; Pyrrolidines; Saimiri; Treatment Outcome | 2014 |
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.
Topics: Adenoviridae; Animals; Antiparkinson Agents; Behavior, Animal; Denervation; Diphtheria Toxin; DNA, Complementary; Dyskinesia, Drug-Induced; Hydroxydopamines; Image Processing, Computer-Assisted; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Parasympathetic Nervous System; Parkinsonian Disorders | 2014 |
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Tryptophan | 2014 |
Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
Topics: Animals; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Neurites; Neurons; Parkinson Disease; Rats, Wistar; Synapses | 2014 |
Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2014 |
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Gene Expression; Homeostasis; Levodopa; Mice | 2014 |
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Endocannabinoids; Gene Expression; Gene Ontology; Levodopa; Male; Microarray Analysis; Motor Activity; Oxidopamine; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2014 |
Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Retrospective Studies; Severity of Illness Index | 2014 |
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Imidazoles; Levodopa; Macaca fascicularis; MPTP Poisoning | 2014 |
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Benzamides; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Extracellular Space; Female; Levodopa; Microdialysis; Neostriatum; Nomifensine; Parkinson Disease; Positron-Emission Tomography; Proto-Oncogene Proteins c-fos; Pyrrolidines; Rats, Sprague-Dawley; Receptors, Dopamine; Serotonin | 2014 |
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Minisatellite Repeats; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D2 | 2014 |
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase | 2014 |
Parkinson disease: A role for serotonergic neurons in levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Serotonergic Neurons | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos | 2014 |
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Topics: Aged; Antiparkinson Agents; Chi-Square Distribution; Cohort Studies; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Tropanes | 2014 |
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals | 2014 |
The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunction.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; MPTP Poisoning; Neural Pathways; Time Factors | 2015 |
Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa | 2014 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins | 2014 |
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice, Knockout; Neuronal Plasticity; Neurons; Nitriles; Oxidopamine; Parkinsonian Disorders; Protein Kinase Inhibitors; ras-GRF1; Tissue Culture Techniques | 2015 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test | 2015 |
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Imidazoles; Levodopa; Macaca mulatta; Male; Motor Activity; MPTP Poisoning; Pyridines; Receptor, Metabotropic Glutamate 5; Severity of Illness Index; Time Factors | 2014 |
The acute brain response to levodopa heralds dyskinesias in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Decision Making; Dyskinesia, Drug-Induced; Female; Head Movements; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease; Psychomotor Performance; Reaction Time; Time Factors | 2014 |
Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions.
Topics: Animals; Antiparkinson Agents; Anxiety; Cholinergic Neurons; Cocaine; Corpus Striatum; Diphtheria Toxin; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Heparin-binding EGF-like Growth Factor; Humans; Interneurons; Levodopa; Mice, Transgenic; Monosaccharide Transport Proteins; Movement; Neural Pathways; Neurotoxins; Promoter Regions, Genetic; Substantia Nigra | 2014 |
(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Aporphines; Base Sequence; Disease Models, Animal; DNA Primers; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Serotonin Receptor Agonists | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats | 2014 |
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; MPTP Poisoning; Nicotinic Agonists; Quinuclidines; Saimiri | 2014 |
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Age of Onset; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Data Interpretation, Statistical; Disease Progression; Dyskinesia, Drug-Induced; Female; Ghana; Humans; Italy; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Young Adult | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease.
Topics: Aged; Awareness; Dopamine Agents; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Self Concept | 2014 |
Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
Topics: Action Potentials; Aged; Antiparkinson Agents; Basal Ganglia; Biophysical Phenomena; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Nerve Net; Neurons; Parkinson Disease; Severity of Illness Index; Statistics as Topic | 2014 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2016 |
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A | 2014 |
Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antiparkinson Agents; Blotting, Western; Disease Models, Animal; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
A new quantitative rating scale for dyskinesia in nonhuman primates.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Observer Variation; Parkinsonian Disorders; Reproducibility of Results; Severity of Illness Index; Video Recording | 2015 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1 | 2014 |
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Nicotinic Agonists; Ovariectomy; Time Factors | 2014 |
Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Topics: Action Potentials; Age Factors; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Inhibitory Postsynaptic Potentials; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease; Pars Reticulata; Receptor, Adenosine A1; Receptors, Dopamine D1; Xanthines | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2015 |
Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; GABAergic Neurons; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Metabotropic Glutamate; Receptors, Purinergic P1 | 2014 |
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Ribosomal Protein S6 Kinases, 90-kDa | 2016 |
Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase Type I; Oxidopamine; Rats; Rats, Wistar | 2015 |
Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Topics: Animals; Corpus Striatum; Denervation; Desipramine; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Phosphorylation; Rats; Rats, Sprague-Dawley; Substantia Nigra; Synapses | 2014 |
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2015 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors | 2015 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Half-Life; High-Throughput Screening Assays; Humans; Hyperthermia, Induced; Indoles; Levodopa; Male; Mice; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrrolidinones; Rats, Sprague-Dawley | 2015 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatum; Dimerization; Dominance, Cerebral; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinsonian Disorders; Putamen; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2015 |
A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Efferent Pathways; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Prefrontal Cortex; Theta Rhythm; Transcranial Magnetic Stimulation | 2015 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophysiology; Female; Genes, Immediate-Early; Habenula; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2016 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation | 2015 |
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Random Allocation | 2014 |
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Cyclic AMP; Cyclic GMP; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Putamen; Rats; Rats, Wistar | 2014 |
Dyskinesias and motor symptoms onset in Parkinson disease.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Movement; Parkinson Disease; Retrospective Studies | 2014 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
Topics: Animals; Antiparkinson Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Pilot Projects; Pioglitazone; Thiazolidinediones | 2015 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2015 |
Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; C-Reactive Protein; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins | 2015 |
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine | 2015 |
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2015 |
Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dyskinesia, Drug-Induced; Homeostasis; Levodopa; Male; Neuronal Plasticity; Parkinson Disease; Rats, Sprague-Dawley; Sleep; Sleep Deprivation | 2015 |
Can levodopa-induced dyskinesias go beyond the motor circuit?
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Prefrontal Cortex | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase | 2015 |
Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Biomarkers; Case-Control Studies; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra | 2015 |
Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychometrics; Qualitative Research; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Cholinergic Neurons; Corpus Striatum; Dicyclomine; Disease Models, Animal; Dyskinesia, Drug-Induced; Famotidine; Histamine H2 Antagonists; Interneurons; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Receptors, Histamine H2 | 2015 |
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Piperazines | 2015 |
Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
Topics: Animals; Cell Nucleus; Cytosol; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Mitogen-Activated Protein Kinases; Neostriatum; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction | 2015 |
Quantitative motor assessment of dyskinesias in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; ROC Curve; Severity of Illness Index | 2015 |
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Gels; Humans; Hungary; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Haloperidol; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2015 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Random Allocation | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P | 2015 |
Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Anti-Dyskinesia Agents; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Phosphatidylethanolamines; Plasmalogens | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2015 |
Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
Topics: Analgesics, Opioid; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Male; Nalbuphine; Neostriatum; Parkinson Disease; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2015 |
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Motor Activity; Parkinsonian Disorders; Propranolol; Rats; Rats, Sprague-Dawley | 2015 |
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Association Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Receptor, Adenosine A2A | 2015 |
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Neuroimaging; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Psychomotor Performance; Putamen | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-fos; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ethanol; Gynostemma; Levodopa; Locomotion; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Solvents | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation | 2015 |
Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Sulfonamides | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome | 2015 |
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Piperidines; Pyrimidines; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index | 2015 |
Motor complications in an incident Parkinson's disease cohort.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Scotland | 2016 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Mice; Parkinson Disease; Receptors, Neurotransmitter; Severity of Illness Index; Time Factors | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
Topics: Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Distress Syndrome; Subthalamic Nucleus; Treatment Outcome | 2015 |
Parkinson's disease related dyskinesia in a Tanzanian population.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tanzania | 2015 |
Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Posture; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index; Signal Detection, Psychological | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Glutamate Decarboxylase; Levodopa; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine D1; Receptors, G-Protein-Coupled | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Ovariectomy; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1B | 2015 |
Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Period; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome | 2015 |
The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Inhibition; Parkinson Disease | 2015 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission | 2015 |
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Fibroblasts; Globus Pallidus; Levodopa; Macaca mulatta; Parkinsonian Disorders | 2015 |
Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2015 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric | 2016 |
Striatal NELF-mediated RNA polymerase II stalling controls L-dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cell Culture Techniques; Corpus Striatum; Cytoskeletal Proteins; Disease Models, Animal; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Levodopa; Male; Nerve Tissue Proteins; Neurons; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; RNA Polymerase II; Transcription Factors | 2016 |
Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
Topics: Animals; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2017 |
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamic Acid; GTP-Binding Proteins; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Multiprotein Complexes; Neurons; Neuroprotective Agents; Sirolimus; Substantia Nigra; TOR Serine-Threonine Kinases | 2016 |
[The use of piribedil in early and late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piribedil | 2015 |
[Pain fluctuations in Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease | 2015 |
Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Transcranial Direct Current Stimulation; Treatment Outcome | 2016 |
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
Topics: Amino Acid Transport Systems, Acidic; Animals; Circadian Rhythm; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Skills Disorders; Parkinsonian Disorders | 2015 |
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra | 2015 |
[An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Parkinson Disease; Serotonergic Neurons | 2015 |
Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus | 2016 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists | 2016 |
Bridging the Gap: Muscarinic M4 Receptors Promote Striatal Plasticity in Health and Disease.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Neostriatum; Neuronal Plasticity; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins | 2015 |
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction | 2015 |
Levodopa-Induced Motor and Dopamine Receptor Changes in Caenorhabditis elegans Overexpressing Human Alpha-Synuclein.
Topics: Actigraphy; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Dyskinesia, Drug-Induced; Humans; Levodopa; Microscopy, Confocal; Motor Activity; Motor Neurons; Parkinsonian Disorders; Pattern Recognition, Automated; Receptors, Dopamine | 2016 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases | 2016 |
Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ketamine; Levodopa; Male; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Time Factors | 2016 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins | 2016 |
Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D3 | 2016 |
D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
Topics: Aged; Carbon Radioisotopes; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3; Up-Regulation; Ventral Striatum | 2016 |
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2016 |
Detection of Levodopa Induced Dyskinesia in Parkinson's Disease patients based on activity classification.
Topics: Accelerometry; Activities of Daily Living; Aged; Algorithms; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Wearable Electronic Devices | 2015 |
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain Waves; Disease Models, Animal; Dopaminergic Neurons; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Electroencephalography; Female; Levodopa; Rats; Rats, Sprague-Dawley | 2016 |
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists | 2016 |
Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Coffee; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2016 |
The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
Topics: Animals; Dopamine Agents; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin | 2016 |
Unraveling the Mechanism of Dyskinesia One Transcription Factor at a Time.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Transcription Factors | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2016 |
Altered inhibitory interaction among inferior frontal and motor cortex in l-dopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2016 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra | 2016 |
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 2016 |
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Parkinson Disease; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar | 2016 |
Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Topics: Aged; Biomarkers; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon | 2016 |
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Neostriatum; Nicotine; Nicotinic Agonists; Optogenetics | 2016 |
Transcranial Non-Invasive Brain Stimulation in Parkinson's Disease Patients with Dyskinesias. Where is the Optimal Target?
Topics: Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2017 |
A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Prospective Studies | 2016 |
Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Video Recording | 2016 |
Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Connectome; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Prognosis; Putamen; Sensorimotor Cortex | 2016 |
Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Optogenetics; Parkinson Disease; Rats; Subthalamic Nucleus | 2016 |
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Humans; Interviews as Topic; Italy; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Phenotype; Risk; Severity of Illness Index; Time Factors | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Levodopa; Mice; Oxidopamine; Rotarod Performance Test; Taurine; Tyrosine | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Rats; Receptors, Dopamine D1; tau Proteins; Thiadiazoles; Tyrosine 3-Monooxygenase | 2016 |
Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyskinesia, Drug-Induced; Female; Ibuprofen; Levodopa; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Piroxicam; Random Allocation; Rats; Substantia Nigra; Time Factors | 2016 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Neural Stem Cells; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2016 |
Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Cell Death; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Peptide Fragments; Protein Domains; Proto-Oncogene Proteins c-fos; Rats; Substantia Nigra; Tetanus Toxin; Tyrosine 3-Monooxygenase | 2016 |
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bites and Stings; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Indoles; Laryngeal Diseases; Levodopa; Lewy Body Disease; Middle Aged; Olanzapine; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiophenes; Tongue Diseases | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Oxidopamine; Protein Precursors; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Using epigenetic networks for the analysis of movement associated with levodopa therapy for Parkinson's disease.
Topics: Accelerometry; Antiparkinson Agents; Data Mining; Dyskinesia, Drug-Induced; Epigenomics; Gene Regulatory Networks; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease | 2016 |
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; Dyskinesia, Drug-Induced; Endocannabinoids; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice, Inbred C57BL; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; PPAR gamma; Receptor, Cannabinoid, CB1; TRPV Cation Channels; Tyrosine 3-Monooxygenase | 2016 |
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.
Topics: Animals; Biocompatible Materials; Blotting, Western; Chitosan; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Immunohistochemistry; Levodopa; Liposomes; Male; MAP Kinase Signaling System; Nanoparticles; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Reproducibility of Results; Treatment Outcome | 2016 |
[Motor levodopa-induced complications in Parkinson's disease].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2016 |
Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Calbindins; Caudate Nucleus; Cerebellum; Chlorocebus aethiops; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Male; Mesencephalon; Microglia; MPTP Poisoning; Neurons; Putamen; Tyrosine 3-Monooxygenase | 2017 |
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition Disorders; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hypokinesia; Levodopa; Macaca fascicularis; Motor Skills Disorders; MPTP Poisoning; Purines; Treatment Outcome | 2016 |
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus; Tremor | 2016 |
Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biophysics; Case-Control Studies; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Parkinson Disease; Theta Rhythm; Transcranial Magnetic Stimulation | 2016 |
Unilateral Subthalamic Nucleus Stimulation in the Treatment of Asymmetric Parkinson"s Disease with Early Motor Complications.
Topics: Aftercare; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2017 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Outcome Assessment, Health Care; Oxidopamine; Parkinson Disease; Reproducibility of Results; Time Factors | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spine; Sympatholytics | 2016 |
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Parkinson Disease; Problem Behavior; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Transcranial Magnetic Stimulation; Tyrosine 3-Monooxygenase | 2016 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley | 2016 |
Subthalamic oscillatory activity in parkinsonian patients with off-period dystonia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2016 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dyskinesia, Drug-Induced; Encephalitis; Functional Laterality; Gene Expression Regulation; Levodopa; Lipopolysaccharides; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics; Tumor Necrosis Factor-alpha | 2016 |
Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vasomotor System | 2016 |
Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Contraindications; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Neurosurgery; Parkinson Disease; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Time Factors; Treatment Outcome; Visual Analog Scale | 2017 |
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2017 |
Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.
Topics: Action Potentials; Animals; Antiparkinson Agents; Automation, Laboratory; Corpus Striatum; Delta Rhythm; Dyskinesia, Drug-Induced; Electrodes, Implanted; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Neurons; Pattern Recognition, Automated | 2017 |
Motor cortex plasticity can indicate vulnerability to motor fluctuation and high L-DOPA need in drug-naïve Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2017 |
The impact of early versus late levodopa administration.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Time Factors | 2017 |
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor | 2018 |
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; Mirtazapine; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced | 2017 |
Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.
Topics: Activities of Daily Living; Deep Brain Stimulation; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2017 |
Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Retrospective Studies; Vomiting | 2017 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 2017 |
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Gases; Isoflurane; Ketamine; Levodopa; Parkinson Disease; Rats | 2017 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Topics: Animals; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Jaw; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Tremor; Urea | 2008 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Motor Skills; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Receptor Agonists; Stereotyped Behavior | 2008 |
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Dopa Decarboxylase; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; France; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Practice Patterns, Physicians'; Retrospective Studies | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Infusion Pumps; Levodopa; Male; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation | 2008 |
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Anxiety Disorders; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Learning Disabilities; Levodopa; Male; Maze Learning; Memory Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thiazoles | 2008 |
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphorylation; Purinones; Rats; Rats, Sprague-Dawley; Second Messenger Systems; Substantia Nigra; Sympatholytics; Synaptic Transmission | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Isradipine; Levodopa; Male; Motor Activity; Nimodipine; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Sympatholytics | 2009 |
Use of clozapine in Brazilian patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Retrospective Studies | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2008 |
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Gene Expression; Genotype; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic; Receptor, trkB; Risk Factors; Synapses; Time Factors | 2009 |
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Graft Survival; Levodopa; Mesencephalon; Microdialysis; Neurons; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Models, Animal; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2009 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Risk Factors; Rotation; Species Specificity; Sympatholytics; Time Factors; Treatment Outcome | 2009 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences?
Topics: Age Factors; Aged; Antiparkinson Agents; Brain; Brain Mapping; Constipation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Odds Ratio; Parkinson Disease; REM Sleep Behavior Disorder; Sex Factors; Tomography, Emission-Computed, Single-Photon | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
A new perspective on brain derived neurotrophin factor polymorphism in L-dopa induced dyskinesia.
Topics: Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Genetic Markers; Genotype; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic | 2009 |
Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue; Trihexyphenidyl | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics | 2009 |
Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos.
Topics: Analysis of Variance; Antiparkinson Agents; Biomedical Engineering; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Tremor; Video Recording | 2008 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase | 2009 |
Chronic intermittent L-DOPA treatment induces changes in dopamine release.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Potassium; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists | 2009 |
Levodopa-induced dyskinesia and striatal signaling pathways.
Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Signal Transduction | 2009 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Piperazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Sigma-1 Receptor | 2009 |
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2009 |
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Agents | 2009 |
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2009 |
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2009 |
Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.
Topics: Antiparkinson Agents; Dopamine Agonists; Duodenum; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Parkinson Disease; Suspensions | 2008 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics | 2009 |
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Graft Survival; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; In Situ Hybridization; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Receptor, Cannabinoid, CB1; Severity of Illness Index | 2011 |
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; China; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Time Factors | 2009 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger | 2009 |
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2009 |
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Dyskinesia, Drug-Induced; Gadolinium DTPA; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Time Factors | 2009 |
Why are some Parkinson disease patients unaware of their dyskinesias?
Topics: Aged; Antiparkinson Agents; Awareness; Dyskinesia, Drug-Induced; Feedback, Psychological; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Self Concept | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase | 2009 |
Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.
Topics: Bromocriptine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Indoles; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Randomized Controlled Trials as Topic; Time; Treatment Outcome | 2009 |
Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
[Long term experience with Stalevo in Szeged, Hungary].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease.
Topics: Aged; Analysis of Variance; Cerebellum; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic Stimulation | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger | 2009 |
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Tetrahydronaphthalenes; Thiophenes | 2009 |
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinsonian Disorders; Phosphotransferases (Alcohol Group Acceptor); Proteins; Receptors, Dopamine D1; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2009 |
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors | 2009 |
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Brain; Cocaine; Disease Models, Animal; Docosahexaenoic Acids; Drug Interactions; Dyskinesia, Drug-Induced; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; MPTP Poisoning; Nuclear Receptor Subfamily 4, Group A, Member 1; Protein Binding; RNA, Messenger; Statistics as Topic | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Levodopa; Male; Neurons; Oxidopamine; Protein Precursors; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger | 2009 |
Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Hand Strength; Humans; Italy; Levodopa; Male; Middle Aged; Motor Skills; Movement; Movement Disorders; Parkinson Disease; Retrospective Studies | 2009 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Maze Learning; Medial Forebrain Bundle; Memory, Short-Term; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Time Factors | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome | 2010 |
Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Brain; Callithrix; Catechol O-Methyltransferase; Cell Membrane; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Levodopa; Liver; Male; MPTP Poisoning; Neuroglia; Neurons; RNA, Messenger | 2010 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
Topics: Animals; Antiparkinson Agents; Callithrix; Disability Evaluation; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Locomotion; Male; MPTP Poisoning; Receptors, Dopamine D2; Time Factors; Treatment Outcome | 2010 |
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
Topics: Animals; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2010 |
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, AMPA; Synapses; Synaptic Vesicles | 2010 |
Levodopa-induced dyskinesias detection based on the complexity of involuntary movements.
Topics: Aged; Antiparkinson Agents; Biological Clocks; Biomechanical Phenomena; Brain; Cognition; Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Entropy; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neuropsychological Tests; Predictive Value of Tests; Signal Processing, Computer-Assisted; Time Factors | 2010 |
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2010 |
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Memantine; N-Methylaspartate; Parkinson Disease | 2010 |
BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme-Linked Immunosorbent Assay; Female; Levodopa; Macaca fascicularis; MPTP Poisoning | 2010 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2010 |
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation | 2011 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2010 |
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Topics: Animals; Behavior, Animal; Biomarkers; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gait Disorders, Neurologic; Infusion Pumps, Implantable; Levodopa; Locomotion; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction; Thionucleotides | 2010 |
Levodopa-induced dyskinesias in spinocerebellar ataxia type 2.
Topics: Antiparkinson Agents; Atrophy; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Rhombencephalon; Spinocerebellar Ataxias | 2010 |
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2010 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2010 |
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Hyperkinesis; Levodopa; Parkinsonian Disorders; Reproducibility of Results | 2010 |
Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Topics: Amphetamine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Calcium Channel Blockers; Central Nervous System Stimulants; Cocaine; Conotoxins; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Mecamylamine; Neostriatum; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Stereotyped Behavior | 2010 |
Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Chorea; Dyskinesia, Drug-Induced; Extremities; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index | 2010 |
Objective measurement of dyskinesia in Parkinson's disease using a force plate.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Pressure; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index | 2010 |
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
Topics: Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2010 |
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Piperidines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase | 2010 |
Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?
Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2010 |
Age of Parkinson's disease onset as a predictor for the development of dyskinesia.
Topics: Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Proportional Hazards Models; Risk Factors | 2010 |
Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease--case report.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2010 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca mulatta; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2010 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |
[Optimal time for beginning treatment with levodopa].
Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2010 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists | 2010 |
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
Topics: Animals; Autoradiography; Brain; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission | 2012 |
Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Child; Child, Preschool; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Male; Pallidotomy; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric | 2010 |
mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Levodopa; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinson Disease; Proteins; Receptors, Dopamine D1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
Movement disorders ii: chorea, dystonia, myoclonus, and tremor.
Topics: Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Lupus Erythematosus, Systemic; Myoclonus; Tremor | 2010 |
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dependovirus; Disease Susceptibility; Dopamine; Down-Regulation; Dyskinesia, Drug-Induced; Female; Gene Knockdown Techniques; Levodopa; Microdialysis; Neostriatum; Neurons; Presynaptic Terminals; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Recombination, Genetic; RNA, Small Interfering; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2010 |
Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluorescent Dyes; Levodopa; Long-Term Potentiation; Neuronal Plasticity; Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia.
Topics: Adolescent; Antiparkinson Agents; Child; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Male; Neurons; Parkinsonian Disorders; Peptides; Taiwan; Ubiquitin | 2010 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2010 |
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.
Topics: Analysis of Variance; Animals; Autoradiography; Brain; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Statistics, Nonparametric; Treatment Outcome; Tyrosine 3-Monooxygenase | 2010 |
Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.
Topics: Adolescent; Brain; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Magnetic Resonance Imaging; Neurodegenerative Diseases; Parkinsonian Disorders; Young Adult | 2010 |
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.
Topics: Animals; Catalepsy; Cocaine; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Fluorescent Antibody Technique; Green Fluorescent Proteins; Haloperidol; Immunohistochemistry; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Activity; Neuronal Plasticity; Neurons; Synaptic Potentials | 2010 |
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Rats; Signal Transduction | 2010 |
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Neurites; Parkinsonian Disorders; Serotonin; Tryptophan Hydroxylase | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Severity of Illness Index; Substantia Nigra; Up-Regulation | 2011 |
Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; DNA, Mitochondrial; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Mitochondria; Neurons; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Putamen; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial | 2010 |
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors | 2010 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Partial Agonism; Dyskinesia, Drug-Induced; Hyperkinesis; Levodopa; Male; Microdialysis; Motor Activity; Oxazepines; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2010 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Probability; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2011 |
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Female; Levodopa; Motor Activity; MPTP Poisoning; Oleic Acids; Palmitic Acids; Psychoses, Substance-Induced | 2011 |
L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?
Topics: Biomarkers, Pharmacological; Dyskinesia, Drug-Induced; Levodopa; Models, Neurological; Presynaptic Terminals; Serotonin | 2010 |
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
Topics: Animals; Autoradiography; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2012 |
Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Brain Waves; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electrophysiology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2011 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carotid Arteries; Conditioning, Operant; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Injections, Intravenous; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Radionuclide Imaging; Radiopharmaceuticals; Substantia Nigra | 2011 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Thyrotropin-Releasing Hormone | 2010 |
Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Rats; Rats, Wistar; Substantia Nigra | 2010 |
Automated Levodopa-induced dyskinesia assessment.
Topics: Acceleration; Algorithms; Antiparkinson Agents; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Equipment Design; Humans; Levodopa; Models, Statistical; Monitoring, Ambulatory; Parkinson Disease; Programming Languages; Reproducibility of Results; Signal Processing, Computer-Assisted | 2010 |
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apolipoproteins E; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Retrospective Studies | 2011 |
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Humans; Levodopa; Mice; Mice, Knockout; Neurons; ras-GRF1; Signal Transduction | 2010 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2011 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depression; Male; Microinjections; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Piperazines; Purinones; Pyrimidinones; Rats; Rats, Wistar | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Transmission; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Synapses | 2011 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Motor Activity; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra | 2011 |
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2011 |
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
Topics: Aged; Analysis of Variance; Brain; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Receptors, N-Methyl-D-Aspartate | 2011 |
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Statistics, Nonparametric | 2011 |
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
Topics: Antiparkinson Agents; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2011 |
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Tanzania | 2011 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2 | 2011 |
Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.
Topics: Aged; Anesthetics, Intravenous; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Midazolam; Parkinson Disease; Rhabdomyolysis | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A | 2011 |
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesia, Drug-Induced; Fluorescent Antibody Technique; GABAergic Neurons; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Levodopa; Macaca fascicularis; Male; Neurons, Efferent; Parkinsonian Disorders; Polymerase Chain Reaction; Statistics, Nonparametric; Thalamus; Vesicular Glutamate Transport Protein 1 | 2011 |
Gender effect on time to levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Risk Factors; Sex Factors | 2011 |
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Dyskinesia, Drug-Induced; Electrochemistry; Female; Functional Laterality; Levodopa; Oxidopamine; Potassium Chloride; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; MPTP Poisoning; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereoisomerism | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger | 2012 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid | 2011 |
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin; Sympatholytics | 2011 |
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Aged; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A | 2011 |
Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Cortex; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2011 |
Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Topics: Animals; Antiparkinson Agents; Autoradiography; Bridged Bicyclo Compounds, Heterocyclic; Corpus Striatum; Cotinine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Oxidopamine; Pyridines; Receptors, Nicotinic; Substantia Nigra; Sympatholytics | 2011 |
A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene.
Topics: Adult; Aged; Base Sequence; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree | 2011 |
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Hydroxydopamines; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2011 |
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Membrane Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions; Time Factors | 2012 |
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Assessment; Risk Factors; Tremor | 2011 |
An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2012 |
Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Respiration Disorders | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Experimental Models of l-DOPA-Induced Dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders | 2011 |
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients.
Topics: Aged; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nerve Net; Parkinson Disease; Positron-Emission Tomography; Theta Rhythm; Transcranial Magnetic Stimulation | 2012 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics | 2011 |
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice; Motor Activity; Neurons; Oxidopamine; Rotarod Performance Test; Substantia Nigra | 2012 |
MPTP-induced models of Parkinson's disease in mice and non-human primates.
Topics: Animals; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning | 2005 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Fructose; Levodopa; Male; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Topiramate | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 2012 |
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2012 |
Lees' syndrome: a case series.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2011 |
Mechanisms underlying and medical management of L-Dopa-associated motor complications.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa | 2011 |
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
Topics: Adult; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Oxygen; Parkinson Disease; Prefrontal Cortex; Regression Analysis; Severity of Illness Index | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Carbon Isotopes; Cocaine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Microdialysis; Motor Activity; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonergic Neurons; Serotonin Receptor Agonists | 2012 |
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, Transformed; Corpus Striatum; Culture Media, Serum-Free; Disability Evaluation; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Regulation; GTP-Binding Proteins; Humans; Immunosuppressive Agents; Levodopa; Mice; Mice, Knockout; Movement; Mutation; Neurons; Neurotoxicity Syndromes; Oxidopamine; Phosphorylation; Protein Binding; Radioligand Assay; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection | 2011 |
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Levodopa; Male; Morpholines; Motor Activity; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Wistar | 2012 |
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Culture Techniques; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2012 |
Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Mood Disorders; Parkinson Disease; Regression Analysis; Severity of Illness Index; Time Factors | 2012 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia?
Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Prefrontal Cortex | 2012 |
Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Electromyography; Entropy; Evoked Potentials, Motor; Female; Forearm; Functional Laterality; Human Body; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 2012 |
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.
Topics: Aged; Antiparkinson Agents; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regression Analysis; Social Change; Social Perception; Surveys and Questionnaires | 2012 |
Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Neostriatum; Nerve Tissue Proteins; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Protein Subunits; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction | 2012 |
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation | 2012 |
An automated methodology for levodopa-induced dyskinesia: assessment based on gyroscope and accelerometer signals.
Topics: Aged; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2013 |
Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus | 2012 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; GTP-Binding Protein alpha Subunits; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement; Mutation; Oxidopamine; Psychomotor Performance; Receptors, AMPA; Signal Transduction; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Topics: Animals; Benzimidazoles; Buspirone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; RGS Proteins; Serotonin Antagonists; Serotonin Receptor Agonists | 2012 |
Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enkephalin, D-Penicillamine (2,5)-; Levodopa; Male; Neurons; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta | 2012 |
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Carriers; Drug Delivery Systems; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Scanning; Mitogen-Activated Protein Kinase Kinases; Nanomedicine; Nanoparticles; Particle Size; Phosphorylation; Proto-Oncogene Proteins c-fos; Rats; tau Proteins | 2012 |
Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Databases, Factual; Dyskinesia, Drug-Induced; Female; Health Care Costs; Humans; Insurance, Health; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; United States | 2012 |
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments.
Topics: Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Exercise Test; Exercise Therapy; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Physical Therapy Modalities; Pilot Projects; Treatment Outcome | 2012 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Predisposition to Disease; Glycine; Humans; Israel; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Longitudinal Studies; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Retrospective Studies; Serine; Statistics, Nonparametric; Young Adult | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution | 2012 |
Dyskinesia in Parkinson disease - an unmet therapeutic challenge.
Topics: Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2012 |
Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Parkinson Disease; Prefrontal Cortex | 2013 |
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease | 2013 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley | 2012 |
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
Topics: Age of Onset; Alleles; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Gene Expression; Genetic Predisposition to Disease; Genotype; Humans; Huntington Disease; Levodopa; Long-Term Care; Motor Cortex; Movement Disorders; Polymorphism, Single Nucleotide; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2012 |
Recurrent bilateral metatarsal "stress-and-insufficiency" fractures in a levodopa-treated young woman with Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Fractures, Stress; Humans; Levodopa; Metatarsal Bones; Middle Aged; Osteoporotic Fractures; Parkinson Disease; Radiography; Recurrence | 2013 |
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regression Analysis; Subthalamic Nucleus | 2012 |
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2013 |
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
Topics: Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Female; Histone Deacetylase Inhibitors; Levodopa; Parkinsonian Disorders | 2013 |
Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Presynaptic Terminals; Receptors, Nicotinic; Saimiri | 2013 |
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.
Topics: Animals; Corpus Striatum; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Macaca; Male; Membrane Proteins; Parkinson Disease; Protein Transport; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synapses | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2013 |
Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Ibotenic Acid; Levodopa; Macaca fascicularis; MPTP Poisoning; Subthalamic Nucleus | 2013 |
1-Hz repetitive transcranial magnetic stimulation and diphasic dyskinesia in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Transcranial Magnetic Stimulation | 2013 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Microinjections; Nociceptin; Opioid Peptides; Oxidopamine; Postural Balance; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2012 |
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Receptors, Dopamine D2 | 2012 |
Overweight is more prevalent in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mexico; Middle Aged; Obesity; Overweight; Parkinson Disease; Prevalence; Severity of Illness Index; Thinness | 2012 |
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Female; Fluorescent Antibody Technique; Levodopa; Microelectrodes; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tyrosine 3-Monooxygenase | 2012 |
Validating an objective video-based dyskinesia severity score in Parkinson's disease patients.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Observer Variation; Parkinson Disease; Severity of Illness Index; Video Recording | 2013 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microscopy, Immunoelectron; Neuropeptides; Parkinsonian Disorders; Rats; Rats, Wistar | 2013 |
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Nitriles | 2013 |
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Butyrophenones; Cloning, Molecular; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 2013 |
Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Topics: Aged, 80 and over; Antiparkinson Agents; Dementia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease | 2013 |
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immunoprecipitation; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar; Receptors, Dopamine D1 | 2013 |
Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Mutant Strains; Motor Activity; Receptors, Dopamine D1 | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic | 2013 |
Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons.
Topics: Antiparkinson Agents; Brain; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Tropanes | 2013 |
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1 | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency.
Topics: Child; Child, Preschool; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Infant; Levodopa | 2013 |
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Injections, Intraventricular; Levodopa; Potassium; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Signal Transduction | 2013 |
Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders | 2002 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity | 2002 |
Hiccoughs--an unusual dyskinetic side-effect of L-Dopa.
Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Hiccup; Humans; Levodopa; Male; Parkinson Disease | 2002 |
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Caudate Nucleus; Corpus Striatum; Culture Techniques; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Female; In Situ Hybridization; Levodopa; Locomotion; Male; Piribedil; RNA, Messenger; Severity of Illness Index; Time Factors | 2002 |
Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
Topics: Antiparkinson Agents; Brain; Culture Techniques; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Humans; Levodopa; Middle Aged; Neurofibrillary Tangles; Supranuclear Palsy, Progressive | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2001 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2002 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug | 2002 |
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2002 |
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neurologic Examination; Observer Variation; Parkinson Disease; Sensitivity and Specificity | 2003 |
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Time Factors; Treatment Outcome | 2002 |
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Treatment Outcome | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autoradiography; Brain; Case-Control Studies; Dopamine; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Postmortem Changes; Receptors, GABA; Receptors, GABA-A; Receptors, GABA-B | 2003 |
Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.
Topics: Acceleration; Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Joints; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Neural Networks, Computer; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Software | 2003 |
[Current preclinical findings on substances against Parkinson's disease].
Topics: Animals; Antiparkinson Agents; Caenorhabditis elegans; Corpus Striatum; Dopamine Agonists; Drug Evaluation, Preclinical; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders | 2003 |
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Nerve Tissue Proteins; Neuronal Plasticity; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Rats; Rats, Wistar; Synaptic Transmission | 2003 |
[Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors | 2003 |
L-DOPA, dyskinesia and striatal plasticity.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neuronal Plasticity | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors | 2003 |
Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Severity of Illness Index | 2003 |
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Haplorhini; Humans; Isoquinolines; Levodopa; Molecular Structure; Motor Activity; MPTP Poisoning; Naphthalenes; Neostriatum; Piperazines; Pyrrolidines; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2003 |
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Polymorphism, Genetic; Psychoses, Substance-Induced; Receptors, Dopamine; Retrospective Studies | 2003 |
D3 receptors and levodopa-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2003 |
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Sprague-Dawley | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamine Agents; Dyskinesia, Drug-Induced; Facial Expression; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Postural Balance; Posture; Time Factors; Tremor | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 2003 |
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
Agonists versus levodopa in PD: the thrilla of whitha.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2003 |
The art of treating Parkinson disease in the older patient.
Topics: Aged; Antiparkinson Agents; Australia; Dopamine Agonists; Dyskinesia, Drug-Induced; Family Practice; Female; Geriatrics; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Treatment Outcome | 2003 |
Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Central Nervous System; Depression; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Sleep Wake Disorders | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fatal Outcome; Female; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Tremor | 2003 |
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Binding Sites; Binding, Competitive; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Radioligand Assay; Receptors, N-Methyl-D-Aspartate | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Chlorobenzenes; Cyclobutanes; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Postural Balance; Stereotyped Behavior | 2004 |
Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.
Topics: Aged; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Statistics, Nonparametric | 2004 |
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
Topics: Animals; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levetiracetam; Levodopa; Macaca fascicularis; MPTP Poisoning; Piracetam | 2004 |
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
Topics: Antiparkinson Agents; Biological Clocks; Circadian Rhythm; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Models, Statistical; Parkinson Disease; Presynaptic Terminals; Synaptic Vesicles | 2004 |
The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Hallucinations; Humans; Levodopa; Multiple Sclerosis; Oxidative Stress; Parkinson Disease; Parkinson Disease, Postencephalitic; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Vitamin B Complex | 2004 |
Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.
Topics: Aged; Antiparkinson Agents; Body Composition; Body Mass Index; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Energy Metabolism; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome; Weight Gain | 2004 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
Clozapine for the treatment of levodopa-induced dyskinesias.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Randomized Controlled Trials as Topic | 2004 |
L-dopa-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
Topics: Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nocturnal Myoclonus Syndrome; Parkinson Disease; Predictive Value of Tests; Sleep Apnea, Obstructive | 2004 |
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
Topics: Aged; Aged, 80 and over; Brain; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male | 2004 |
Grip force abnormalities in de novo Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2004 |
Do on-off variations cause discrepancies in the historical items of the UPDRS?
Topics: Activities of Daily Living; Antiparkinson Agents; Cannabis; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Phytotherapy | 2004 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol; Mice; Mice, Inbred C57BL; Motor Skills; Oxidopamine; Protein Binding; Substantia Nigra | 2004 |
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure | 2004 |
L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index | 2004 |
Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report.
Topics: Antiparkinson Agents; Device Removal; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Equipment Design; Female; Humans; Leg; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Parkinson Disease; Remission Induction; Subthalamic Nucleus | 2004 |
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Caudate Nucleus; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Synapses | 2004 |
Impact of the motor complications of Parkinson's disease on the quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Health Status Indicators; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2005 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Male; Parkinson Disease; Pedigree; Phenotype; Point Mutation | 2004 |
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exons; Female; Gene Deletion; Genomic Imprinting; Homozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Polymerase Chain Reaction; Severity of Illness Index; Subthalamic Nucleus; Ubiquitin-Protein Ligases | 2004 |
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.
Topics: Animals; Calcium-Transporting ATPases; Carrier Proteins; Corpus Striatum; Cytoskeleton; Dopamine Agents; Dyskinesia, Drug-Induced; Energy Metabolism; Gene Expression; Gene Expression Profiling; Homeostasis; Ions; Levodopa; Microfilament Proteins; Mitochondria; Multigene Family; Neurotransmitter Agents; Oligonucleotide Array Sequence Analysis; Phosphoric Monoester Hydrolases; Phosphotransferases; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; RNA, Messenger; Synapses | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Subcutaneous; Levodopa; Locomotion; Male; MPTP Poisoning; Nitriles; Severity of Illness Index; Substantia Nigra; Time Factors | 2005 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2005 |
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Fructose; Levodopa; MPTP Poisoning; Parkinson Disease; Topiramate | 2005 |
Swallowing abnormalities and dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Deglutition Disorders; Dyskinesia, Drug-Induced; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Oropharynx; Parkinson Disease; Severity of Illness Index; Videotape Recording | 2005 |
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Topics: Adult; Antiparkinson Agents; Brazil; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Exons; Female; Follow-Up Studies; Foot; Genotype; Heterozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation; Ubiquitin-Protein Ligases | 2005 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine | 2005 |
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Topics: Animals; Corpus Striatum; Dependovirus; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2005 |
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cognition; Combined Modality Therapy; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Postoperative Complications; Radiosurgery; Subthalamic Nucleus; Treatment Outcome | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa.
Topics: Animals; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Nomifensine; Saimiri | 2005 |
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Basal Ganglia; Deoxyglucose; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Limbic System; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Septal Nuclei; Somatosensory Cortex; Substantia Nigra; Subthalamic Nucleus | 2005 |
Current controversies: levodopa in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2005 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra | 2005 |
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Predictive Value of Tests; Risk Factors | 2005 |
Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Arm; Disability Evaluation; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Spectrum Analysis | 2005 |
Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy.
Topics: Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Globus Pallidus; Humans; Immunohistochemistry; Levodopa; Magnetic Resonance Imaging; Middle Aged; Multiple System Atrophy; Nerve Tissue Proteins; Neuropsychological Tests; Staining and Labeling; Synucleins; Ubiquitin | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dynorphins; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Parkinson Disease; Rats; Rats, Wistar; Serotonin Receptor Agonists | 2005 |
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Callithrix; Cannabinoid Receptor Modulators; Dyskinesia, Drug-Induced; Endocannabinoids; Female; gamma-Aminobutyric Acid; Glycerides; Levodopa; Male; MPTP Poisoning; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam | 2005 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piracetam | 2005 |
[L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
Topics: Antiparkinson Agents; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Treatment Outcome | 2005 |
Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease.
Topics: Action Potentials; Antiparkinson Agents; Arm; Biological Clocks; Dyskinesia, Drug-Induced; Electromyography; Female; Globus Pallidus; Humans; Levodopa; Middle Aged; Muscle, Skeletal; Neurons; Parkinson Disease | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin | 2005 |
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blotting, Western; Brain; Callithrix; Diagnostic Imaging; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Immunoradiometric Assay; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Nerve Tissue Proteins; Neurofilament Proteins; Protein Subunits; Rats; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2005 |
Reciprocal interactions between oscillatory activities of different frequencies in the subthalamic region of patients with Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Biological Clocks; Dopamine Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus | 2005 |
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders | 2005 |
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Motor Activity; Movement Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Severity of Illness Index | 2006 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; Humans; Japan; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Time Factors | 2005 |
Levodopa addiction in idiopathic Parkinson disease.
Topics: Aged; Bipolar Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quadriplegia; Spinal Cord Diseases; Substance-Related Disorders | 2005 |
[The role of dopaminagonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Female; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reproducibility of Results; Sympatholytics | 2005 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2006 |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Protein Subunits; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Synapses; Transfection | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance | 2006 |
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine; Receptors, Opioid, mu; Risk; Smoking | 2006 |
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity | 2006 |
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Paraphilic Disorders; Parkinson Disease; Pedophilia; Pergolide | 2006 |
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation | 2006 |
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 2006 |
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Minnesota; Parkinson Disease; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation | 2006 |
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hospitals, University; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Patient Admission; Retrospective Studies; Risk Factors; Turkey | 2006 |
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Environment; Housing, Animal; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Reproducibility of Results | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors | 2006 |
Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 2006 |
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Apomorphine; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles | 2006 |
Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Japan; Levodopa; Male; Middle Aged; Mobility Limitation; Neurologic Examination; Parkinson Disease; Prognosis; Retrospective Studies; Severity of Illness Index; Sex Factors | 2006 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents | 2006 |
Opioids and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Opioid | 2006 |
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Triazoles | 2006 |
The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Human Body; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Rotation; Severity of Illness Index | 2007 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus | 2007 |
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzothiazoles; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Piperazines; Pramipexole; Pyridines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley | 2006 |
Punding and dyskinesias.
Topics: Aged; Aged, 80 and over; Demography; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Stereotyped Behavior | 2006 |
Long-term monitoring of gait in Parkinson's disease.
Topics: Adult; Algorithms; Antiparkinson Agents; Calibration; Computers, Handheld; Drug Monitoring; Dyskinesia, Drug-Induced; Electronics, Medical; Feasibility Studies; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease | 2007 |
Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
Topics: Antiparkinson Agents; Brain Injuries; Child, Preschool; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Substantia Nigra | 2006 |
Inhaled cocaine used to relieve "off" periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases.
Topics: Administration, Inhalation; Cocaine; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Self Medication | 2006 |
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, AMPA; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; Treatment Outcome | 2007 |
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2007 |
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Brain; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Tissue Donors | 2007 |
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Mesencephalon; Motor Skills; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Sympatholytics | 2007 |
Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia.
Topics: 5-Hydroxytryptophan; Adult; Antidepressive Agents, Second-Generation; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Longitudinal Studies; Male; Phenylketonurias; Treatment Outcome | 2006 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A | 2006 |
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Homozygote; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Predictive Value of Tests; Psychoses, Substance-Induced; Risk Factors | 2007 |
Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias.
Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Neurons; Oligonucleotides, Antisense; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2006 |
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Locus Coeruleus; Male; Neurons; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Rotarod Performance Test; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2007 |
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Benzofurans; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Indicators and Reagents; Isoquinolines; Levodopa; Receptors, Adrenergic, alpha-2; Structure-Activity Relationship | 2007 |
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Topics: Adrenergic Agents; Animals; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Neurotransmitter Agents; Parkinsonian Disorders; Random Allocation; Rats; Rotarod Performance Test; Serotonin Agents; Statistics, Nonparametric | 2007 |
Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias.
Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Transcranial Magnetic Stimulation; Treatment Outcome | 2007 |
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hypnotics and Sedatives; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Saimiri; Vomiting | 2007 |
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Topics: Animals; Antiparkinson Agents; Cell Compartmentation; Corpus Striatum; Cytoplasm; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Microscopy, Electron, Transmission; Neurons; Parkinsonian Disorders; Protein Transport; Receptor Aggregation; Receptors, Dopamine D1; Receptors, Dopamine D2; Up-Regulation | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission | 2007 |
Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Topics: Antiparkinson Agents; Brain; Cytokines; Dyskinesia, Drug-Induced; Endotoxins; Energy Metabolism; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Levodopa; Parkinson Disease | 2007 |
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
Topics: Animals; Callithrix; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Severity of Illness Index | 2007 |
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Male; Mass Spectrometry; Proteins; Proteomics; Rats; Rats, Sprague-Dawley; Time Factors | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors | 2007 |
In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.
Topics: Animals; Brain; Cerebrovascular Circulation; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Tetrahydronaphthalenes | 2007 |
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Cyclic AMP; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction | 2007 |
Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Chlorpheniramine; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Serotonin Receptor Agonists | 2008 |
Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
Topics: Actins; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Electrophoresis, Polyacrylamide Gel; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; MPTP Poisoning; Neostriatum; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Molecular Structure; Parkinson Disease; Receptor, Cannabinoid, CB1; Triazines | 2007 |
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2007 |
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Tyrosine 3-Monooxygenase | 2007 |
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
Topics: Animals; Benzazepines; Cell Count; Denervation; Dopamine Agents; Dopamine Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Enzyme Activation; Female; Fluorescent Antibody Technique; Immunohistochemistry; In Situ Hybridization; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neostriatum; Neurons, Efferent; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2007 |
Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Entropy; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Spectrum Analysis | 2007 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time | 2007 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzoxazines; Cannabinoids; Capsaicin; Carbamates; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; TRPV Cation Channels | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar | 2008 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity; Nitriles | 2007 |
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase | 2008 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors | 2007 |
Bilateral subthalamotomy for advanced Parkinson disease.
Topics: Aged; Catheter Ablation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Microelectrodes; Middle Aged; Muscle Rigidity; Neural Pathways; Parkinson Disease; Radiosurgery; Subthalamic Nucleus; Time; Treatment Outcome; Tremor | 2007 |
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesia, Drug-Induced; Electric Stimulation; In Vitro Techniques; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2008 |
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Topics: Amino Acids; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Cabergoline; Caudate Nucleus; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Ergolines; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Ovariectomy; Putamen; Receptors, Metabotropic Glutamate; Xanthenes | 2008 |
The management approaches to dyskinesia vary from country to country.
Topics: Antiparkinson Agents; Critical Pathways; Cross-Cultural Comparison; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Humans; Incidence; Japan; Levodopa; Outcome Assessment, Health Care; Parkinson Disease; Referral and Consultation; Retrospective Studies; United States | 2007 |
Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Topics: Aged; Antiparkinson Agents; Arm; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Thorax; Time Factors | 2008 |
Participation of the subthalamic nucleus in executive functions: An intracerebral recording study.
Topics: Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Evoked Potentials; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nervous System Stimulants; Citalopram; Dopamine Agents; Drinking; Dyskinesia, Drug-Induced; Image Processing, Computer-Assisted; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotyped Behavior; Sympatholytics; Synaptic Transmission | 2008 |
Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia.
Topics: Adult; Antiparkinson Agents; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus | 2008 |
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterality; Intralaminar Thalamic Nuclei; Kainic Acid; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Stereotaxic Techniques | 2008 |
Are parkin patients particularly suited for deep-brain stimulation?
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Testing; Heterozygote; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Treatment Outcome; Ubiquitin-Protein Ligases | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger | 2008 |
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Macaca; Mass Spectrometry; Parkinson Disease; Protein Processing, Post-Translational; Proteomics; Rats | 2008 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
Topics: Age Factors; Aged; Antiparkinson Agents; Body Size; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity | 2008 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics | 2007 |
The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary?
Topics: Animals; Basal Ganglia; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Rats; Rats, Wistar | 2008 |
Problems of levodopa treatment.
Topics: Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1984 |
Axial apraxia, a distinct phenomenon.
Topics: Adult; Aged; Apraxias; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1984 |
Dopamine antagonist and agonist treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benserazide; Benzimidazoles; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Sulpiride | 1980 |
[Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
Topics: Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1981 |
The role of anticholinergic drugs in extra-pyramidal syndromes.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1981 |
Drug-induced dyskinesias.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nursing Assessment; Patient Education as Topic | 1982 |
[Problems and future perspectives in the treatment of Parkinson's disease].
Topics: Acetylcholine; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1982 |
Levodopa and receptor sensitivity modification in tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Receptors, Dopamine; Schizophrenia | 1982 |
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary | 1983 |
Sustained levodopa therapy in tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Schizophrenia | 1983 |
A comparison of two iatrogenic dyskinesias.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Extremities; Facial Muscles; Female; Humans; Iatrogenic Disease; Jaw; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue | 1983 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
Topics: Aged; Antipsychotic Agents; Carbidopa; Corpus Striatum; Depressive Disorder; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Metoclopramide; Parkinson Disease, Secondary; Receptors, Dopamine | 1984 |
Levodopa-induced dyskinesia and thalamotomy.
Topics: Adolescent; Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microsurgery; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei | 1984 |
[Long-term therapy of the Parkinson syndrome].
Topics: Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parasympatholytics; Parkinson Disease; Time Factors | 1984 |
Clonidine therapy for tardive dyskinesia and related syndromes.
Topics: Adult; Aged; Clonidine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1984 |
Difficulties in long term management of Parkinson's disease.
Topics: Dementia; Depression; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Parkinson Disease; Time Factors | 1984 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease | 1984 |
[Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease | 1984 |
Fatal hyperpyrexia after withdrawal of levodopa.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1984 |
What to do when Sinemet fails: Part one.
Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1984 |
Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Asian People; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Erythrocytes; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; White People | 1984 |
Behavioral control of L-dopa induced dyskinesia in Parkinsonism.
Topics: Adult; Antiparkinson Agents; Biofeedback, Psychology; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Male; Relaxation Therapy | 1982 |
[Experimental studies on L-dopa induced dyskinesia (author's transl)].
Topics: Animals; Carbidopa; Chlorocebus aethiops; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Motor Activity; Nystagmus, Pathologic | 1980 |
Symptomatic treatment of tardive dyskinesia: a word of caution.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Muscimol; Rats; Receptors, Cholinergic; Receptors, Dopamine | 1981 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine | 1983 |
Abnormal involuntary movements: a study of dopaminergic receptor interaction.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Receptors, Dopamine | 1983 |
Stereotypy and dyskinesias provoked in cats differentiate directly and indirectly-acting psychomotor stimulants.
Topics: Animals; Apomorphine; Cats; Dextroamphetamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Nomifensine; Piribedil; Receptors, Dopamine; Stereotyped Behavior | 1982 |
[Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
Topics: Adult; Aged; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
[Two cases of Parkinson's disease with diphasic dyskinesia, seen during levodopa treatment (author's transl)].
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Management of motor side effects of chronic levodopa therapy.
Topics: Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1982 |
The role of various forms of treatment in the management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1982 |
[Improper treatment of patients with parkinsonism due to drug use].
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotropic Drugs | 1982 |
Blink rates in parkinsonism.
Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Complications of chronic levodopa therapy: long-term efficacy of drug holiday.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome | 1981 |
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1981 |
[Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
Topics: Aged; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1980 |
Iris pigmentation (melanin) in idiopathic dystonic syndromes including torticollis.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dyskinesia, Drug-Induced; Dystonia; Eye Color; Humans; Levodopa; Melanins; Middle Aged; Torsion Abnormality; Torticollis; White People | 1981 |
Electroconvulsive therapy in Parkinsonian patients with the "on-off" syndrome.
Topics: Depression; Dyskinesia, Drug-Induced; Dystonia; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
The impact of treatment with levodopa on Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1980 |
Levodopa-induced dyskinesias are improved by fluoxetine.
Topics: Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Levodopa; Middle Aged | 1995 |
Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1994 |
Parkinsonism and bipolar affective disorder.
Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary | 1995 |
What respiratory abnormalities result from neuroleptics and levodopa?
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Respiration Disorders | 1995 |
Adverse reactions to Sinemet CR.
Topics: Aged; Antiparkinson Agents; Carbidopa; Confusion; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa | 1995 |
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Imidazoles; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA | 1995 |
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Topics: Afferent Pathways; Animals; Apomorphine; Axonal Transport; Brain Mapping; Chorea; Dyskinesia, Drug-Induced; Dystonia; Globus Pallidus; Horseradish Peroxidase; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus; Wheat Germ Agglutinins | 1993 |
[A pharmacological study of levodopa solution therapy for a patient with Parkinson's disease with motor fluctuations].
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Solutions | 1995 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl | 1994 |
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Activity; Receptors, Dopamine; Reserpine | 1994 |
Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1994 |
Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Foot; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
Topics: Aged; Clozapine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Levodopa: rational and irrational pharmacology.
Topics: Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
Topics: Aged; Clozapine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Baclofen; Clonidine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Meperidine; Methoxydimethyltryptamines; Neurotransmitter Agents; Yohimbine | 1993 |
A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Basal Ganglia; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Tremor | 1993 |
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Topics: Activities of Daily Living; Adult; Aged; Chorea; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine D1; Video Recording | 1994 |
Levodopa, rice eating and on-off phenomenon.
Topics: Dietary Carbohydrates; Dietary Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Oryza; Parkinson Disease | 1993 |
Apomorphine and diphasic dyskinesia.
Topics: Aged; Apomorphine; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
[A case of multiple system atrophy presenting a regular involuntary movement of the neck muscles synchronous with respiration].
Topics: Amantadine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy; Neck Muscles; Respiration; Trihexyphenidyl | 1993 |
The spectrum of levodopa-related fluctuations in Parkinson's disease.
Topics: Aged; Depression; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Restless Legs Syndrome; Urinary Incontinence | 1993 |
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary | 1993 |
Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.
Topics: Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electromyography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prostheses and Implants; Thalamic Nuclei; Tremor | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring.
Topics: Adult; Aged; Circadian Rhythm; Data Display; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microcomputers; Middle Aged; Monitoring, Physiologic; Motor Activity; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted; Sleep Stages | 1993 |
Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Posture; Tremor | 1993 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chorea; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Female; Isoquinolines; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1996 |
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide | 1996 |
[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 1995 |
Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording.
Topics: Antiparkinson Agents; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Cerebral Cortex; Chorea; Deoxyglucose; Dyskinesia, Drug-Induced; Electrodes, Implanted; Energy Metabolism; Fluorodeoxyglucose F18; Globus Pallidus; Humans; Levodopa; Motor Neurons; Neural Pathways; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, Emission-Computed; Tremor | 1995 |
Chronic anterior pallidal stimulation for Parkinson's disease.
Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Monitoring, Intraoperative; Motor Skills; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted | 1995 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary | 1995 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D1 | 1996 |
Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Injections, Subcutaneous; Levodopa; Male; Mice; Motor Activity; Pramipexole; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Spiperone; Stereotyped Behavior; Sulpiride; Thiazoles | 1997 |
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior | 1996 |
Selection criteria for unilateral posteroventral pallidotomy.
Topics: Antiparkinson Agents; Blood Glucose; Dominance, Cerebral; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Patient Selection; Postoperative Complications; Stereotaxic Techniques; Tomography, Emission-Computed; Treatment Outcome | 1997 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes | 1997 |
High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases.
Topics: Adult; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Gait; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Speech Disorders; Stereotaxic Techniques; Thalamic Nuclei; Treatment Outcome; Tremor | 1997 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Time Factors | 1997 |
Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients.
Topics: Activities of Daily Living; Age of Onset; Antiparkinson Agents; Drug Resistance; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Pilot Projects; Prospective Studies; Severity of Illness Index; Treatment Outcome | 1997 |
Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Topics: Adult; Aged; Antiparkinson Agents; Binding, Competitive; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Caudate Nucleus; Diprenorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Narcotic Antagonists; Occipital Lobe; Parkinson Disease; Putamen; Receptors, Opioid; Thalamic Nuclei | 1997 |
Motor complications of chronic levodopa therapy in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques | 1997 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2 | 1998 |
Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease; Postoperative Complications; Treatment Outcome | 1998 |
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease.
Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Thalamic Nuclei | 1998 |
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
Topics: Aged; Analysis of Variance; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Multivariate Analysis; Parkinson Disease; Reference Values; Tomography, Emission-Computed, Single-Photon | 1998 |
Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Family Health; Female; GTP Cyclohydrolase; Haloperidol; Humans; Levodopa; Male; Point Mutation | 1998 |
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Chronotherapy; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps, Implantable; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
Current and emerging drug therapies in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1998 |
Inhibition of levodopa effects by internal pallidal stimulation.
Topics: Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1998 |
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease | 1998 |
Gamma knife radiosurgery as a lesioning technique in movement disorder surgery.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Dopamine Agents; Dyskinesia, Drug-Induced; Electroencephalography; Female; Follow-Up Studies; Gait; Globus Pallidus; Hemianopsia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neuropsychological Tests; Parkinson Disease; Radiosurgery; Radiotherapy Dosage; Safety; Single-Blind Method; Thalamus; Tremor | 1998 |
Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disabled Persons; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1998 |
Pallidotomy revisited. Analysis of posteroventral pallidotomy.
Topics: Aged; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; MMPI; Movement Disorders; Muscle Rigidity; Parkinson Disease; Postoperative Period; Stereotaxic Techniques; Thalamic Nuclei; Thalamus; Treatment Outcome; Tremor | 1997 |
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Confusion; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Middle Aged | 1998 |
Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.
Topics: Adult; Aged; Carbidopa; Case-Control Studies; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Thalamus; Tomography, Emission-Computed | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1998 |
New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination | 1998 |
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Topics: Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1998 |
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Thalamic Nuclei | 1998 |
Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index | 1998 |
Treating Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei | 1998 |
Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Antiparkinson Agents; Cause of Death; Chi-Square Distribution; Cognition Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Likelihood Functions; Male; Parkinson Disease; Poisson Distribution; Risk Factors | 1998 |
Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Statistics, Nonparametric | 1998 |
Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Parkinson Disease | 1998 |
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease | 1998 |
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
Topics: Aged; Antiparkinson Agents; Blepharospasm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Recurrence; Sulpiride; Tetrabenazine | 1999 |
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
Topics: Analysis of Variance; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Problem Solving; Severity of Illness Index; Speech; Volition | 1999 |
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Quinolones; Receptors, Dopamine D1; Thiophenes | 1999 |
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Riluzole; Treatment Outcome | 1999 |
Protease inhibitors enhance levodopa effects in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Synergism; Dyskinesia, Drug-Induced; HIV Protease Inhibitors; Humans; Indinavir; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
Topics: Adult; Antiparkinson Agents; Chorea; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Thalamic Nuclei | 1999 |
Glutamate receptor-mediated mechanisms in levodopa-induced motor fluctuations in an experimental model of parkinsonism.
Topics: Animals; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Rotation; Stereotyped Behavior; Time Factors | 1999 |
Reversal of levodopa failure syndrome by posteroventral-ansa pallidotomy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Middle Aged; Movement; Treatment Outcome | 1999 |
Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.
Topics: Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinson Disease; Thalamic Nuclei | 1999 |
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oocytes; Parkinson Disease, Secondary; Rats; Receptors, N-Methyl-D-Aspartate; Valine; Xenopus laevis | 1999 |
Drug treatments of levodopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Patient Selection; Receptors, N-Methyl-D-Aspartate; Riluzole; Treatment Outcome | 1999 |
Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies.
Topics: Animals; Antiparkinson Agents; Brain; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Self-Assessment; Treatment Outcome | 1999 |
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 1999 |
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Parkinson Disease | 1999 |
Levodopa-induced dyskinesias treated by pallidotomy.
Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Topics: Adult; Aged; Alleles; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Dyskinesias; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Tandem Repeat Sequences | 1999 |
Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1 | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Odds Ratio; Parkinson Disease | 1999 |
Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Age of Onset; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Risk Factors; Survival Analysis; Time Factors | 1999 |
High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei | 2000 |
Weight gain following unilateral pallidotomy in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Eating; Globus Pallidus; Humans; Levodopa; Linear Models; Longitudinal Studies; Motor Activity; Neuropsychological Tests; Nutrition Assessment; Parkinsonian Disorders; Severity of Illness Index; Smell; Stereotaxic Techniques; Surveys and Questionnaires; Weight Gain | 2000 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Idazoxan; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease | 2000 |
Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change.
Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Research Design; Treatment Outcome | 2000 |
Is levodopa toxic?
Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Parkinson Disease | 2000 |
Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease.
Topics: Adult; Aged; Basal Ganglia; Brain; Cognition Disorders; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Preoperative Care; Subthalamic Nucleus; Surveys and Questionnaires | 2000 |
[Efficacy and safety of posteroventral pallidotomy for the treatment of advanced Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 2000 |
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Monitoring, Intraoperative; Movement; Parkinson Disease; Patient Care Planning; Radiology, Interventional; Red Nucleus; Safety; Stereotaxic Techniques; Subthalamic Nucleus; Tremor | 2000 |
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Nitriles; Oligonucleotide Probes; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index | 2000 |
Serotonergic decompensation in the akinetic expression of Parkinson's disease.
Topics: Brain; Chromatography, High Pressure Liquid; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Levodopa; Methoxyhydroxyphenylglycol; Norepinephrine; Parkinson Disease; Serotonin; Synaptic Transmission | 2000 |
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Epilepsy; Levodopa; Macaca mulatta; Male; Motor Activity; Movement; MPTP Poisoning; Parkinson Disease, Secondary; Predictive Value of Tests; Receptors, Dopamine D1 | 1999 |
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
Topics: Adult; Aged; Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2000 |
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Denervation; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; Saimiri; Substantia Nigra | 2000 |
Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Motor Skills; Neurologic Examination; Parkinson Disease | 2000 |
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Phenotype; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Rotation; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Treatments for Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Hydroxydopamines; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Mesencephalon; Neostriatum; Nerve Endings; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sympathomimetics | 2000 |
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders | 2000 |
Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica.
Topics: Aged; Analgesics, Opioid; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Intervertebral Disc Displacement; Levodopa; Lumbar Vertebrae; Male; Middle Aged; Morphine; Parkinson Disease; Sciatica | 1999 |
Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
Topics: Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Pyridines; Zolpidem | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Sleep | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Hallucinations; Humans; Indoles; Levodopa; Parkinson Disease | 2000 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life | 2000 |
Endogenous dopaminergic tone and dopamine agonist action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Apomorphine; Benzopyrans; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Levodopa; Locomotion; Male; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2000 |
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Memantine; N-Methylaspartate; Parkinsonian Disorders; Treatment Outcome | 2000 |
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
Topics: Age of Onset; Aged; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Outpatients; Parkinson Disease; Prevalence; Quality of Life; Regression Analysis; Treatment Outcome | 2000 |
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric | 2000 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction | 2000 |
Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Diagnosis, Computer-Assisted; Diagnosis, Differential; Dyskinesia, Drug-Induced; Feasibility Studies; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index | 2000 |
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Thalamic Nuclei | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2 | 2001 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Locomotion; Male; Mazindol; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Protein Precursors; Recovery of Function; RNA, Messenger; Substantia Nigra; Tachykinins; Tritium; Tyrosine 3-Monooxygenase | 2001 |
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Acceleration; Activities of Daily Living; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index | 2001 |
High dose naltrexone for dyskinesias induced by levodopa.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naltrexone; Reproducibility of Results | 2001 |
Does stimulation of the GPi control dyskinesia by activating inhibitory axons?
Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Evoked Potentials, Visual; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Microelectrodes; Monitoring, Intraoperative; Neural Inhibition; Parkinson Disease; Periodicity | 2001 |
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Narcotic Antagonists; Oxidopamine; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Sympatholytics; Tritium | 2001 |
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Topics: Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; France; Health Care Costs; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Sex Distribution | 2001 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone | 2001 |
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indoles; Levodopa; Neurologic Examination; Parkinsonian Disorders | 2001 |
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Idazoxan; Levodopa; Male; Neurologic Examination; Neurons; Norepinephrine; Substantia Nigra | 2001 |
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
Topics: Animals; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Movement Disorders | 2001 |
Levodopa induces dyskinesias in normal squirrel monkeys.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Reference Values; Saimiri | 2001 |
Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
Topics: Adult; Aged; Antiparkinson Agents; Brain Tissue Transplantation; Chorea; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Fetal Tissue Transplantation; Globus Pallidus; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease | 2001 |
Relationship between lesion location and the outcome of pallidotomy for Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Globus Pallidus; Humans; Intelligence Tests; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2001 |
Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study.
Topics: Animals; Benzazepines; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Dopamine; Receptors, Purinergic P1 | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families.
Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 1; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Gait Disorders, Neurologic; Genes, Recessive; Haplotypes; Humans; Italy; Levodopa; Lod Score; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenotype; Syndrome; Tremor; Videotape Recording | 2001 |
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. 2000.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; History, 20th Century; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus | 2001 |
[A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1999 |
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome | 2002 |
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dyskinesia, Drug-Induced; Enkephalins; Humans; In Situ Hybridization; Levodopa; Parkinson Disease; Protein Precursors; Putamen; RNA, Messenger; Statistics as Topic | 2002 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics | 2002 |
Dystonia in multiple system atrophy.
Topics: Aged; Brain; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease, Secondary | 2002 |
Literature alert.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; Humans; Incidence; Indoles; Levodopa; Neurons; Parkinson Disease | 2001 |
Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Hand Strength; Humans; Levodopa; Middle Aged; Movement; Muscle Contraction; Parkinson Disease; Weight-Bearing | 2002 |
Levodopa-induced dyskinesias in normal squirrel monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Saimiri | 2002 |
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole | 2001 |
[Rush dyskinesia scale or Goetz scale].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2002 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Huntington Disease; Hydrazines; Levodopa; Male; Phentolamine; Rats; Trifluoperazine; Tyramine | 1976 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Levodopa; Physostigmine; Receptors, Dopamine; Reserpine; Stimulation, Chemical; Thioridazine | 1977 |
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induced; Epilepsy; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Limbic System; Neural Pathways; Neurons; Neurotransmitter Agents; Parkinson Disease; Psychopharmacology | 1979 |
Tiapride in Parkinson's disease.
Topics: Antiparkinson Agents; Benzamides; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Placebos | 1978 |
Long-term effects of home-made levodopa in 43 cases of paralysis agitans.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
Therapeutics of disordered movement.
Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1977 |
Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Huntington Disease; Levodopa; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synapses; Tranquilizing Agents | 1977 |
Estrogens, dopamine and dyskinesias.
Topics: Dyskinesia, Drug-Induced; Estrogens, Conjugated (USP); Female; Humans; Levodopa; Middle Aged; Receptors, Dopamine; Tranquilizing Agents | 1978 |
Levodopa-induced dopaminergic hypersensitivity in the pathogenesis of psychiatric and neurologic disorders.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Receptors, Dopamine | 1979 |
L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation.
Topics: Adenylyl Cyclases; Animals; Behavior, Animal; Caudate Nucleus; Denervation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Activation; Levodopa; Mice | 1977 |
Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
Topics: Adult; Age Factors; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Oral Manifestations; Parkinson Disease; Tranquilizing Agents | 1977 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parasympatholytics; Parkinson Disease, Secondary; Therapeutic Equivalency; Time Factors | 1977 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Tiapride in levodopa-induced involuntary movements.
Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Radioligand Assay; Rats; Receptors, Dopamine; Receptors, Drug; Spiperone | 1979 |
[Abnormal movements induced by psychotropic drugs].
Topics: Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Movement Disorders; Parkinson Disease, Secondary; Psychotropic Drugs; Receptors, Dopamine; Receptors, Drug; Tremor | 1979 |
Role of the caudate nucleus in production of dyskinesia [proceedings].
Topics: Animals; Apomorphine; Cats; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Electric Stimulation; Levodopa; Movement Disorders; Neural Pathways; Substantia Nigra; Tremor | 1979 |
[Value of sulpiride and tiapride in geriatrics. Antagonism between Parkinson disease and chorea].
Topics: Aged; Benzamides; Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Sulpiride; Tiapamil Hydrochloride | 1979 |
Antagonism by piperidine of levodopa effects in Parkinson disease.
Topics: Aged; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1977 |
Methylphenidate-induced chorea: case report and pharmacologic implications.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child, Preschool; Chorea; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; Humans; Hyperkinesis; Levodopa; Male; Methylphenidate; Stereotyped Behavior | 1978 |
L-dopa induced dyskinesias in asymmetrical parkinsonism.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Pathways; Parkinson Disease | 1979 |
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Topics: Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
[On and off phenomenon].
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease | 1977 |
Levodopa-induced dopamine receptor hypersensitivity.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Receptors, Dopamine; Stereotyped Behavior | 1977 |
Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease, Secondary; Time Factors | 1978 |
Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea.
Topics: Adult; Basal Ganglia Diseases; Central Nervous System; Dyskinesia, Drug-Induced; Dyspnea; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Receptors, Dopamine; Tranquilizing Agents | 1978 |
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
Topics: Aged; Benzimidazoles; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1978 |
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged | 1978 |
Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
Topics: Animals; Carbidopa; Disease Models, Animal; Drug Combinations; Dyskinesia, Drug-Induced; Hydrazines; Levodopa; Rats; Receptors, Dopamine | 1978 |
[Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
Topics: Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
The relationship between parkinsonism and tardive dyskinesia.
Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Methyltyrosines; Mouth; Parkinson Disease; Piperidines; Tranquilizing Agents | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Ocular dyskinesias in patients with Parkinson's disease treated with levodopa.
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Oculomotor Muscles; Parkinson Disease; Syndrome | 1977 |
["Beginning and end of dose" dyskinesias caused by L-DOPA].
Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
A neuroendocrine study of supersensitivity in tardive dyskinesia.
Topics: Adult; Apomorphine; Chronic Disease; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Prolactin; Receptors, Dopamine; Schizophrenia; Tranquilizing Agents | 1977 |
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (4) Dyskinesia caused by levodopa].
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Oral dyskinesia (author's transl)].
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Masticatory Muscles; Movement Disorders; Tongue Habits; Trihexyphenidyl | 1976 |
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Follow-Up Studies; Growth Hormone; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1976 |
Levodopa induced ON-OFF motor fluctuations in Parkinson's disease related to rhythmical masticatory jaw movements.
Topics: Administration, Oral; Aged; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mastication; Masticatory Muscles; Middle Aged; Neurologic Examination; Neurons; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synaptic Transmission | 1992 |
Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland | 1992 |
Magnetic fields in the treatment of Parkinson's disease.
Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland | 1992 |
Levodopa.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Neurons; Parkinson Disease; Substantia Nigra; Time Factors | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Topics: Adult; Aged; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Middle Aged; Movement | 1992 |
Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Estradiol; Female; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Progesterone | 1992 |
Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
Topics: Carbidopa; Circadian Rhythm; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Evaluation Studies as Topic; Humans; Levodopa; Parkinson Disease | 1992 |
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Vigabatrin | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: Animals; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary | 1991 |
Is levodopa harmful?
Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1991 |
Early onset parkinsonism in Chinese.
Topics: Adolescent; Adult; Age Factors; China; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1991 |
Motor blocks in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Risk Factors | 1992 |
A computational model of levodopa pharmacodynamics in Parkinson's disease.
Topics: Basal Ganglia; Corpus Striatum; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease | 1991 |
Dopaminergic activity and idiopathic edema.
Topics: Adult; Brain; Diuresis; Dopamine; Dyskinesia, Drug-Induced; Edema; Female; Galactorrhea; Haloperidol; Humans; Levodopa; Receptors, Dopamine; Substance Withdrawal Syndrome | 1991 |
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
Psychotic complications of long-term levodopa treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1991 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |
Neurotransmitter and receptor alterations in the rat persistent dyskinesia model induced by iminodipropionitrile.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Bromocriptine; Ceruletide; Dyskinesia, Drug-Induced; Levodopa; Male; Neurotoxins; Neurotransmitter Agents; Nitriles; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Muscarinic | 1990 |
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
Topics: Adult; Aging; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Probability; Severity of Illness Index; Time Factors | 1991 |
Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1991 |
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
Topics: Aged; Analysis of Variance; Cohort Studies; Dementia; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1991 |
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Topics: Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1991 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1991 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
Topics: Chorea; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Parkinson Disease; Videotape Recording | 1990 |
Terguride in the treatment of Parkinson disease: preliminary experience.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1990 |
Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Saimiri; Substantia Nigra | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Saimiri; Sincalide | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Saimiri | 1990 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors | 1989 |
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1989 |
Blink reflex in dyskinetic and nondyskinetic patients with Parkinson's disease.
Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Pathogenesis of dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Induced; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Exertion | 1985 |
A therapeutic approach to tardive dyskinesia.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Colitis; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Nausea; Paranoid Disorders; Psychomotor Agitation; Psychoses, Substance-Induced; Psychotic Disorders; Receptors, Dopamine; Reserpine; Tetrabenazine; Time Factors | 1985 |
The effect of dopamine antagonists in spontaneous and tardive dyskinesia.
Topics: Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Receptors, Dopamine; Tourette Syndrome | 1985 |
When to use levodopa in parkinsonism.
Topics: Acute Disease; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
When should levodopa be started?
Topics: Adult; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1986 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Tetrabenazine | 1987 |
Ethical issues in drug studies.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Ethics, Medical; Humans; Levodopa; Research; Schizophrenia; Schizophrenic Psychology | 1988 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines | 1988 |
Experimental study on resting tremor and L-dopa-induced dyskinesia.
Topics: Animals; Cercopithecus; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca; Movement Disorders; Receptors, Dopamine; Receptors, Dopamine D2; Tegmentum Mesencephali; Tremor | 1987 |
Lisuride infusion pump in Parkinson's disease. A report of two cases.
Topics: Aged; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Lisuride; Mental Disorders; Parkinson Disease | 1988 |
Pathophysiology of L-dopa-induced abnormal involuntary movements.
Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Spiperone; Substance Withdrawal Syndrome; Substantia Nigra; Synapses; Synaptic Transmission | 1985 |
Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Naloxone; Parkinson Disease; Receptors, Opioid | 1986 |
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.
Topics: Aged; Carbimazole; Dyskinesia, Drug-Induced; Female; Humans; Hyperthyroidism; Levodopa; Movement Disorders; Parkinson Disease | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1986 |
Open pilot trial of ritanserin in parkinsonism.
Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pilot Projects; Piperidines; Ritanserin | 1986 |
[Long-term problems of levodopa therapy in Parkinson disease].
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors | 1987 |
Isoniazid therapy in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Isoniazid; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Topics: Adult; Aged; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors | 1988 |
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1988 |
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscular Diseases; Parkinson Disease; Personality; Substantia Nigra | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
Topics: Aged; Dyskinesia, Drug-Induced; Eye Movements; Head; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Reflex, Abnormal; Vestibule, Labyrinth | 1986 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines | 1987 |
Young onset Parkinson's disease.
Topics: Adult; Age Factors; Circadian Rhythm; Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedigree; Risk Factors; Tremor | 1987 |
Response of tardive and L-dopa-induced dyskinesias to antidepressants.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Trazodone | 1987 |
Long-term follow-up of early dopa treatment in Parkinson's disease.
Topics: Dementia; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
[An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
Topics: Adult; Aged; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
[Therapy in Parkinson syndrome].
Topics: Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa | 1986 |
Respiratory dyskinesia in Parkinson's disease.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders; Tiapamil Hydrochloride | 1986 |
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
Topics: Adult; Aged; Domperidone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Injections, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1986 |
Efficacy of pergolide and mesulergine.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1986 |
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Outcome and Process Assessment, Health Care; Parkinson Disease; Pergolide; Time Factors | 1985 |
Levodopa-induced dyskinesia: clinical observations.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk | 1985 |
The symptoms of patients treated for Parkinson's disease.
Topics: Adult; Age Factors; Aged; Carboxy-Lyases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Surveys and Questionnaires | 1985 |
[Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tiapamil Hydrochloride | 1985 |
[Useful data on parkinsonian syndromes].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease, Secondary | 1985 |
[Oral lisuride in Parkinson's disease].
Topics: Adult; Aged; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
[Long-term evaluation of tiapride in patients with various forms of dyskinesia].
Topics: Benzamides; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Meige Syndrome; Movement Disorders; Safety; Tiapamil Hydrochloride | 1985 |